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Background: Smoking is a known lung cancer cause, but no detailed quantitative systematic review exists.
We summarize evidence for various indices.
Methods: Papers published before 2000 describing epidemiological studies involving 100+ lung cancer cases
were obtained from Medline and other sources. Studies were classified as principal, or subsidiary where cases
overlapped with principal studies. Data were extracted on design, exposures, histological types and confounder
adjustment. RRs/ORs and 95% CIs were extracted for ever, current and ex smoking of cigarettes, pipes and
cigars and indices of cigarette type and dose–response. Meta-analyses and meta-regressions investigated how
relationships varied by study and RR characteristics, mainly for outcomes exactly or closely equivalent to all
lung cancer, squamous cell carcinoma (“squamous”) and adenocarcinoma (“adeno”).
Results: 287 studies (20 subsidiary) were identified. Although RR estimates were markedly heterogeneous, the
meta-analyses demonstrated a relationship of smoking with lung cancer risk, clearly seen for ever smoking
(random-effects RR 5.50, CI 5.07-5.96) current smoking (8.43, 7.63-9.31), ex smoking (4.30, 3.93-4.71) and pipe/cigar
only smoking (2.92, 2.38-3.57). It was stronger for squamous (current smoking RR 16.91, 13.14-21.76) than adeno
(4.21, 3.32-5.34), and evident in both sexes (RRs somewhat higher in males), all continents (RRs highest for
North America and lowest for Asia, particularly China), and both study types (RRs higher for prospective studies).
Relationships were somewhat stronger in later starting and larger studies. RR estimates were similar in cigarette
only and mixed smokers, and similar in smokers of pipes/cigars only, pipes only and cigars only. Exceptionally no
increase in adeno risk was seen for pipe/cigar only smokers (0.93, 0.62-1.40). RRs were unrelated to mentholation,
and higher for non-filter and handrolled cigarettes. RRs increased with amount smoked, duration, earlier starting
age, tar level and fraction smoked and decreased with time quit. Relationships were strongest for small and
squamous cell, intermediate for large cell and weakest for adenocarcinoma. Covariate-adjustment little affected
RR estimates.
Conclusions: The association of lung cancer with smoking is strong, evident for all lung cancer types, dose-related
and insensitive to covariate-adjustment. This emphasises the causal nature of the relationship. Our results quantify
the relationships more precisely than previously.* Correspondence: PeterLee@pnlee.co.uk
P N Lee Statistics and Computing Ltd, Sutton, Surrey, United Kingdom
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Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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It has been known for many years that smoking causes
lung cancer. An association was clearly documented in
case–control studies conducted in Germany in the
1930s [1], and in the United States and Great Britain
[2,3] in the 1950s, and was strengthened by surveys
of large cohorts. This led the US Surgeon General to
conclude in 1964 [4] that “cigarette smoking is a cause
of lung cancer in men, and a suspected cause of lung
cancer in women”. Further reports [5,6] have defined the
relationship in more detail, and it has been estimated
that, in the United States, 90% of male lung cancer
deaths and 75%-80% of female lung cancer deaths are
caused by smoking [7].
While some meta-analyses of the evidence have been
published in recent years [8-10] none consider more
than a relatively small fraction of the published evidence.
We attempt to rectify this omission, though the sheer
extent of the available data, and resources available, has
meant limiting attention to papers published in the last
century and studies involving over 100 lung cancer
cases. As will be seen, this still gives us an extensive
database involving almost 300 studies.
Because the relationship of smoking to the two major
types of lung cancer (squamous cell carcinoma and
adenocarcinoma) is known to vary [5,6], we present
detailed results relating, not only to total lung cancer
risk, but also to these two histological types of lung
cancer. We also present some more limited results for
other lung cancer types. To provide a broad description
of the relationship of smoking to lung cancer, we do not
concentrate on a single primary analysis, but quantify
the relationships to each of a range of indices of smok-
ing, investigating how these relationships vary accord-
ing to characteristics such as sex, age, location, study
design, period considered, definition of exposure and
extent of confounder adjustment. The style of this
systematic review is similar to one we have recently pub-
lished for smoking and COPD, chronic bronchitis and
emphysema [11].
Methods
Full details of the methods used are described in
Additional file 1: Methods, and are summarized below.
Throughout this paper, we use the term relative risk
(RR) to include its various estimators, including the odds
ratio and the hazard ratio.
Inclusion and exclusion criteria
Attention was restricted to epidemiological prospective
or case–control studies published up to and including
1999, which involved 100 lung cancers or more, and
which provided RR estimates for one or more defined
major, cigarette-type or dose-related smoking indices.The “major indices” compare ever, current or ex smok-
ing with never or non-current smoking, and refer to
smoking of any product, cigarettes, pipes, cigars and
combinations, or of specific types of cigarette. The
“cigarette type indices” compare smokers of different
types of cigarette – filter with plain, manufactured
with handrolled and mentholated with non-mentholated.
The “dose-related indices” concern amount smoked,
age of starting to smoke, duration of smoking, duration
of quitting, tar level, butt length or fraction smoked.
Pack-years was not considered as it was felt more
important to separate effects of extent and duration of
exposure. Uncontrolled case studies were not included.
There were no further exclusion criteria.
Literature searching
Between 1997 and 2001 potentially relevant papers were
sought from Medline and Emtree searches, from British
Library monthly bulletins, from files on smoking and
health accumulated over many years by P N Lee Statistics
and Computing Ltd, and from references cited in papers
obtained, until ultimately no paper examined cited a
paper of possible relevance not previously examined.
Identification of studies
Relevant papers were allocated to studies, noting mul-
tiple papers on the same study, and papers reporting on
multiple studies. Each study was given a unique refer-
ence code (REF) of up to 6 characters (e.g. COMSTO
or LUBIN2), based on the principal author’s name and
distinguishing multiple studies by the same author.
Some studies were noted as having overlaps with other
studies. To minimize problems in meta-analysis arising
from double-counting of cases, overlapping studies
were divided into two categories, as shown in Additional
file 2: Studies. The first category involved minor overlap,
which could not be disentangled, and which it was
decided to ignore. The second category contains sets
of studies which probably or definitely overlap. Here
the set member containing the most comprehensive data
(e.g. largest number of cases or longest follow-up) was
called the ‘principal study’, other members being ‘subsid-
iary studies’ only considered in meta-analyses where the
required RR was unavailable from the principal study.
Data recorded
Relevant information was entered onto a study database
and two linked RR databases. Data entry was carried out
in two stages. In 1997–2002, data were entered on the
first RR database for the major smoking indices,
cigarette type indices, and amount smoked. In 2009–
2010, data were entered on the second RR database for
the remaining dose-related indices.
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describing the following aspects: relevant publications;
study title; study design; sexes considered; age range,
race(s) and other details of the population studied; loca-
tion; timing and length of follow-up; whether principal
or subsidiary, with details of overlaps or links with other
studies; number of cases and extent of histological con-
firmation; number of controls or subjects at risk; types
of controls and matching factors used in case–control
studies; use of proxy respondents, interview setting and
response rates; confounding variables considered; avail-
ability of results by histological types; and availability of
results for all smoking indices (including those indices
not considered here, such as pack-years).
The RR databases hold the detailed results, typically
containing multiple records for each study. Each record
is linked to the relevant study and refers to a specific
RR, recording the comparison made and the results.
This record includes the sex, age range, race, lung can-
cer type, and (for prospective studies) the follow-up
period. The smoking exposure of the numerator of the
RR is defined by the smoking status (ever, current or ex),
smoking product (e.g. any, cigarettes, cigarettes only,
pipes only) and cigarette type (e.g. any, mainly hand-
rolled cigarettes, filter cigarettes only, mentholated cigar-
ettes). Similar information is recorded about the denom-
inator of the RR. For dose-related indices, the level of
exposure is recorded. The source of the RR is also
recorded, as are details on adjustment variables. Results
recorded include numbers of cases for the numerator
and denominator, and, for unadjusted results, numbers
of controls, persons at risk or person-years at risk. The
RR itself and its lower and upper 95% confidence limits
(LCL and UCL) are always recorded. These may be as
reported, or derived by various means (see below), with
the method of derivation noted.Identifying which RRs to enter
RRs were entered relating to defined combinations of
lung cancer type, smoking index (major, cigarette type
or dose-related), confounders adjusted for, and strata,
as described below.Lung cancer type
Results were entered for all lung cancer, for Kreyberg I
(as originally presented, or by combining squamous,
small and large cell carcinoma) and Kreyberg II (as ori-
ginally presented, or by combining adenocarcinoma and
others not in Kreyberg I), and for squamous, small, and
large cell carcinoma and for adenocarcinoma separately.
Additionally, the following groups were constructed if
not originally presented: all lung cancer or nearest
equivalent, but at least squamous cell carcinoma andadenocarcinoma; squamous cell carcinoma or nearest
equivalent; adenocarcinoma or nearest equivalent.
Major and cigarette type smoking indices
The intention was to enter RRs comparing current smo-
kers, ever smokers or ex smokers with never or non
smokers. Near-equivalent definitions were accepted
when stricter definitions were unavailable, so that, for
example, never smokers could include occasional smo-
kers (or exceptionally, light smokers), while current
smokers could include, and ex-smokers exclude, recent
quitters. RRs were to be entered relating to smoking
of defined products and, when the product related to
cigarette smoking, to defined cigarette types (see also
Additional file 1: Methods). If available, results (for each
of current, ex and ever smoking) were entered for five
comparisons: any product vs. never any product, cigar-
ettes vs. never any product, cigarettes only vs. never any
product, cigarettes vs. never cigarettes, and cigarettes
only vs. never cigarettes (and also for five equivalent
comparisons for current vs non smoking). Here “cigar-
ettes” ignores whether other products (i.e. pipes and
cigars) are also smoked, while “cigarettes only” excludes
mixed smokers. Additionally, when the numerator related
to the smoking of filter, handrolled or mentholated cigar-
ettes, RRs were entered with the denominator defined
as relating to plain, manufactured or non-mentholated
smokers respectively.
Dose-related smoking indices
RRs were entered for seven measures: amount smoked,
age of starting, duration of smoking, duration of quit-
ting, tar level, butt length and fraction smoked. RRs were
expressed relative to never smokers (or near equivalent),
if available, or relative to non smokers otherwise. For
duration of quitting, RRs were also expressed relative to
current smokers. Except for amount smoked, further
RRs were entered, restricted to smokers, and expressed
relative to the level expected to have the lowest risk (e.g.
shortest duration or latest age started).
Confounders adjusted for
For case–control studies, results were entered adjusted
for the greatest number of potential confounding vari-
ables for which results were available, and also unadjusted
(or adjusted for the smallest number of confounders). For
prospective studies, results were entered adjusted for
age and the greatest number of confounders, and for age
only or age and the smallest number of confounders, with
unadjusted results entered only if no age-adjusted results
were available. These alternative RRs are subsequently
referred to as “most-adjusted” and “least-adjusted”. For
dose-related RRs restricted to smokers, results with “most
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smoking were also entered if available.
Strata
Three strata were considered – sex, age and race. Results
were entered for males and females separately when
available, with combined sex results only entered when
sex-specific results were not available. Results were
entered for all ages combined and for individual age
groups, and for all races and for individual racial groups.
Derivation of RRs
Adjusted RRs and their 95% CIs were entered as pro-
vided, when available. Unadjusted RRs and CIs were cal-
culated from their 2 × 2 table, using standard methods
(e.g. [12]), noting any discrepancies between calculated
values and those provided by the author. Sometimes
the 2 × 2 table was constructed by summing over groups
(e.g. adding current and ex smokers to obtain ever smo-
kers) or from a percentage distribution. Various other
methods were used as required to provide estimates of
the RR and CI. Some more commonly used methods are
summarized below, fuller details being given in Additional
file 1: Methods.
Correction for zero cell
If the 2 × 2 table has a zero cell, 0.5 was added to each
cell, and the standard formulae applied.
Combining independent RRs
RRs were combined over ℓ strata (e.g. from a 2 × 2 × ℓ
table) using fixed-effect meta-analysis [13], giving an
estimate adjusted for the stratifying variable.
Combining non-independent RRs
The Hamling et al. method [14] was used (e.g. to derive
an adjusted RR for ever smokers from available adjusted
RRs for current and ex smokers, each relative to never
smokers, or to combine adjusted RRs for several histo-
logical types, each relative to a single control group).
Estimating CI from crude numbers
If an adjusted RR lacked a CI or p-value but the corre-
sponding 2 × 2 table was available, the CI was estimated
assuming that the ratio UCL/LCL was the same as for
the equivalent unadjusted RR.
Data entry and checking
Master copies of all the papers in the study file were
read closely, with relevant information highlighted to
facilitate checking. Where multiple papers are avail-
able for a study, a principal publication was identified,
although details described only in other publications
were also recorded. Preliminary calculations and dataentry were carried out by one author and checked by
another, and automated checks of completeness and
consistency were also conducted. RR/CIs underwent
validation checks [15].
Meta-analyses conducted – overview
A pre-planned series of meta-analyses was conducted
for various smoking indices for each of the three main
outcomes (all lung cancer, squamous cell carcinoma, and
adenocarcinoma) and also for some indices for two other
outcomes (large cell carcinoma and small cell carcin-
oma). Nearest equivalent definitions are allowed for the
three main outcomes, with the terms “squamous” and
“adeno” used subsequently to distinguish these results
from those specifically for these cell types. Each meta-
analysis was repeated, based on most-adjusted RRs and
on least-adjusted RRs. For each meta-analysis conducted,
combined estimates were made first for all the RRs
selected, then for RRs subdivided by level of various
characteristics, testing for heterogeneity between levels.
Selecting RRs for the meta-analyses
All meta-analyses are restricted to records with available
RR and CI values. The process of selecting RRs for
inclusion in a meta-analysis must try to include all rele-
vant data and to avoid double-counting. For a given
analysis (e.g. of current cigarette smoking), several defi-
nitions of RR may be acceptable (e.g. cigarette smoking,
or cigarette only smoking), so, for studies with multiple
RRs, the one to be used is determined by a preference
order defined for the meta-analysis. Preference orders
may be required for smoking status, smoking product,
the unexposed base, and extent of confounder adjust-
ment. As the definitions of RR available may differ by
sex (e.g. a study may provide RRs for any product smok-
ing for males, but only for cigarette smoking for
females), the RRs chosen for each sex may not necessar-
ily have the same definition.. Sexes combined results are
only considered where sex-specific results are not avail-
able. Similarly RRs from a subsidiary study are only used
where eligible RRs are unavailable from the principal
study. When multiple preference orders are involved,
the sequence of implementation may affect the selection,
so preferences for the most important aspects, usually
concerning smoking, are implemented first.
Carrying out the meta-analyses
Fixed-effect and random-effects meta-analyses were con-
ducted using the method of Fleiss and Gross [13], with
heterogeneity quantified by H, the ratio of the hetero-
geneity chisquared to its degrees of freedom, which is
directly related to the statistic I2 [16] by the formula
I2 = 100 (H-1)/H. For all meta-analyses, Egger’s test of
publication bias [17] was also included.
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corresponding to the sub-sections of the results section of
the paper. A full list of the analyses is given in Additional
file 1: Methods.The major smoking indices
For the major smoking indices, the first four sets of
meta-analyses relate to: A ever smoking, B current
smoking, C ever smoking (but with current smoking
used if ever smoking not available), referred to subse-
quently as “ever/current” smoking, and D ex smoking.
In what is referred to as the main analysis in each set,
smoking of any product is preferred by selecting RRs in
the following preference order: 1. smoking of any prod-
uct vs. never smoked any product; 2. smoking of cigar-
ettes vs. never smoked any product, 3. smoking of
cigarettes only vs. never smoked any product; 4. smoking
of cigarettes vs. never smoked cigarettes; 5. smoking of
cigarettes only vs. never smoked cigarettes; with options
6–10 the same as options 1–5 except that “never
smoked” is replaced by “never smoked near equivalent”.
A variant analysis prefers cigarette smoking (by changing
the preference order to 4, 5, 2, 3, 1, 9, 10, 7, 8, 6). In
meta-analyses of type C, a further variant analysis
reverses the preference so current smoking results are
preferred to those for ever smoking, referred to subse-
quently as “current/ever” smoking. Other variant ana-
lyses are based on RRs for specified age ranges.
A further set of meta-analyses, E, concerns smoking of
pipes and/or cigars (but not cigarettes), referred to sub-
sequently as smoking of “pipes/cigars only”, smokers of
pipes only, smokers of cigars only, and smokers of cigar-
ettes and pipes/cigars (“mixed” smokers). Separate meta-
analyses were conducted for ever smoking, current
smoking, ever/current smoking, current/ever smoking
and ex smoking.The cigarette type indices
Meta-analyses were conducted, in set F, for only filter vs.
only plain, ever filter vs. only plain, only filter vs. ever
plain, handrolled vs. manufactured, and mentholated vs.
non-mentholated. These were only conducted for ever/
current smoking, and preferring RRs for cigarettes over
RRs for cigarettes only. The analyses with only filter as
the numerator used the preference order of filter only,
always, mainly, both, equally, and ever, while the ana-
lyses with ever filter as the numerator used the reverse
preference. Similar preference orders applied to the
denominators. The analyses of handrolled vs. manufac-
tured cigarettes used the preference order of any, both,
mainly, and only for handrolled, and only ever, only
current, any and ever for manufactured.The dose-related smoking indices
For the dose-related indices, sets of meta-analyses were
conducted for: G amount smoked, H age of starting to
smoke, I duration of smoking, J duration of quitting
compared to never smokers (or long-term ex smokers),
K duration of quitting compared to current smokers (or
short-term quitters), L tar level, and M butt length or
fraction smoked (taking short butt length as being
equivalent to a large fraction smoked). For any measure,
a study typically provides a set of non-independent RRs
for each dose-category, expressed relative to a common
base. To avoid double-counting only one was included
in any one meta-analysis. Two approaches were adopted.
The first involves specifying a scheme with a number of
levels of exposure (“key values”), then carrying out meta-
analyses for each level in turn, expressed relative to
never smokers. For an RR to be allocated to a key value,
its dose-category has to include that key-value and no
other. Schemes with a few, widely spaced, key values
tend to involve more studies, whereas schemes with
more key values, closely spaced, involve RRs from fewer
studies, but ones with dose categories more closely clus-
tered around the key value. The sets of key values used
(with 999 indicating an open-ended category) were 5, 20,
45 and 1, 10, 20, 30, 40, 999 for amount smoked; 26, 18,
14 and 30, 26, 22, 18, 14, 10 for age of starting to smoke;
20, 35, 50 and 5, 20, 30, 40, 50, 999 for duration of
smoking; 12, 7, 3 and 20, 12, 3 for duration of quitting
vs. never; and 3, 7, 12 and 3, 12, 20 for duration of quit-
ting vs. current. No key value analysis was conducted for
tar level, or for butt length/fraction smoked. The second
approach (not conducted for amount smoked) involves
meta-analysing of RRs for the highest compared with
the lowest categories of exposure within smokers avail-
able for each study.
Meta-regression analyses
While full multivariable analysis of the data is consid-
ered beyond the scope of this report, meta-regression
analyses were also carried out using the sets of RRs
selected for the main meta-analyses for ever smoking
and for current smoking. Following preliminary meta-
regressions (not shown), a “fixed model” was fitted to
examine the effect on the results of six different categor-
ical variables (sex, location, start year of study, major
study type, number of lung cancer cases and number
of adjustment factors). Note that the number of lung
cancer cases (in the study as a whole), which is referred
to subsequently as “number of cases”, is used as an indi-
cator of study size. The significance of each of these
variables was estimated by an F-test based on the
increase in deviance resulting from its exclusion from
the basic model. A list of secondary variables was also
defined (relating to more detailed aspects of location,
Table 1 Literature searching and study identification
N (%)
Papers
Identified as potentially relevant 5993 100%
Not obtainable 244 4.1%
Obtained 5749 95.9%
Did not provide relevant data at all 4901 81.8%
Satisfied inclusion criteria except
less than 100 lung cancer cases
175 2.9%
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cigarette tobacco type, the product smoked, the denomin-
ator used in the RR, use of proxy respondents, whether
the study required 100% histological confirmation of
lung cancer, whether the population studied worked in
risky occupations, the age of the subjects, and the deriv-
ation of the RR) with the significance of adding each
characteristic to the fixed model estimated by an F-test
based on the increase in deviance. Fuller details are given
in Additional file 1: Methods.
Additional analyses
Additional tests of the relationship of lung cancer risk to
various characteristics of interest were based on corre-
sponding pairs of RR and CI estimates within the same
study for the same definition of outcome and exposure,
and deriving the ratio of the two RRs. Where the pairs
involved independent sets of subjects, the variance of
the ratio was also derived, and meta-analyses of the
ratio were conducted. Where the pairs involved non-
independent sets of subjects the numbers of ratios
greater and less than 1 were compared using the sign
test. Tests of independent pairs related to sex (males vs.
females), age (oldest vs. youngest age group) and race
(white people vs. non-white or black people). Tests of
non-independent pairs related to level of adjustment
(most-adjusted vs. least-adjusted), and to comparisons of
product smoked (mixed smokers vs. cigarette only smo-
kers, and vs. smokers of pipes/cigars only). Tests were
always carried out for all lung cancer and ever/current
smoking. For sex, additional analyses were conducted
for current and for ever smoking, for squamous and
adeno, and also within level of amount smoked. For level
of adjustment, two sets of analyses were run. The first,
relating to RRs for ever/current smoking were based on
the most-adjusted/least-adjusted ratio, while the second,
for highest vs. lowest RRs for age of starting to smoke,
duration, years quit and tar level, compared RRs that were
most- or least-adjusted for other aspects of smoking.
Software
All data entry and most statistical analyses were carried
out using ROELEE version 3.1 (available from P.N. Lee
Statistics and Computing Ltd, 17 Cedar Road, Sutton,
Surrey SM2 5DA, UK). Some analyses were conducted
using Quattro Pro 9 or Excel 2003.
Results
Studies identified
A total of 5,993 potentially relevant papers were identi-
fied, providing information on 287 eligible studies
(Table 1).
Table 2 presents selected details of the 287 studies
while Table 3 gives the distribution of their majorcharacteristics. Additional file 2: Studies gives fuller
descriptions of the studies.
Of the 287 studies, 267 are classified as principal, 209
(78.3%) of these being case–control studies, 52 (19.5%)
prospective, 5 (1.9%) nested case–control and 1 (0.4%)
case-cohort. Note that the last three study designs,
where exposure was determined before diagnosis, are
combined into one category in Table 3 (and the text
below based on it). The other 20 studies are classified as
subsidiary. Of the principal studies, 262 provide data for
all lung cancer, 84 for squamous and 86 for adeno. Only
rarely did these studies provide data only for squamous
(1 study) or adeno (3 studies). The data come less often
from case–control designs for all lung cancer (77.9%)
than for squamous (86.9%) and adeno (87.2%).
Of the 267 principal studies, 158 (59.2%) provide
results for both sexes, 90 (33.7%) for males only, and 19
(7.1%) for females only. One hundred and ninety-six
(73.4%) of the studies included subjects who are under
30 years old (or allowed their inclusion by having no age
restriction), while only 31 (11.6%) were restricted to sub-
jects aged 40 or more. Subjects aged 80 years or more
were included by 200 (74.9%), while only 16 (6.0%) were
restricted to subjects aged 60 or less. Prospective studies
were much more likely than case–control studies to spe-
cify age restrictions, e.g. 62.1% vs. 16.7% for age 30 years
or more, and 48.3% vs. 18.7% for age less than 80 years.
Eighty-nine (33.3%) principal studies were conducted in
USA or Canada, with 22 (8.2%) in the UK, 25 (9.4%) in
Scandinavia, 43 (16.1%) in other parts of Europe, 37
(13.9%) in China, 18 (6.7%) in Japan, 17 (6.4%) in the
rest of Asia and 16 (6.0%) elsewhere – in South or Cen-
tral America, Africa or Australia. Of the 58 prospective
studies, all but 12 were conducted in North America,
UK or Scandinavia. Of the principal studies, 42 (15.7%)
were conducted in countries where at least 75% of cigar-
ettes smoked are made from Virginia tobacco, with 184







Brief study descriptiona Outcome(s)b Casesc Full
Histd
Princ REFe
ABELIN [29] [30] Switzerland rural CC 1941-64 All 118 No
ABRAHA [31] [32] Hungary Budapest cohort 1975-94 All,Sq,Ad 571 No
AGUDO [33] Spain Barcelona area CC 1989-92 All 103 No
AKIBA [34] [35-37] Japan atomic bomb survivors cohort 1963-87 All 610 No
ALDERSf [38] [39,40] UK CC 1977-82 All,Sq,Ad 1448 No
AMANDU [41] US metal miner cohort 1959-75 All 132 No
AMES [42] [43] US 4 NIOSH coal miner cohorts nested CC 1959-75 All 317 No
ANDERS [44] [45-47] US Iowa Women's Health cohort 1986-94 All,Sq,Ad 343 No
ARCHER [48] [49-53] US uranium miners cohort 1950-74 All 146 No
ARMADA [54] Spain CC 1986-90 All 325 Yes
AUSTIN [55] [56] US Ohio foundry workers CC 1970-86 All 166 No
AUVINE [57] [58-60] Finland radon CC 1986-92 All 517 No
AXELSO [61] Sweden radon CC 1960-81 All 152 No
AXELSS [62] [63-65] Sweden 26 municipality CC 1989-93 All 436 No
BAND [66] Canada occupational CC 1983-90 All,Sq,Ad 2831 Yes
BARBON [67] [68-72] Italy Trieste CC 1979-86 All,Sq,Ad 755 Yes
BECHER [73] [74,75] Germany pilot for BIPS CC 1985-86 All,Sq,Ad 194 Yes
BENHAM [76] [77-81] France CC 1976-80 All,Sq,Ad 1625 Yes LUBIN2
BENSHL [82] [83-85] UK Whitehall civil servants cohort 1967-87 All 486 No
BERRIN [86] [87] Italy CC 1977-80 All 1101 Yes LUBIN2
BEST [88] [89-91] Canada war veteran pensioners cohort 1955-62 All 381 No
BLOHMK [92] Germany Heidelberg personality CC All 888 Yes
BLOT1 [93] US Georgia CC 1970-76 All 458 No
BLOT3 [94] [95,96] US Florida CC 1976-79 All 321 No
BLOT4 [97] [96] US Pennsylvania CC 1974-77 All 335 No
BOFFET [98] West Europe pipe and cigar CC 1988-94 All 5621 No
BOUCHA [99] France Paris CC 1988-92 Sq 150 Yes
BOUCOT [100] [101-103] US Philadelphia LC Research cohort 1951-65 All,Sq,Ad 121 No
BRESLO [104] [105] US California CC 1949-52 All,Sq,Ad 518 Yes
BRETT [106] UK X-ray volunteers cohort 1960-63 All 150 No
BROCKM [107] Germany Berlin CC study 1990-92 All 117 Yes
BROSS [108] [109] US Roswell Park Memorial CC study 1960-66 All 974 No
BROWN1 [110] US Colorado adenocarcinoma CC 1979-82 Ad 102 Yes
BROWN2 [111] US Missouri CC 1984-90 All,Sq,Ad 14596 Yes
BUELL [112] US California American Legion cohort 1957-62 All 304 No
BUFFLE [113] [114-118] US Texas 6 counties CC 1976-80 All,Sq,Ad 943 No
BYERS1 [119] US Roswell Park Memorial CC 1957-65 Sq,Ad 1002 No BROSS,
GRAHAM
BYERS2 [120] US Western New York Diet CC 1980-84 All 448 Yes
CARPEN [121] [122-126] US California Genetics CC 1991-94 All 356 No
CASCO2 [127] Germany Berlin NAT2 Genotyping CC 1991-94 All 155 No
CASCOR [127] Germany Berlin NAT2 Phenotyping CC All 389 Yes
CEDERL [128] [129-131] Sweden cohort 1963-89 All 491 No
CHAN [132] Hong Kong 5 hospital CC 1976-77 All,Sq,Ad 397 No
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Table 2 Selected details of the 287 studies of lung cancer (Continued)
CHANG [133] US California cholesterol cohort 1972-91 All 136 No
CHATZI [134] Greece Athens CC 1987-88 All 282 Yes
CHEN [135] Taiwan Taipai CC Sq,Ad 323 Yes
CHEN2 [136] [137] China Guangzhou CC All 193 No
CHEN3 [137] [138,139] China Zhengzhou CC All 254 No
CHIAZZ [140] [141] US Owens-Corning Fiberglass Newark CC 1940-82 All 144 No
CHOI [142] South Korea Cancer Centre CC 1985-88 All,Sq,Ad 375 No
CHOW [143] US Lutheran Brotherhood Ins. cohort 1966-86 All 219 No
CHYOU [144] [145,146] US Hawaii Oahu Japanese cohort 1965-90 All,Sq,Ad 227 Yes
COMSTO [147] US Washington Co Serum Bank nested CC 1975-93 All,Sq,Ad 258 No
COOKSO [148] Zimbabwe-Rhodesia Harare CC 1961-72 All 234 Yes
CORREA [149] [95,96,150-152] US Louisiana CC 1979-82 All,Sq,Ad 1359 No
CPSIg [153] [154-178] US ACS million person CPSI cohort 1959-72 All,Sq,Ad 5138 No
CPSII [179] [6,175-178,180-188] US 2nd ACS cancer prevention cohort 1982-94 All,Sq,Ad 3229 No
DAMBER [189] [190-196] Sweden North CC 1972-77 All,Sq,Ad 579 No
DARBY [197] UK SW England radon CC 1988-93 All 982 No
DAVEYS [198] [198-201] Germany Thuringia (Schairer&Schoniger) CC 1930-41 All 109 No
DEAN [202] [203] South Africa CC 1947-56 All 603 No
DEAN2 [204] [205] UK/N Ireland CC 1960-62 All 954 No
DEAN3h [206] [207] UK Cleveland Co CC 1969-73 All 766 No
DEKLER [208] [209,210] Australia Kalgoorlie miners cohort 1961-93 All 138 No
DESTE2 [211] [211-217] Uruguay Montevideo CC 1993-96 All,Sq,Ad 463 No
DESTEF [218] [219-221] Uruguay Montevideo CC 1988-94 All,Sq,Ad 497 Yes
DOCKER [222] [223] US Harvard six cities cohort 1974-91 All 120 No
DOLL [3] [224-227] UK original Doll and Hill CC 1948-52 All,Sq,Ad 1465 No
DOLL2i [228] [229-239] UK British Doctors cohort 1951-91 All 920 No
DORANT [240] [241-243] Netherlands case-cohort 1986-89 All 550 Yes
DORGAN [244] [95,96,245-250] US New Jersey CC 1980-83 All,Sq,Ad 2026 Yes
DORN [251] [252-260] US Veterans cohort 1954-80 All,Sq,Ad 5097 No
DOSEME [261] Turkey Istanbul CC 1979-84 All,Sq,Ad 1210 No
DROSTE [262] Belgium Antwerp CC 1995-97 All 478 Yes
DU [263] [264] China Guangzhou CC 1985 All 849 No
DUNN [265] US California 9 occupations cohort 1954-58 All 139 No
EBELIN [266] Germany Berlin (Lichtenberg) CC 1980-85 All 130 No
ENGELA [267] [268-270] Norway cohort 1964-93 All,Sq,Ad 435 No
ENSTRO [271] US California CPSI cohort 1959-97 All 2879 No
ESAKI [272] Japan Omuta and Arao CC 1961-71 All 245 No
FAN [273] China Sino-MONICA-Beijing Project CC 1990-91 All,Sq,Ad 403 No
GAO [274] [137,139,275-281] China Shanghai CC 1984-86 All,Sq,Ad 1405 No
GAO2 [282] [283] Japan Tokai diet CC 1988-91 All 282 No
GARCIA [284] [285-287] US Boston genetics CC 1992-96 All 416 Yes
GARDIN [288] [289] UK/Scotland Airdrie avian CC 1988-92 All 143 No
GARSHI [290] US railroad workers diesel CC 1981-82 All 1081 No
GENG [291] [292] China Tianjin CC All 292 No
GER [293] [294] Taiwan Tri-Service General Hospital 1990-91 All,Sq,Ad 141 No
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Table 2 Selected details of the 287 studies of lung cancer (Continued)
GILLIS [295] [87] UK/Scotland West CC 1977-81 All,Sq,Ad 656 No LUBIN2
GODLEY [296] [297] US 1966–68 NMFS & 1967 current pop survey CC All 1986 No
GOLLED [298] [299] UK Teeside CC 1952-62 All 443 No
GOODMA [300] [301] US Hawaii CC 1983-85 All 326 Yes
GRAHAM [302] US Roswell Park Memorial CC 1956-60 All 685 No
GREGOR [303] UK Brompton Hospital vitamin A CC 1976-77 All 104 Yes
GSELL [304] [305] Switzerland St Gallen CC 1937-54 All 150 Yes
GUO [306] China Quanshan county Jiangsu CC 1984-86 All 196 No
HAENSZ [307] US Multiple hospital CC 1955-57 All,Sq,Ad 158 Yes
HAMMO2 [308] [309-312] US & Canada asbestos workers cohort 1967-76 All 450 No
HAMMON [313] [314-320] US 9 state cohort 1952-55 All,Sq,Ad 448 No
HANSEN [321] [322] Denmark welding companies cohort 1968-86 All 105 No
HEGMAN [323] [324] US Utah radon CC 1989-91 All,Sq,Ad 282 Yes
HEIN [325] Denmark Copenhagen Male cohort 1970-88 All 144 No
HENNEK [326] [327] US doctors betacarotene trial cohort 1982-95 All 169 No
HINDS [328] US Hawaii CC 1968-78 All,Sq,Ad 292 No
HIRAY2 [329] [330] Japan Tokyo CC 1950-52 All 145 No
HIRAYAj [331] [330,332-345] Japan 6 prefecture cohort 1965-82 All 1917 No
HITOSU [346] Japan Amagaski and Nishinomiya CC 1960-66 All 216 No
HOLEk [347] [348-351] UK/Scotland Renfrew & Paisley cohort 1972-85 All 225 No
HOROWI [352] Canada Montreal CC 1956-67 All 236 No
HORWIT [353] US Yale/New Haven CC 1977-82 All 112 No
HU [354] China Heilongjiang 5 hospital CC study 1985-87 All 227 Yes
HU2 [355] [137,139,356] China Harbin CC study 1977-79 All 523 No
HUANG [357] China Sichuan CC 1990-91 All 135 No
HUMBLE [358] [359-362] US New Mexico statewide CC 1980-82 All 521 No
ISHIMA [363] [364] Japan A bomb survivors CC 1961-70 All,Sq,Ad 180 Yes AKIBA
JAHN [365] [366-369] Germany BIPS CC 1988-93 All,Sq,Ad 1004 No BOFFET
JAIN [370] [371,372] Canada Ontario CC 1981-85 All,Sq,Ad 845 No
JARUP [373] [374,375] Sweden smelter workers CC 1928-81 All 102 No
JARVHO [376] Sweden Goteborg asbestos CC 1983-84 All 147 No
JEDRYC [377] [378-382] Poland CC 1980-87 All,Sq,Ad 1630 No
JIANG [383] [137,139] China Nanchang CC 1984 All,Sq,Ad 125 No
JOLY [384] Cuba Havana CC 1978-80 All,Sq,Ad 826 No
JUSSAW [385] India Greater Bombay CC 1964-73 All,Sq,Ad 792 No
KAISE2 [386] [387,388] US California Kaiser cohort 1979-91 All 318 No
KAISER [389] [390] US California Kaiser cohort 1964-80 All 714 No
KANELL [391] [391,392] Greece Hellenic Anticancer Inst CC 1950-62 All 862 No
KATSOU [393] Greece Athens CC 1987-89 All,Sq,Ad 101 No
KAUFMA [394] US & Canada tar level CC 1981-86 All 881 No
KELLER [395] US Illinois CC 1985-87 All 15038 No
KHUDER [396] US Philadelphia 15 hospital CC 1985-87 All,Sq,Ad 482 Yes
KIHARA [397] [398] Japan Kanagawa genetic CC 1991-98 All,Sq,Ad 440 No
KINLEN [399] UK tea drinking cohort 1967-86 All 718 No
KJUUS [400] [401,402] Norway Telemark and Vestfold CC 1979-83 All 176 No
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Table 2 Selected details of the 287 studies of lung cancer (Continued)
KNEKT [403] [404-407] Finland Mobile Clinic Health cohort 1966-91 All 515 No
KO [408] Taiwan Kaohsiung CC 1992-93 All 117 Yes
KOHLME [409] Germany Berlin pet birds CC 1990 All 239 No
KOO [410] [411-414] Hong Kong 8 hospital CC 1981-83 All,Sq,Ad 200 No
KOULUM [415] Finland Helsinki CC 1936-52 All 812 No
KREUZE [416] [417,418] Germany radon CC 1990-96 All 2260 No BOFFET
KREYBE [419] [420,421] Norway CC 1948-53 All,Sq,Ad 300 Yes
KUBIK [422] [423] Czechoslovakia Kolin district cohort 1965-71 All 108 No
LAMTH [424] [411] Hong Kong 8 hospital CC 1983-86 All,Sq,Ad 445 No
LAMWK [425] [411] Hong Kong Queen Mary Hospital CC 1981-84 All,Sq,Ad 163 No
LAMWK2 [426] [132,413] Hong Kong Queen Mary Hospital CC 1976-80 All,Sq,Ad 480 No
LANGE [427] [428-430] Denmark Copenhagen City Heart cohort 1976-89 All 268 No
LAURIL [431] [432,433] Finland ATBC nested CC 1988-93 All 230 No
LAUSSM [434] Germany Aue/Saxony uranium miners CC 1982-89 All 432 No
LEI [435] China Guangzhou CC 1986 All 792 No
LEMARC [436] US Hawaii Oahu genotyping CC 1992-97 All 341 Yes
LETOUR [437] Canada Winnipeg radon CC 1983-90 All 738 Yes
LEVIN [438] [302,439,440] US Roswell Park Memorial CC 1938-52 All 475 No
LIAW [441] Taiwan 12 township cohort 1982-94 All 127 No
LICKIN [442] [443,444] Germany West CC All 224 No
LIDDEL [445] [446-449] Canada Quebec chrysotile mine cohort 1970-88 All 304 No
LIU [450] China Shun Yi CC 1980-86 All 229 No
LIU2 [451] China Guangzhou CC 1983-84 All 316 No
LIU3 [452] [137,453,454] China Xuanwei farmers CC 1985-86 All 110 No
LIU4 [455] China million deaths 1986-88 All 100000 No
LIU5 [456] [137] China Wuhan CC 1978-79 All 111 No
LOMBA2 [457] [458] US Boston CC 1960-67 All,Sq,Ad 225 No
LOMBAR [458] [457,459] US Boston CC 1951-64 All 1040 No
LUBIN [460] [460-462] China Yunnan tin miners CC 1984-88 All,Sq,Ad 427 No XIANGZ
LUBIN2 [463] [464-469] West Europe CC 1976-80 All,Sq,Ad 7804 Yes
LUO [470] China Fuzhou CC 1990-91 All,Sq,Ad 102 Yes
MACLEN [471] Singapore CC 1972-73 All 233 No
MAGNUS [472] [473] Norway nickel workers cohort 1953-93 All 203 No
MARSH [474] US Arizona 6 smelter town CC 1979-90 All 150 No
MARSH2 [475] US Arizona 4 smelter town CC 1979-90 All 114 No
MARTIS [476] UK Tyneside asbestos CC 1972-73 All 201 No
MASTRA [477] Italy silica CC 1973-80 All 309 No
MATOS [478] Argentina Buenos Aires CC 1994-96 All,Sq,Ad 200 No
MATSUD [479] [330] Japan Osaka CC 1965 All,Sq,Ad 179 No
MCCONN [480] UK Liverpool CC 1946-49 All 100 Yes
MCDUFF [481] Canada Saskatchewan CC 1979-83 All 165 No
MCLAUG [482] China 5 region silica workers CC 1972-89 All 316 No
MIGRAN [483] [484,485] UK British part of migrant cohort 1964-77 All 259 No
MILLER [486] US Erie County CC 1972-84 All 168 No
MILLS [487] US Ohio CC 1940-47 All 444 No
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Table 2 Selected details of the 287 studies of lung cancer (Continued)
MOLLO [488] Italy Turin CC 1982-92 All,Sq,Ad 145 Yes
MRFIT [489] [490] US MRFIT initial screening cohort 1973-82 All 2004 No
MRFITR [489] [490-492] US MRFIT randomized subjects cohort 1973-85 All 119 No MRFIT
MURATA [493] Japan Chiba gastric screen nested CC 1984-93 All 107 No
MZILEN [494] South Africa Northern Province black people CC All 374 No
NAM [495] US National Mortality Followback 1986 All 1199 No
NOTAN2 [496] [497] India Tata Memorial Hospital CC 1963-71 All 683 No
NOTANI [498] India Tata Memorial Hospital CC 1986-90 All 246 No
NOU [499] Sweden Uppsala CC 1971-76 All,Sq,Ad 273 No
ODRISC [500] [501] UK Salford Bronchoscopy Database CC All 446 No
ORMOS [502] Hungary Szeged CC 1947-59 All,Sq,Ad 119 Yes
OSANN [503] US Orange Co. Cancer Surveillance CC 1984-86 All,Sq,Ad 1986 No
OSANN2 [504] [505] US California Kaiser nested CC 1969-77 All,Sq,Ad 217 Yes KAISER
PARKIN [506] Zimbabwe-Rhodesia Bulawayo CC 1963-77 All 877 No
PASTOR [507] Italy Lombardy CC 1976-79 All 204 No
PAWLEG [508] Poland Cracow CC 1992-94 All 176 Yes
PERNU [509] Finland CC 1944-58 All 1606 No
PERSH2 [510] Sweden 109 municipality CC 1980-84 All 1022 No
PETO [511] UK FEV cohort 1954-81 All 103 No
PEZZO2 [512] Argentina Rosario CC 1992-98 All 367 Yes
PEZZOT [513] Argentina Rosario CC 1987-91 All,Sq,Ad 215 Yes
PIKE [514] US California LA County air poll. CC 1972-75 All 731 No
PISANI [515] [87] Italy Lombardy diet CC 1980-81 All 417 No LUBIN2
POFFIJ [516] [517] West Europe Ardennes-Eifel radon CC 1990-95 All 971 No
POLEDN [518] US Toxic waste dumpsite CC 1978-81 All 209 No
PRESCO [519] [520] Denmark 3 Copenhagen cohort studies pooled 1964-93 All,Sq,Ad 867 No HEIN, LANGE
QIAO [521] [522,523] China Yunnan tin miners CC 1985 All 107 No XIANGZ
QIAO2 [524] China Yunnan tin miners cohort 1992-95 All 241 No
RACHTA [525] Poland Cracow CC 1991-94 All 118 Yes
RADZIK [526] Poland lung cancer relatives CC 1986-87 All 189 No
RANDIG [527] Germany Berlin CC 1951-54 All 448 No
REN [137] China CC All 244 No
RESTRE [528] Colombia CC 1978-80 All 102 No
RIMING [529] UK Mass radiography cohort 1970-76 All 104 No
RONCO [530] Italy Turin CC 1976-80 All 126 No
ROOTS [531] Germany Berlin debrisoquine CC All 270 Yes CASCOR
ROTHSC [532] US Southern Louisiana CC 1971-77 All 284 No
SAARIK [533] Finland genetics CC 1988-96 All,Sq,Ad 205 Yes
SADOWS [534] US National Cancer Institute CC 1938-43 All 477 No
SANKAR [535] India Trivandrum diet CC 1990 All 281 No
SCHWAR [536] [537] US Michigan CC 1984-87 All,Sq,Ad 5588 Yes
SEGI [538] Japan nationwide CC 1948-52 All 159 No
SEGI2 [539] Japan Tokyo and Sendai CC 1962-70 All,Sq,Ad 378 No
SEOW [540] Singapore NAT2 CC 1997-98 All,Sq,Ad 153 Yes
SHAW [541] US & Canada Bethesda/Quebec debrisoquine CC 1988-92 All 335 Yes
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Table 2 Selected details of the 287 studies of lung cancer (Continued)
SHIMIZ [542] Japan Sendai Kosei Hospital CC 1977-82 All,Sq,Ad 751 No
SIEMIA [543] [544-547] Canada Montreal occupational CC 1979-85 All,Sq,Ad 857 Yes
SIMARA [548] Thailand Chiang Mai CC 1971-72 All 115 No
SITAS [549] South Africa Johannesburg black people CC −1997 All * No
SOBUE [550] [551,552] Japan Osaka CC 1986-88 All,Sq,Ad 1376 Yes
SOBUE2 [553] Japan Osaka CC 1965-83 All,Sq,Ad 2083 No
SPEIZE [554] [555] US Nurses' Health cohort 1976-92 All 593 Yes
SPITZ [556] [557-566] US Texas University Genetics All 177 Yes
STASZE [567] Poland Gliwice CC 1954-58 All,Sq,Ad 281 Yes
STAYNE [568] [569] US Third National Cancer Survey CC 1969-71 All,Sq,Ad 420 No
STOCKS [570] [571,572] UK British Empire Cancer Campaign CC 1952-55 All 2932 No
STOCKW [573] US Florida phosphate mining area CC 1981-83 All 22161 No
STUCKE [574] France GSTM1 CC 1989-92 All 247 Yes
SUN [575] China Liaoning genetics CC 1992-94 All 207 Yes
SUZUK2 [576] [577] Brazil Rio de Janeiro CC 1991-92 All,Sq,Ad 123 Yes
SUZUKI [578] Japan Osaka CC 1978-86 Ad 238 Yes
SVENSS [579] [580,581] Sweden Stockholm County CC 1983-86 All,Sq,Ad 210 No
TANG [582] [583] US Columbia Presbyterian genetics CC All 119 Yes
TANG2 [584] UK 4 cohort studies pooled 1967-90 All 836 No BENSHL,
HOLE, WALD
TAO [585] China Shanghai CC 1988-90 All 723 No
TENKAN [586] [587-591] Finland part Finland/Norway cohort 1962-87 All 242 No
TIZZAN [592] Italy CC 1959-61 All,Sq,Ad 1358 No
TOKARS [593] [594-597] Russia Nuclear Workers nested CC 1966-91 All,Sq,Ad 162 Yes
TOUSEY [598] US Duval County CC 1993-96 All 507 Yes
TSUGAN [599] Japan National Cancer Centre CC 1976-85 All,Sq,Ad 134 Yes
TULINI [600] Iceland Rejkjavik cohort 1967-95 All 472 No
TVERDA [601] Norway cohort 1972-88 All 238 No
ULMER [602] Germany Bochum CC 1971-75 All 726 No
VEIERO [603] Norway Health Screening cohort 1977-91 All 153 No TVERDA
VUTUC [604] [604-620] Austria CC 1976-80 All,Sq,Ad 1877 No LUBIN2
WAKAI [621] Japan Okinawa CC 1988-91 All,Sq,Ad 333 Yes
WALD [622] UK BUPA cohort 1975-93 All 102 No
WANG [623] China Guangdong CC 1990-93 All,Sq,Ad 390 Yes
WANG2 [624] [137,139] China Tai Yuan CC 1980-82 All 103 No
WANG3 [137] [139,625] China Nanjing CC All 293 No
WANG4 [626] China Xuanwei farmers cohort 1976-96 All 1170 No
WARSIN [442] Netherlands CC All 134 No
WATSON [627] [628] US New York Memorial Hospital CC 1950-52 All 301 Yes
WICKLU [629] US Washington County orchardists CC 1968-80 All 155 No
WIGLE [630] Canada Alberta CC 1971-73 All 728 No
WILKIN [631] UK London Chest Hospital CC 1992-93 All 271 No
WU [632] US California LA County CC 1981-82 All,Sq,Ad 220 Yes
WU2 [633] US California LA County CC 1983-86 Ad 336 Yes
WUNSCH [634] [635] Brazil Sao Paulo CC study 1990-91 All 398 No
WUWILL [636] [137,139,637-640] China Shenyang and Harbin CC study 1985-87 All,Sq,Ad 965 No
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Table 2 Selected details of the 287 studies of lung cancer (Continued)
WYNDE2 [641] [642-644] US New York CC study 1962-64 All,Sq,Ad 404 Yes
WYNDE3 [645] US New York Memorial CC study 1966-69 All,Sq,Ad 350 Yes
WYNDE4 [2] [646] US 8 state CC study 1948-50 All,Sq,Ad 684 No
WYNDE5 [647] [648] US 4 city CC study 1969-76 All,Sq,Ad 1365 Yes WYNDE6
WYNDE6l [649] [644,650-677] US 4 city CC study 1969-96 All,Sq,Ad 4423 Yes
WYNDE7 [676] US 6 city CC study 1977-84 All,Sq,Ad 2085 Yes WYNDE6
WYNDE8 [677] US 4 city CC study 1985-90 All,Sq,Ad 1044 Yes WYNDE6
WYNDER [678] Cuba Havana CC study 1956-57 All 120 No
XIANGZ [679] China Yunnan tin miners cohort study 1976-87 All 983 No
XU [637] [137,139,638,639] China Shenyang CC study 1985-87 All,Sq,Ad 729 No
XU2 [680] [639] China Anshan Iron-Steel workers CC study 1987-93 All 610 No
XU3 [681] [137] China Tianjin CC study 1981 All, Sq, Ad 135 No
XU4 [137] [682] China 26 city air pollution CC study All 206 No
YAMAGU [683] Japan occupational CC study 1989-90 All 144 Yes
YONG [684] [260] US NHANES I - NHEFS cohort study 1971-92 All 216 No
YUAN [685] China Shanghai cohort study 1986-93 All 142 No
ZHANG [686] [137] China Jinzhou CC study 1988-89 All 100 No
ZHENG [687] [137,139,688] China Shanghai CC study 1982-84 All,Sq,Ad 540 Yes
ZHOU [689] China Medical Univ CC study 1978-94 All,Sq,Ad 1360 No
a CC = case–control, date range for cohort study is from start at baseline interview to end of follow-up.
b Indicates whether the study provided data for all lung cancer (All), squamous cell carcinoma (Sq) or adenocarcinoma (Ad), or a near equivalent definition
(see Methods).
c Number of lung cancer cases.
d Whether or not full histological confirmation of cases was carried out.
e For subsidiary studies, this column shows the relevant principal study.
f Additional sources were two unpublished reports made available by personal communication from P N Lee.
g Additional sources were two unpublished reports made available by personal communication from Dr E C Hammond.
h An additional source was an unpublished report made available by personal communication from Dr G Dean.
i An additional source was an unpublished report made available by personal communication from Dr J Peto.
j An additional source was an unpublished report made available by personal communication from Dr T Hirayama.
k An additional source was an unpublished report made available by personal communication from Dr V Hawthorne.
l An additional source was an unpublished report made available by personal communication from Dr G C Kabat.
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are from blended tobaccos. Forty seven (17.6%) started
before 1960. Studies starting after 1979 were predomin-
antly (92.4%) case–control. Thirty-six (13.5%) involved
at least 1,000 lung cancer cases. Seven (2.6%) were con-
ducted in miners, with a further 11 (4.1%) conducted in
other occupational groups with a known relationship
with lung cancer. Proxy respondents were used for some
subjects in 74 (27.7%), with full histological confirmation
of cases reported to be carried out in 68 (25.5%).
Most study groups (i.e. a principal study or one of its
subsidiaries) provide some results for the major indices
compared to never smokers, 240 (89.9%) for ever smo-
kers, 134 (50.2%) for current smokers and 127 (47.6%)
for ex smokers. Many studies provide results for smok-
ing of any product (162 studies, 60.7%) or for cigarettes
(147, 55.1%), but less do so for cigarette only smoking
(55, 20.6%), smoking of pipes/cigars only (62, 23.2%),
mixed smoking (29, 10.9%), or for the cigarette typeindices filter/plain cigarette smoking (38, 14.2%), hand-
rolled cigarette smoking (15, 5.6%), or mentholated
cigarette smoking (3, 1.1%). Though dose–response data
are most commonly available by amount smoked (162,
60.7%), many studies provide data by age of starting
to smoke (62, 23.2%), duration (77, 28.8%), and time
quit (58, 21.7%). Few studies provide data on tar level
(11 studies, 4.1%), fraction smoked (9 studies, 3.4%),
or butt length (2 studies, 0.7%).
Relative risks
A total of 16,616 RRs were entered, the number
recorded per study varying from 1 to 1,029. Of these,
1,266 relate to subsidiary studies. Table 4 summarizes
the distribution of various characteristics of the RRs by
outcome, sex, study type and location.
Of the total of 16,616 RRs, 71.9% relate to case–
control studies, and 93.8% are sex-specific. 40.2% come
from North American studies, 36.8% from Europe, 16.7%
Table 3 Distribution of the main characteristics of the 287 studies of lung cancer
Characteristic Level Principal studies Subsidiary studies All studies
Outcomea Study typeb Total Total
All Squamous Adeno CC prosp Total
Study status Principal 262 84 86 209 58 267 - 267
Subsidiary (19) (12) (12) (15) (5) (20) 20 20
Study type Case–control 204 73 75 209 - 209 15 224
Prospective 52 9 9 - 52 52 4 56
Other 6 2 2 - 6 6 1 7
Study sex Both 154 53 54 133 25 158 11 169
Male 90 19 19 59 31 90 8 98
Female 18 12 13 17 2 19 1 20
Lowest agec <20 or unlimited 177 56 57 165 16 181 13 194
20-29 15 3 3 9 6 15 2 17
30-39 39 15 16 26 14 40 5 45
40+ 31 10 10 9 22 31 0 31
Highest age <60 16 2 2 10 6 16 3 19
60-69 21 6 6 6 15 21 1 22
70-79 29 11 12 23 7 30 3 33
80+ or unlimited 196 65 66 170 30 200 13 213
Location North America 87 29 31 63 26 89 6 95
United Kingdom 22 2 2 13 9 22 2 24
Scandinavia 25 6 6 14 11 25 2 27
Other Europe 42 13 12 39 4 43 7 50
China 37 10 10 34 3 37 2 39
Japan 17 8 9 15 3 18 1 19
Other Asia 16 10 10 16 1 17 0 17
Other 16 6 6 15 1 16 0 16
Start year of study <1960 47 12 12 33 14 47 1 48
1960-69 40 13 13 21 19 40 6 46
1970-79 59 17 19 45 16 61 7 68
1980-89 83 33 33 78 8 86 5 91
1990+ 33 9 9 32 1 33 1 34
Number of casesd 100-249 109 25 26 84 28 112 5 117
250-499 70 25 26 57 15 72 3 75
500-999 47 14 14 38 9 47 3 50
1000+ 36 20 20 30 6 36 9 45
Risky occupational population No 244 83 85 203 46 249 18 267
Mining 7 0 0 0 7 7 2 9
Other risky 11 1 1 6 5 11 0 11
National cigarette tobacco type Virginia 42 6 6 30 12 42 2 44
Blended 180 66 68 142 42 184 16 200
Othere 40 12 12 37 4 41 2 43
Any proxy use None/unknown 189 66 67 137 56 193 17 210
Yes 73 18 19 72 2 74 3 77
Full histological confirmation No 199 49 49 145 54 199 12 211
Yes 63 35 37 64 4 68 8 76
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Table 3 Distribution of the main characteristics of the 287 studies of lung cancer (Continued)
Main outcome(s)a All 262 82 82 204 58 262 19 281
Squamous 82 84 83 73 11 84 12 96
Adeno 82 83 86 75 11 86 12 98
All only 180 - - 133 47 180 8 188
Squamous only - 1 - 1 0 1 0 1
Adeno only - - 3 3 0 3 0 3
more than one 82 83 83 72 11 83 12 95
a Indicates whether the study provided data for all lung cancer, squamous cell carcinoma or adenocarcinoma, or their near equivalent definitions (see Methods).
For squamous, the near equivalent definitions included are: Kreyberg I; squamous cell or small carcinoma; squamous cell or undifferentiated carcinoma; and not
adenocarcinoma. For adeno, the near equivalent definitions included are: Kreyberg II; adenocarcinoma or large cell carcinoma; adenocarcinoma, alveolar or
bronchioloalveolar carcinoma; not squamous cell or small cell carcinoma; and not squamous cell or undifferentiated carcinoma.
b CC= case–control, prosp = prospective.
c At start of study.
d In study as a whole.
e Indicates China and Taiwan.
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unadjusted for potential confounding variables and
18.7% are adjusted for sex and/or age only. 70.1% are
given directly or are calculated by standard methods, the
rest being derived by more complex methods.
Of the total RRs, 5,061 relate to the major smoking
indices, where the denominator is never or non smok-
ing, with 3,614 of these relating to smoking of any prod-
uct or cigarettes (regardless of pipe or cigar smoking),
678 to cigarette only smoking and 769 to pipe, cigar or
mixed smoking. Four hundred and forty-eight relate to
cigarette type comparisons, most commonly (303 RRs)
to the filter vs. plain comparison. All the 25 RRs for the
mentholated/non-mentholated comparison come from
North American studies, while none of those for the
handrolled/manufactured comparison do. There are
10,921 RRs for dose-related indices, based mainly on
3,625 sets, 2,047 vs. never or non smoking, 1,327 vs. the
low level, and 251 vs. current smoking. There are most
sets for amount smoked (1,145) and least for butt length
(5). For amount smoked, age of starting, duration of
smoking, years quit (vs. never and vs. current) there are
sufficient numbers of dose–response sets to study vari-
ation in RR by sex, study type and continent.
None of the RRs included in the meta-analyses and
meta-regressions show more than minor failures of the
validation tests used, attributable to rounding errors or
small imprecisions or uncertainties in estimating the RRs
and CIs. Additional file 3: RRs provides further detail.
For dose-related indices, Additional file 4: Dose Not
Meta gives results originally presented in forms unsuit-
able for meta-analysis.
The meta-analyses and meta-regressions
The main findings are summarized in the following sec-
tions, with tables and forest plots. Additional file 5: Detailed
Analysis Tables fully presents all the meta-analyses and
meta-regressions conducted. The interested reader shouldfirst see Additional file 1: Methods, which lists the other
files, and describes their content and structure.
Findings are generally presented for three outcomes,
referred to as “all lung cancer”, “squamous” or “adeno”.
These outcomes are defined in the Methods section, and
also in the footnotes to the tables, and allow the inclu-
sion of results based on alternative similar definitions.
(Note that the terms “squamous cell carcinoma” and
“adenocarcinoma” are only used when reference is made
to results specifically for the particular cell type).
A. Risk from ever smoking
Figures 1, 2, 3, 4 and 5 (all lung cancer), Figures 6, 7
(squamous) and Figure 8, 9 (adeno) present the results
of the main meta-analyses for ever smoking any product
(or cigarette smoking for studies without RRs for any
product), based on most-adjusted RRs. Table 5 presents
additional results subdivided by level of certain charac-
teristics, while Table 6 presents results of some alterna-
tive meta-analyses of ever smoking. From these findings,
various observations can be made.
First, the RRs for all three outcomes are markedly het-
erogeneous. As shown in Table 5, H is estimated as
22.84 for all lung cancer, 5.17 for squamous and 8.78
for adeno (p < 0.001). Individual RRs vary up to 125.27
for all lung cancer (study STUCKE for males), 92.66 for
squamous (ABRAHA/males), and 34.45 for adeno
(SCHWAR/males). Based on random-effects estimates, a
positive association is seen, strongest for squamous (RR
10.47, 95% CI 8.88-12.33, based on 102 RRs), but also
clearly evident for all lung cancer (5.50, 5.07-5.96,
n = 328) and adeno (2.84, 2.41-3.35, n = 107). Although
the strength of association varies markedly by study, the
consistency of direction is clear, with only two of the all
lung cancer RRs, none of the 102 squamous RRs, and
nine of the 107 adeno RRs below 1.0.
As shown in Table 6, the overall estimates for each out-
come were virtually unchanged by using least-adjusted
Table 4 Distribution of the main characteristics of the relative risksa
Smoking indexb Dose response RRsb,c Total Principald By lung cancer typea By sex
All Squamous Adeno Combined Male Female
All 16616 15350 11316 2268 1698 1031 11202 4383
Any product or
cigarettes vs. never/non
3614 3366 2359 488 432 342 2065 1207
Cig only smoking vs.
never/non
678 621 535 72 56 18 513 147
Pipe/Cigar/Mixed vs.
never/non
769 678 644 61 53 22 717 30
Handrolled vs.
manufactured
120 104 74 22 14 8 93 19
Filter vs. Plain 303 264 167 74 37 9 182 112
Menthol vs. non-menthol 25 16 20 2 1 5 10 10
Amount smoked All RRs 3627 3509 2708 412 310 198 2459 970
Sets vs. never/non 1145 1104 858 123 100 64 741 340
Age of starting All RRs 1442 1344 1052 167 128 67 970 405
Sets vs. never/non 256 242 188 29 24 13 159 84
Sets vs. low 301 285 197 44 35 14 196 91
Non-categorical RRs 14 14 6 2 2 2 7 5
Duration of smoking All RRs 2337 2129 1544 342 240 202 1470 665
Sets vs. never/non 374 337 248 54 40 37 221 116
Sets vs. low 434 384 261 75 56 38 260 136
Non-categorical RRs 72 70 32 19 20 1 39 32
Years quit (vs. never) All RRs 1665 1504 991 276 198 64 1241 360
Sets vs. never/non 207 194 124 35 26 11 146 50
Sets vs. low 255 234 157 39 27 8 190 57
Non-categorical RRs 3 3 3 0 0 2 1 0
Years quit (vs. current) All RRs 1421 1248 867 221 145 55 1076 290
Sets vs. current 251 231 155 38 25 11 183 57
Sets vs. low 244 223 158 33 23 10 177 57
Non-categorical RRs 0 0 0 0 0 0 0 0
Tar All RRs 222 198 156 33 33 18 127 77
Sets vs. never/non 22 18 16 3 3 4 13 5
Sets vs. low 41 36 33 4 4 3 24 14
Non-categorical RRs 55 55 19 18 18 0 27 28
Butt length All RRs 15 15 15 0 0 0 6 9
Sets vs. never/non 3 3 3 0 0 0 1 2
Sets vs. low 2 2 2 0 0 0 1 1
Non-categorical RRs 2 2 2 0 0 0 1 1
Fraction smoked All RRs 192 192 42 70 40 5 140 47
Sets vs. never/non 40 40 10 14 8 1 29 10
Sets vs. low 50 50 12 18 10 1 34 15
Non-categorical RRs 0 0 0 0 0 0 0 0
Lung cancer type
(near equivalent definitions)a
All 11316 10553 11316 0 0 760 7700 2856
Squamous 2268 2038 0 2268 0 113 1538 617
Adeno 1698 1532 0 0 1698 68 1098 532
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Table 4 Distribution of the main characteristics of the relative risksa (Continued)
Lung cancer type
(exact definitions)
All lung cancer 10980 10247 10980 0 0 671 7571 2738
Squamous cell carcinoma 1064 1004 0 1064 0 66 710 288
Adenocarcinoma 1172 1112 0 0 1172 64 726 382
Large cell carcinoma 393 392 0 0 0 13 266 114
Small cell carcinoma 718 662 0 0 0 29 497 192
Other 223 173 0 0 0 48 103 72
Adjustment None 10113 9266 6740 1362 1086 651 6613 2849
Sex and/or age only 3099 3053 2423 264 234 132 2307 660
Other (but not sex or age) 701 686 442 142 63 51 418 232
Sex and/or age plus other 2703 2345 1711 365 315 197 1864 642
Derivation Original 1853 1705 1088 261 254 163 1157 533
Standard calculations 9803 8983 6701 1371 996 663 6376 2764
Other methods 4960 4662 3527 638 448 205 3669 1086
Continent Study type
Total North America Europe Asia Other Case–control Other
All 16616 6676 6122 2770 1048 11945 4671
Any product or cigarettes vs.
never/non
3614 1493 1163 771 187 2716 898
Cigarette only smoking vs.
never/non
678 284 340 27 27 345 333
Pipe/Cigar/Mixed vs.
never/non
769 380 327 39 23 428 341
Handrolled vs. manufactured 120 0 68 30 22 90 30
Filter vs. Plain 303 74 178 27 24 268 35
Menthol vs. non-menthol 25 25 0 0 0 13 12
Amount smoked All RRs 3627 1601 1288 612 126 2240 1387
Sets vs. never/non 1145 507 404 189 45 712 433
Age of starting All RRs 1442 496 512 301 133 1017 425
Sets vs. never/non 256 82 93 58 23 186 70
Sets vs. low 301 93 105 71 32 224 77
Non-categorical RRs 14 10 1 3 0 14 0
Duration of smoking All RRs 2337 939 706 462 230 1816 521
Sets vs. never/non 374 148 111 80 35 287 87
Sets vs. low 434 154 141 94 45 353 81
Non-categorical RRs 72 60 9 3 0 70 2
Years quit (vs. never) All RRs 1665 668 657 196 144 1339 326
Sets vs. never/non 207 89 75 23 20 170 37
Sets vs. low 255 86 111 33 25 208 47
Non-categorical RRs 3 3 0 0 0 3 0
Years quit (vs. current) All RRs 1421 457 674 177 113 1155 266
Sets vs. current 251 76 112 36 27 213 38
Sets vs. low 244 84 102 31 27 198 46
Non-categorical RRs 0 0 0 0 0 0 0
Tar All RRs 222 158 64 0 0 182 40
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Table 4 Distribution of the main characteristics of the relative risksa (Continued)
Sets vs. never/non 22 16 6 0 0 19 3
Sets vs. low 41 25 16 0 0 26 15
Non-categorical RRs 55 55 0 0 0 54 1
Butt length All RRs 15 0 13 0 2 15 0
Sets vs. never/non 3 0 3 0 0 3 0
Sets vs. low 2 0 2 0 0 2 0
Non-categorical RRs 2 0 0 0 2 2 0
Fraction smoked All RRs 192 32 56 99 5 190 2
Sets vs. never/non 40 10 8 21 1 40 0
Sets vs. low 50 12 16 21 1 48 2
Non-categorical RRs 0 0 0 0 0 0 0
Lung cancer type
(near equivalent)a
All 11316 4879 3955 1765 717 6942 4374
Squamous 2268 773 931 445 119 2131 137
Adeno 1698 615 618 346 119 1601 97
Lung cancer type
(exact definitions)
All lung cancer 10980 4654 3923 1686 717 6608 4372
Squamous carcinoma 1064 205 433 307 119 1008 56
Adenocarcinoma 1172 308 435 310 119 1097 75
Large cell carcinoma 393 208 94 88 3 379 14
Small cell carcinoma 718 148 427 108 35 669 49
Other 223 53 97 18 55 223 0
Adjustment None 10113 4105 3489 1847 672 8126 1987
Sex and/or age only 3099 1515 1153 399 32 1216 1883
Other (but not sex or age) 701 177 409 79 36 579 122
Sex and/or age plus other 2703 879 1071 445 308 2024 679
Derivation Original 1853 649 649 379 176 1436 417
Standard calculations 9803 3865 3519 1811 608 7703 2100
Other methods 4960 2162 1954 580 264 2806 2154
a RRs relating to all lung cancer (all), squamous cell carcinoma (squamous) or adenocarcinoma (adeno) or to a near equivalent definition.
b “never/non” indicates never smoker or non smoker.
c Sets are dose response results for an identical definition of smoking product, strata and confounding variables. Sets vs. low are sets where the RR has been
calculated compared to the level with the lowest expected risk, i.e. the smallest amount smoked, or the latest age of starting. Non-categorical RRs are typically
where RRs and CIs are not available, but some other information was provided.
d RRs from principal studies.
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increased by restricting attention to estimates using a
more precise outcome definition, the random-effects esti-
mates changing to 5.59 (5.15-6.07) for the 317 estimates
specifically for all lung cancer, 11.56 (9.68-13.81) for the
74 estimates specifically for squamous cell carcinoma,
and 2.99 (2.49-3.58) for the 87 estimates specifically for
adenocarcinoma. The overall estimates for each outcome
were virtually unchanged when RRs for ever smoking
cigarettes were preferred to RRs for ever smoking any
product. This is partly due to many studies providing only
one type of RR, so that for all lung cancer, for example,
250 of the 328 RRs are common to both meta-analyses.
A much smaller number of estimates were available forcigarette only smoking; RRs from these were slightly
higher: 6.45 (5.41-7.70, n= 54) for all lung cancer, 11.50
(7.47-17.69, n = 11) for squamous, and 2.87 (1.49-5.55,
n = 11) for adeno. Estimates were also extracted specific-
ally for populations of age <56, 50–70 or 65+ years (with
age determined at baseline for prospective studies). As
shown in Table 6, data were rather limited for squamous
and adeno, particularly for older populations. For all lung
cancer, the three RRs: 6.57 (4.94-8.74, n= 38) for age
<56 years, 6.46 (4.99-8.35, n=31) for age 50–70 years,
and 5.48 (4.59-6.55, n=37) for age 65+ years were all con-
sistent with the overall RR of 5.50, with no clear trend.
Returning to the main meta-analysis (most-adjusted
and preferring ever smoking any product), there is a
0.20 0.40 1.00 25.00 50.00
CONT START REF SEX Relative RiskRelative Risk
95% CI95% CI
)29.6,14.3(68.4N AMERICA 1938 LEVIN m
)03.7,18.1(36.3mSWODAS8391
          1940 CHIAZZ m 26.17 (3.32, 206.50)
          1940 MILLS m 1.33 (1.09, 1.63)
          1948 WYNDE4 m 9.11 (4.98, 16.67)
          1948 WYNDE4 f 2.87 (1.48, 5.55)
          1949 BRESLO m 6.47 (2.88, 14.54)
          1949 BRESLO f 1.38 (0.45, 4.20)
          1950 ARCHER m 6.33 (2.80, 14.33)
          1951 BOUCOT m 40.95 (2.55, 658.45)
          1951 LOMBAR m 8.84 (5.04, 15.53)
          1952 HAMMON m 6.80 (4.06, 11.37)
          1954 DORN m 7.04 (5.60, 8.84)
          1954 DUNN m 18.43 (4.56, 74.42)
          1955 BEST m 25.46 (3.57, 181.46)
          1955 BEST f 2.24 (0.59, 8.44)
          1955 HAENSZ f 2.19 (1.48, 3.24)
          1956 GRAHAM m 7.01 (4.39, 11.20)
          1956 HOROWI m 3.58 (2.17, 5.90)
          1956 HOROWI f 1.82 (0.91, 3.62)
)82.51,72.2(98.5mUDNAMA9591
          1959 AMES m 4.89 (2.72, 8.81)
          1959 CPSI m 9.18 (7.36, 11.45)
          1959 CPSI f 2.79 (2.22, 3.51)
          1960 BROSS m 5.15 (3.57, 7.41)
          1960 LOMBA2 f 1.33 (0.96, 1.83)
          1962 WYNDE2 m 8.44 (4.07, 17.51)
)69.52,89.11(36.71mRESIAK4691
          1964 KAISER f 5.63 (3.89, 8.14)
          1965 CHYOU m 8.35 (4.76, 14.64)
          1966 CHOW m 11.08 (4.87, 25.21)
          1966 GODLEY m 6.84 (5.60, 8.35)
          1966 GODLEY f 5.54 (4.29, 7.15)
          1966 WYNDE3 m 8.10 (4.00, 16.38)
          1966 WYNDE3 f 3.12 (1.67, 5.85)
          1967 HAMMO2 m 22.82 (3.20, 162.75)
          1968 HINDS f 5.65 (4.14, 7.72)
          1968 WICKLU m 4.60 (2.80, 7.60)
          1969 STAYNE m 3.67 (2.69, 4.99)
          1969 WYNDE6 m 10.03 (7.96, 12.65)
          1969 WYNDE6 f 10.40 (8.58, 12.60)
          1970 AUSTIN c 11.12 (3.95, 31.28)
          1970 LIDDEL m 3.61 (2.27, 5.73)
          1971 ROTHSC c 5.55 (2.97, 10.37)
          1971 WIGLE m 8.80 (5.15, 15.02)
          1971 WIGLE f 4.40 (2.88, 6.73)
          1971 YONG c 6.74 (4.47, 10.18)
          1972 CHANG m 5.20 (2.12, 12.77)
          1972 CHANG f 3.68 (1.90, 7.10)
          1972 MILLER f 4.99 (2.06, 12.10)
          1972 PIKE m 5.25 (3.08, 8.98)
          1972 PIKE f 4.83 (3.04, 7.66)
)59.846,15.2(73.04mRTIFRM3791
          1974 BLOT4 m 14.51 (6.91, 30.51)
)60.11,66.1(92.4cREKCOD4791
          1975 COMSTO m 10.82 (3.87, 30.24)
          1975 COMSTO f 8.95 (4.69, 17.06)
          1976 BUFFLE m 10.54 (4.15, 26.76)
          1976 BUFFLE f 7.12 (4.93, 10.30)
          1976 SPEIZE f 7.08 (5.40, 9.28)
          1977 HORWIT f 11.31 (5.73, 22.34)
          1978 POLEDN c 9.24 (5.23, 16.33)
)00.51,07.8(04.11cAERROC9791
          1979 KAISE2 m 5.40 (3.05, 9.57)
          1979 KAISE2 f 10.09 (5.29, 19.27)
          1979 MARSH c 6.80 (3.30, 13.99)
          1979 MARSH2 m 1.89 (0.70, 5.14)
Figure 1 Forest plot of ever smoking of any product and all lung cancer – part 1. Table 5 presents the results of a main meta-analysis
for all lung cancer based on 328 relative risk (RR) and 95% confidence interval (CI) estimates for ever smoking of any product (or cigarettes if
any product not available). The individual study estimates are shown numerically and graphically on a logarithmic scale in Figures 1, 2, 3, 4, 5.
The studies are sorted in order of sex within study reference (REF) within start year of study (START) within continent (CONT), with the exception
of study LIU4 shown at the end of Figure 5. In the graphical representation individual RRs are indicated by a solid square, with the area of the
square proportional to the weight (inverse-variance of log RR). Arrows indicate where the CI extends outside the range allocated.
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CONT START REF SEX Relative RiskRelative Risk
95% CI95% CI
          1979 MARSH2 f 5.28 (1.89, 14.72)
          1979 MCDUFF m 6.13 (2.48, 15.14)
          1979 SIEMIA m 12.10 (6.60, 22.30)
)61.71,26.5(28.9mNAGROD0891
)01.67,49.6(99.22mNAGROD0891
          1980 DORGAN f 7.83 (5.96, 10.30)
          1980 DORGAN f 8.36 (3.18, 21.95)
          1980 HUMBLE m 12.10 (5.12, 28.60)
          1980 HUMBLE m 11.88 (2.65, 53.30)
          1980 HUMBLE f 11.36 (5.32, 24.23)
          1980 HUMBLE f 15.40 (4.87, 48.74)
          1981 GARSHI m 5.81 (4.17, 8.10)
          1981 JAIN m 8.30 (4.53, 17.00)
          1981 JAIN f 9.20 (5.95, 15.10)
          1981 KAUFMA c 12.38 (8.59, 17.85)
          1981 STOCKW c 10.45 (9.94, 10.98)
          1981 WU f 3.03 (1.81, 5.07)
          1982 CPSII m 12.83 (10.28, 16.01)
          1982 CPSII f 8.16 (6.93, 9.62)
          1982 HENNEK m 6.24 (4.02, 9.67)
          1983 BAND m 9.96 (7.38, 13.44)
          1983 GOODMA m 10.80 (5.60, 20.82)
          1983 GOODMA f 8.29 (4.74, 14.52)
          1983 LETOUR c 12.96 (8.38, 20.05)
          1984 BROWN2 m 9.10 (8.30, 10.00)
          1984 BROWN2 f 12.70 (11.50, 13.90)
          1984 OSANN m 19.70 (14.40, 26.80)
          1984 OSANN f 15.00 (11.80, 19.10)
          1984 SCHWAR m 8.21 (6.60, 10.22)
          1984 SCHWAR m 6.53 (4.54, 9.39)
          1984 SCHWAR f 9.96 (8.28, 12.00)
          1984 SCHWAR f 11.56 (7.90, 16.90)
)25.11,38.8(90.01mRELLEK5891
)68.91,02.9(25.31mRELLEK5891
          1985 KELLER f 12.49 (11.09, 14.08)
          1985 KELLER f 9.45 (6.91, 12.93)
          1985 KHUDER m 7.86 (5.06, 12.19)
          1986 ANDERS f 13.10 (9.61, 17.87)
          1986 NAM m 8.71 (5.87, 12.93)
          1986 NAM f 8.88 (6.35, 12.40)
          1988 SHAW c 11.85 (6.24, 22.50)
)54.42,29.01(43.61cNAMGEH9891
          1991 CARPEN c 14.88 (8.46, 26.18)
          1992 GARCIA c 8.52 (5.26, 13.80)
          1992 LEMARC c 5.63 (3.74, 8.49)
          1992 SPITZ c 18.39 (8.35, 40.53)
          1992 TANG c 8.08 (3.66, 17.82)
)86.35,81.7(36.91mYESUOT3991
          1993 TOUSEY f 15.68 (8.67, 28.34)
)33.02,08.2(45.7mPURAJ8291EPORUE
)24.61,04.1(97.4mSYEVAD0391
          1930 DAVEYS f 0.72 (0.04, 14.66)
          1936 KOULUM m 35.43 (14.02, 89.55)
          1937 GSELL m 17.74 (4.15, 75.83)
          1941 ABELIN m 35.38 (8.62, 145.24)
          1944 PERNU m 8.93 (6.92, 11.53)
          1944 PERNU f 1.88 (1.11, 3.21)
          1946 MCCONN m 1.21 (0.41, 3.55)
          1946 MCCONN f 2.75 (0.38, 19.67)
          1947 ORMOS m 9.34 (4.30, 20.28)
          1947 ORMOS f 0.19 (0.03, 1.44)
          1948 DOLL m 9.08 (4.14, 19.92)
          1948 DOLL f 2.05 (1.19, 3.53)
          1948 KREYBE m 6.61 (2.93, 14.92)
          1948 KREYBE f 1.43 (0.71, 2.86)
          1951 DOLL2 m 7.66 (4.86, 12.07)
          1951 RANDIG m 5.03 (1.88, 13.41)
          1951 RANDIG f 2.22 (1.02, 4.84)
Figure 2 Forest plot of ever smoking of any product and all lung cancer – part 2. This is a continuation of Figure 1, presenting further
individual study data included in the main meta-analysis for all lung cancer shown in Table 5. For study DORGAN separate estimates, within sex,
are shown for whites then blacks. For study HUMBLE they are shown for non-hispanic whites then hispanics, and for study KELLER for whites
then non-whites.
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CONT START REF SEX Relative RiskRelative Risk
95% CI95% CI
          1952 GOLLED m 7.51 (4.44, 12.71)
          1952 STOCKS m 5.95 (4.23, 8.36)
          1952 STOCKS f 3.04 (2.35, 3.93)
          1953 MAGNUS m 4.13 (1.94, 8.77)
          1954 PETO m 6.15 (1.52, 24.79)
          1954 STASZE m 10.69 (4.34, 26.33)
          1954 STASZE f 4.34 (1.66, 11.35)
          1959 TIZZAN m 1.93 (1.57, 2.36)
          1959 TIZZAN f 4.07 (2.04, 8.13)
)43.9,02.4(62.6cOSLEXA0691
          1960 BRETT m 3.27 (1.45, 7.40)
          1960 DEAN2 m 3.79 (2.54, 5.67)
          1960 DEAN2 f 2.93 (1.76, 4.90)
          1962 TENKAN m 14.64 (6.29, 34.07)
)21.9,58.3(29.5mLREDEC3691
          1963 CEDERL f 4.18 (2.94, 5.93)
)06.31,59.2(43.6mALEGNE4691
          1964 ENGELA f 4.74 (2.20, 10.22)
          1964 MIGRAN m 3.61 (1.34, 9.72)
          1964 MIGRAN f 4.62 (1.63, 13.09)
          1965 KUBIK m 28.12 (6.94, 113.84)
          1966 KNEKT m 6.42 (2.82, 14.62)
          1966 TOKARS c 6.60 (3.20, 13.70)
)13.31,26.2(09.5mLHSNEB7691
          1967 KINLEN m 10.99 (5.24, 23.06)
          1967 TULINI m 7.71 (4.19, 14.18)
          1967 TULINI f 13.01 (7.24, 23.40)
          1968 HANSEN m 1.53 (0.71, 3.91)
          1969 DEAN3 m 6.14 (3.92, 9.61)
          1969 DEAN3 f 4.63 (3.03, 7.09)
          1970 HEIN m 14.62 (2.05, 104.23)
          1971 NOU m 6.09 (2.58, 14.39)
          1971 NOU f 7.09 (2.17, 23.17)
          1972 DAMBER m 7.15 (4.98, 10.26)
          1972 HOLE m 6.44 (3.03, 13.69)
          1972 MARTIS m 7.00 (2.39, 20.49)
          1972 TVERDA m 4.58 (2.97, 7.06)
)00.02,23.3(41.8mARTSAM3791
          1975 ABRAHA m 8.74 (4.66, 16.42)
          1975 ABRAHA f 4.88 (3.13, 7.62)
          1976 GREGOR m 1.03 (0.43, 2.45)
          1976 GREGOR f 11.00 (1.39, 87.29)
          1976 LANGE m 4.74 (1.77, 12.67)
          1976 LANGE f 4.93 (2.48, 9.81)
          1976 LUBIN2 m 8.50 (7.29, 9.91)
          1976 LUBIN2 f 3.90 (3.29, 4.62)
)07.31,83.3(18.6mROTSAP6791
          1976 RONCO m 5.10 (2.16, 12.01)
)16.61,16.5(56.9mSREDLA7791
          1977 ALDERS f 4.75 (3.55, 6.35)
          1978 BLOHMK m 3.10 (2.45, 3.92)
          1979 BARBON m 11.13 (7.02, 17.64)
          1979 DOSEME m 3.30 (2.60, 4.40)
          1979 KJUUS m 13.74 (3.19, 59.08)
)42.31,36.3(39.6mNILEBE0891
          1980 JEDRYC m 5.46 (3.85, 7.73)
          1980 JEDRYC f 4.54 (2.56, 8.05)
)68.7,64.5(55.6c2HSREP0891
          1982 LAUSSM m 5.70 (4.10, 7.80)
          1983 JARVHO m 27.79 (3.59, 215.09)
          1983 JARVHO f 9.57 (3.24, 28.26)
          1983 SVENSS f 6.18 (3.79, 10.07)
          1985 BECHER m 10.82 (3.32, 35.23)
          1985 BECHER f 11.81 (3.20, 43.56)
          1985 CASCOR c 13.52 (8.56, 21.35)
          1986 ARMADA m 19.68 (7.07, 54.75)
          1986 AUVINE c 13.84 (7.90, 24.25)
          1986 DORANT c 18.00 (10.52, 30.78)
Figure 3 Forest plot of ever smoking of any product and all lung cancer – part 3. This is a continuation of Figure 2, presenting further
individual study data included in the main meta-analysis for all lung cancer shown in Table 5.
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          1986 RADZIK c 1.31 (0.55, 3.15)
          1987 CHATZI c 3.34 (2.14, 5.21)
          1987 KATSOU f 3.30 (1.77, 6.15)
          1988 BOFFET m 14.20 (11.70, 17.20)
          1988 DARBY m 49.30 (15.77, 154.07)
          1988 DARBY f 12.26 (7.89, 19.05)
          1988 GARDIN c 11.09 (4.23, 29.06)
          1988 JAHN f 3.30 (1.99, 5.49)
          1989 AGUDO f 3.10 (1.42, 6.75)
)49.31,26.4(20.8mSSLEXA9891
          1989 AXELSS f 8.63 (4.95, 15.05)
          1989 STUCKE m 125.27 (7.68, 2042.38)
          1990 BROCKM m 1.07 (0.15, 7.80)
          1990 BROCKM f 2.00 (0.61, 6.54)
          1990 KOHLME c 16.40 (6.90, 38.42)
          1990 KREUZE f 9.35 (3.63, 24.08)
          1990 KREUZE f 3.78 (2.68, 5.34)
          1990 POFFIJ c 7.75 (5.81, 10.34)
          1991 CASCO2 c 11.48 (4.90, 26.87)
          1991 RACHTA f 8.21 (3.96, 17.05)
          1992 ODRISC c 48.89 (21.71, 110.07)
          1992 PAWLEG m 12.26 (4.07, 36.95)
          1992 WILKIN c 7.83 (4.45, 13.78)
          1995 DROSTE m 8.62 (3.80, 19.56)
ASIA 1948 SEGI m 1.71 (1.03, 2.82)
          1960 HITOSU m 2.91 (1.34, 6.34)
          1960 HITOSU f 3.40 (2.05, 5.64)
          1961 ESAKI m 1.90 (0.99, 3.65)
          1961 ESAKI f 2.46 (1.23, 4.92)
          1963 AKIBA m 4.75 (3.07, 7.34)
          1963 AKIBA f 3.16 (2.37, 4.21)
          1963 NOTAN2 m 2.99 (2.40, 3.72)
          1964 JUSSAW m 16.83 (11.65, 25.21)
          1965 HIRAYA m 4.36 (3.53, 5.39)
          1965 HIRAYA f 2.36 (1.90, 2.94)
          1965 MATSUD m 21.46 (6.84, 67.33)
          1971 SIMARA m 1.65 (0.97, 2.81)
          1971 SIMARA f 1.63 (0.87, 3.06)
          1972 MACLEN c 2.67 (1.66, 4.29)
          1972 MCLAUG m 3.33 (2.12, 5.25)
          1976 CHAN m 27.51 (6.57, 115.26)
          1976 CHAN f 3.48 (2.26, 5.35)
          1976 LAMWK2 m 2.83 (1.64, 4.88)
          1976 LAMWK2 f 3.21 (2.02, 5.10)
          1976 TSUGAN m 1.26 (0.62, 2.54)
          1976 WANG4 m 1.16 (0.96, 1.42)
          1976 XIANGZ m 2.16 (1.46, 3.18)
          1977 HU2 m 3.03 (2.08, 4.41)
          1977 HU2 f 1.88 (1.23, 2.85)
          1978 LIU5 c 1.91 (1.07, 3.44)
          1978 ZHOU m 2.36 (1.48, 3.77)
          1978 ZHOU f 2.22 (0.95, 5.18)
          1980 LIU c 1.92 (1.40, 2.64)
          1980 REN m 3.58 (1.74, 7.33)
          1980 REN f 4.06 (2.16, 7.64)
          1980 WANG2 c 2.29 (1.12, 4.70)
          1981 CHEN3 c 1.59 (1.09, 2.30)
          1981 KOO f 2.77 (1.84, 4.16)
          1981 LAMWK f 4.12 (2.59, 6.55)
          1981 WANG3 c 2.85 (1.97, 4.13)
          1981 XU3 m 5.99 (2.65, 13.50)
          1981 XU3 f 3.86 (1.39, 10.70)
          1981 XU4 c 2.94 (1.92, 4.52)
          1982 ZHENG m 3.65 (2.36, 5.63)
          1982 ZHENG f 2.09 (1.36, 3.21)
          1983 CHEN2 m 4.57 (2.09, 10.02)
          1983 CHEN2 f 1.67 (0.82, 3.39)
          1983 LAMTH f 3.81 (2.86, 5.08)
Figure 4 Forest plot of ever smoking of any product and all lung cancer – part 4. This is a continuation of Figure 3, presenting further
individual study data included in the main meta-analysis for all lung cancer shown in Table 5.
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          1983 LIU2 m 5.19 (2.03, 13.25)
          1983 LIU2 f 4.65 (2.18, 9.93)
          1984 GAO m 3.90 (2.90, 5.40)
          1984 GAO f 3.30 (2.50, 4.20)
          1984 JIANG m 2.72 (1.08, 6.89)
          1984 JIANG f 2.49 (0.74, 8.35)
          1985 CHOI m 4.20 (2.31, 7.64)
          1985 CHOI f 1.58 (0.82, 3.02)
          1985 DU m 3.53 (2.44, 5.11)
          1985 DU f 1.93 (1.30, 2.87)
          1985 GENG m 5.99 (2.49, 14.42)
          1985 GENG f 2.96 (1.96, 4.48)
          1985 HU m 2.09 (1.30, 3.35)
          1985 HU f 1.73 (0.83, 3.61)
          1985 LIU3 m 1.26 (0.30, 5.26)
          1985 WUWILL f 2.30 (1.90, 2.80)
          1985 XU m 2.70 (2.10, 3.50)
          1986 LEI m 3.68 (2.52, 5.38)
          1986 LEI f 3.49 (2.32, 5.24)
          1986 SOBUE m 3.72 (2.57, 5.38)
          1986 SOBUE f 2.51 (1.89, 3.33)
          1986 YUAN m 6.50 (3.64, 11.60)
          1987 XU2 c 3.80 (2.84, 5.07)
          1988 GAO2 m 5.17 (2.76, 9.69)
          1988 WAKAI m 3.67 (1.84, 7.32)
          1988 WAKAI f 4.49 (2.35, 8.59)
          1988 ZHANG m 4.00 (1.61, 9.91)
          1988 ZHANG f 3.75 (1.80, 10.76)
)04.7,21.2(79.3cUGAMAY9891
          1990 FAN m 2.84 (1.93, 4.18)
          1990 FAN f 3.92 (2.65, 5.81)
          1990 GER c 1.84 (1.06, 3.20)
          1990 HUANG c 2.00 (1.20, 3.32)
          1990 LUO c 2.70 (1.50, 5.00)
)26.02,00.9(26.31mRAKNAS0991
          1990 WANG c 2.88 (1.74, 4.77)
          1991 KIHARA c 3.39 (2.54, 4.51)
          1992 KO f 4.20 (1.10, 15.60)
          1992 QIAO2 m 1.53 (0.81, 2.89)
          1992 SUN c 2.31 (1.62, 3.30)
          1997 SEOW f 5.25 (2.80, 9.84)




          1978 JOLY m 12.17 (6.75, 21.97)
          1978 JOLY f 7.34 (5.04, 10.70)
          1987 PEZZOT m 19.30 (7.02, 53.10)
)51.41,68.5(11.9mFETSED8891
          1990 WUNSCH m 4.75 (2.66, 8.50)
          1990 WUNSCH f 4.43 (2.62, 7.47)
)40.54,63.4(20.41c2KUZUS1991
          1992 PEZ )84.43,35.6(10.51m2OZ
          1993 DESTE2 c 8.70 (5.10, 14.90)
          1994 MATOS m 6.80 (3.50, 13.10)
LIU4
          1986 LIU4 m * 2.76 (2.69, 2.83)
          1986 LIU4 f * 2.86 (2.77, 2.95)
Total (95% CI) 5.50 (5.07, 5.96)
* Symbol size scaled separately from other studies 
Figure 5 Forest plot of ever smoking of any product and all lung cancer – part 5. This is a continuation of Figure 4, presenting the remaining
individual study data included in the main meta-analysis for all lung cancer shown in Table 5. Also shown are the combined random-effect estimates. These
are represented by a diamond of standard height, with the width indicating the 95% CI. Note that the sizes of the squares for the two estimates from
study LIU4 indicate the relative weight of the male and female data, but are not comparable with the sizes of the squares for the other estimates.
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)14.62,91.6(97.21m4EDNYW8491ACIREMAN
          1948 WYNDE4 f 5.82 (2.55, 13.31)
          1949 BRESLO c 3.69 (2.06, 6.62)
          1952 HAMMON m 16.88 (6.29, 45.29)
          1955 HAENSZ f 3.00 (1.90, 4.73)
)00.31,92.5(92.8m1SREYB7591
          1960 LOMBA2 f 4.24 (2.40, 7.50)
          1962 WYNDE2 m 19.72 (6.21, 62.59)
          1964 OSANN2 f 35.10 (4.80, 256.00)
          1966 WYNDE3 m 18.29 (5.71, 58.56)
          1966 WYNDE3 f 6.79 (2.45, 18.82)
          1968 HINDS f 16.13 (7.66, 33.97)
          1969 STAYNE m 3.47 (2.17, 5.56)
          1969 WYNDE6 m 18.59 (12.74, 27.13)
          1969 WYNDE6 f 32.37 (17.66, 59.35)
          1975 COMSTO m 8.07 (1.91, 34.02)
          1975 COMSTO f 46.20 (2.74, 778.83)
          1976 BUFFLE m 14.03 (4.73, 41.61)
          1976 BUFFLE f 13.04 (3.99, 42.66)
)02.34,06.81(03.82cAERROC9791
          1979 SIEMIA m 22.70 (6.90, 75.20)
          1980 DORGAN m 18.90 (7.00, 51.30)
          1980 DORGAN f 11.10 (7.20, 17.10)
          1981 JAIN m 18.00 (5.50, 111.00)
          1981 JAIN f 25.50 (7.93, 156.00)
          1981 WU f 24.29 (3.40, 173.76)
          1983 BAND m 37.45 (17.62, 79.58)
          1984 BROWN2 m 11.10 (9.50, 12.90)
          1984 BROWN2 f 20.10 (16.40, 24.80)
          1984 OSANN m 36.10 (17.80, 73.30)
          1984 OSANN f 26.40 (14.50, 48.10)
          1984 SCHWAR m 32.81 (4.48, 240.23)
          1984 SCHWAR m 1.84 (0.50, 6.78)
          1984 SCHWAR f 43.23 (2.60, 718.15)
          1984 SCHWAR f 62.61 (3.64, 1076.10)
          1985 KHUDER m 7.82 (3.87, 15.77)
          1986 ANDERS f 25.57 (10.29, 63.56)
          1989 HEGMAN c 30.80 (12.48, 76.03)
)97.24,14.2(41.01mSOMRO7491EPORUE
          1948 DOLL m 13.17 (4.12, 42.10)
          1948 DOLL f 2.13 (1.06, 4.27)
          1948 KREYBE m 10.87 (3.47, 34.04)
          1948 KREYBE f 2.29 (0.89, 5.88)
          1954 STASZE m 57.77 (3.58, 933.17)
          1954 STASZE f 32.45 (1.32, 800.04)
          1959 TIZZAN c 2.70 (1.99, 3.67)
)11.12,79.1(54.6mALEGNE4691
          1966 TOKARS c 6.80 (1.20, 38.70)
          1971 NOU m 27.17 (6.60, 111.85)
          1971 NOU f 7.09 (1.35, 37.19)
          1972 DAMBER m 11.80 (6.40, 23.00)
          1975 ABRAHA m 92.66 (5.77, 1488.21)
          1975 ABRAHA f 5.35 (2.22, 12.90)
          1976 LUBIN2 m 16.66 (12.69, 21.86)
          1976 LUBIN2 f 5.78 (4.34, 7.71)
          1977 ALDERS m 14.70 (3.40, 63.64)
          1977 ALDERS f 6.09 (2.68, 13.82)
          1979 BARBON m 14.52 (6.35, 33.20)
          1979 DOSEME m 3.60 (2.60, 5.00)
          1980 JEDRYC m 12.84 (5.58, 29.55)
          1983 SVENSS f 12.62 (3.97, 40.14)
          1985 BECHER f 10.69 (2.43, 47.00)
          1987 KATSOU f 6.11 (2.69, 13.87)
          1988 JAHN m 23.03 (7.29, 72.81)
ASIA 1961 ISHIMA c 21.00 (3.38, 868.40)
          1964 JUSSAW m 25.43 (13.87, 46.63)
          1965 MATSUD m 39.01 (5.44, 279.84)
Figure 6 Forest plot of ever smoking of any product and squamous – part 1. Table 5 presents the results of a main meta-analysis for
squamous based on 102 relative risk (RR) and 95% confidence interval (CI) estimates for ever smoking of any product (or cigarettes if any product
not available). The individual study estimates are shown numerically and graphically on a logarithmic scale in Figures 6, 7. The studies are sorted
in order of sex within study reference (REF) within start year of study (START) within continent (CONT). In the graphical representation individual
RRs are indicated by a solid square, with the area of the square proportional to the weight (inverse-variance of log RR). Arrows indicate where the
CI extends outside the range allocated. For study SCHWAR separate estimates, within sex, are shown for whites then blacks.
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          1976 CHAN m 15.22 (3.61, 64.12)
          1976 CHAN f 6.44 (3.44, 12.06)
)09.71,56.2(98.6m2KWMAL6791
          1976 LAMWK2 f 6.49 (3.27, 12.88)
)73.382,57.0(55.41mNAGUST6791
          1978 ZHOU m 3.14 (1.90, 5.18)
          1978 ZHOU f 3.81 (1.50, 9.68)
          1981 KOO f 4.15 (2.46, 6.98)
          1981 LAMWK f 10.54 (4.19, 26.52)
          1981 XU3 m 5.90 (1.69, 20.57)
          1981 XU3 f 25.67 (4.99, 131.94)
          1982 ZHENG m 16.82 (6.05, 46.71)
          1982 ZHENG f 5.45 (3.11, 9.54)
          1983 LAMTH f 8.10 (4.16, 15.77)
          1984 GAO m 8.40 (4.70, 15.00)
          1984 GAO f 7.20 (4.60, 11.10)
          1984 LUBIN m 6.33 (2.29, 17.45)
          1985 CHOI m 5.45 (2.34, 12.67)
          1985 CHOI f 6.94 (2.68, 17.96)
          1985 WUWILL f 4.20 (3.00, 5.90)
          1986 SOBUE m 17.88 (7.82, 40.87)
          1986 SOBUE f 8.74 (5.09, 15.02)
          1988 WAKAI m 8.61 (2.08, 35.72)
          1988 WAKAI f 25.23 (6.87, 92.66)
          1990 FAN c 11.68 (5.04, 27.04)
          1990 GER c 3.19 (1.08, 9.42)
          1990 LUO c 10.90 (2.50, 47.90)
          1991 KIHARA c 26.97 (10.84, 67.08)
          1997 SEOW f 17.50 (6.95, 44.09)
OTHER 1978 JOLY m 31.21 (7.69, 126.68)
          1978 JOLY f 18.56 (7.74, 44.51)
          1987 PEZZOT m 62.74 (3.86, 1019.50)
)00.722,02.4(00.13c2KUZUS1991
)01.73,07.4(02.31m2ETSED3991
          1994 MATOS m 8.08 (2.59, 25.20)
Total (95% CI) 10.47 (8.88, 12.33)
Figure 7 Forest plot of ever smoking of any product and squamous – part 2. This is a continuation of Figure 6, presenting the remaining
individual study data included in the main meta-analysis for squamous shown in Table 5. Also shown are the combined random-effect estimates.
These are represented by a diamond of standard height, with the width indicating the 95% CI.
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ute to the analysis. This is very marked for all lung can-
cer. Here the 328 estimates provided a combined weight
of 19,346 (mean 59.0), but the male and female estimates
from study LIU4 together contributed a weight of 9,846,
50.9% of the total. Omitting these two estimates sub-
stantially reduced the heterogeneity, H falling from
22.84 to 12.54. The next largest weights were 1,550 in
study STOCKW (sexes combined), 443 in BROWN2
(males) and 428 in BROWN2 (females). For squamous,
the total weight was 1,000 for the 102 RRs (mean 9.8).
The largest contributors to this were 164 for BROWN2/
males, 90 for BROWN2/females, 52 for LUBIN2/males
and 47 for LUBIN2/females, together contributing 35%
of the total weight. For adeno, the total weight was 1,514for the 107 RRs (mean 14.1). Again, BROWN2 and
LUBIN2 were the largest contributors, providing, re-
spectively, 24% and 6% of the total weight.
In investigating sources of heterogeneity, variation
was studied firstly using a univariable approach, the
results for the characteristics considered in Table 5
being summarized below, based on the random-effects
estimates.
Sex
For all three outcomes, RRs were always somewhat
lower for females than for males or for sexes combined,
though the variation by sex was not significant (p ≥ 0.1)
for squamous.
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CONT START REF SEX Relative RiskRelative Risk
95% CI95% CI
N AMERICA1948 WYNDE4 m 1.51 (0.53, 4.34)
          1948 WYNDE4 f 0.60 (0.13, 2.69)
          1949 BRESLO c 1.27 (0.44, 3.68)
          1952 HAMMON m 3.29 (0.79, 13.80)
          1955 HAENSZ f 1.19 (0.65, 2.19)
)51.9,38.1(01.4m1SREYB7591
          1960 LOMBA2 f 0.53 (0.34, 0.81)
          1962 WYNDE2 m 1.67 (0.65, 4.29)
          1964 OSANN2 f 2.50 (1.30, 5.10)
          1966 WYNDE3 m 3.00 (1.26, 7.15)
          1966 WYNDE3 f 1.90 (0.90, 4.01)
          1968 HINDS f 3.89 (2.49, 6.07)
          1969 STAYNE m 3.61 (1.60, 8.11)
          1969 WYNDE6 m 5.75 (4.35, 7.60)
          1969 WYNDE6 f 13.99 (10.18, 19.23)
          1975 COMSTO m 7.89 (1.87, 33.27)
          1975 COMSTO f 4.79 (2.09, 11.00)
          1976 BUFFLE m 4.50 (1.85, 10.95)
          1976 BUFFLE f 4.02 (2.42, 6.67)
          1979 BROWN1 m 4.49 (1.44, 13.98)
          1979 BROWN1 f 3.95 (1.76, 8.80)
)08.8,06.3(06.5cAERROC9791
          1979 SIEMIA m 6.30 (2.50, 16.20)
)00.21,09.1(08.4mNAGROD0891
          1980 DORGAN f 3.90 (2.80, 5.40)
          1981 JAIN m 8.00 (2.28, 50.60)
          1981 JAIN f 3.45 (1.83, 7.10)
          1981 WU f 2.60 (1.53, 4.44)
          1983 BAND m 4.10 (3.01, 5.59)
          1984 BROWN2 m 8.20 (6.90, 9.70)
          1984 BROWN2 f 6.90 (6.10, 7.90)
          1984 OSANN m 17.90 (10.40, 31.00)
          1984 OSANN f 9.50 (6.80, 13.80)
          1984 SCHWAR m 34.45 (4.71, 252.10)
          1984 SCHWAR m 8.08 (0.95, 68.56)
          1984 SCHWAR f 6.73 (3.29, 13.75)
          1984 SCHWAR f 9.76 (2.65, 36.00)
          1985 KHUDER m 8.11 (3.67, 17.93)
          1986 ANDERS f 6.09 (4.11, 9.03)
)76.61,05.5(85.9cNAMGEH9891
)28.521,63.0(67.6mSOMRO7491EPORUE
          1948 DOLL m 0.95 (0.22, 4.02)
          1948 DOLL f 1.97 (0.60, 6.46)
          1948 KREYBE m 2.44 (0.76, 7.86)
          1948 KREYBE f 1.28 (0.60, 2.74)
          1954 STASZE m 8.61 (0.52, 143.15)
          1954 STASZE f 1.08 (0.14, 8.53)
          1959 TIZZAN c 1.57 (0.99, 2.49)
)98.5,29.0(33.2mALEGNE4691
          1966 TOKARS c 4.30 (1.90, 9.90)
          1971 NOU m 4.45 (1.55, 12.77)
          1971 NOU f 0.88 (0.40, 1.93)
          1972 DAMBER m 2.40 (1.10, 5.30)
          1975 ABRAHA m 2.40 (1.15, 5.01)
          1975 ABRAHA f 2.62 (1.35, 5.09)
          1976 LUBIN2 m 2.88 (2.19, 3.79)
          1976 LUBIN2 f 1.28 (0.96, 1.71)
)58.33,94.1(11.7mSREDLA7791
          1977 ALDERS f 3.58 (1.48, 8.65)
          1979 BARBON m 7.02 (3.24, 15.22)
          1979 DOSEME m 2.60 (1.70, 4.20)
          1980 JEDRYC m 3.44 (1.52, 7.78)
          1983 SVENSS f 2.91 (1.56, 5.42)
          1985 BECHER f 10.83 (1.32, 88.70)
          1987 KATSOU f 1.72 (0.80, 3.71)
          1988 JAHN m 5.02 (2.42, 10.41)
ASIA 1961 ISHIMA c 15.00 (2.31, 631.48)
Figure 8 Forest plot of ever smoking of any product and adeno – part 1. Table 5 presents the results of a main meta-analysis for adeno
based on 107 relative risk (RR) and 95% confidence interval (CI) estimates for ever smoking of any product (or cigarettes if any product not
available). The individual study estimates are shown numerically and graphically on a logarithmic scale in Figures 8, 9. The studies are sorted in
order of sex within study reference (REF) within start year of study (START) within continent (CONT). In the graphical representation individual
RRs are indicated by a solid square, with the area of the square proportional to the weight (inverse-variance of log RR). Arrows indicate where
the CI extends outside the range allocated. For study SCHWAR separate estimates, within sex, are shown for whites then blacks.
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          1964 JUSSAW m 9.71 (5.01, 18.82)
          1965 MATSUD m 17.80 (1.08, 293.32)
          1976 CHAN m 30.44 (1.84, 502.58)
          1976 CHAN f 1.95 (1.09, 3.48)
          1976 LAMWK2 m 0.93 (0.48, 1.80)
          1976 LAMWK2 f 1.76 (0.98, 3.17)
          1976 TSUGAN m 0.93 (0.43, 1.99)
          1976 TSUGAN f 0.67 (0.22, 2.07)
          1978 SUZUKI m 4.53 (2.48, 8.29)
          1978 SUZUKI f 2.19 (1.16, 4.14)
          1978 ZHOU m 1.31 (0.77, 2.20)
          1978 ZHOU f 1.43 (0.57, 3.57)
          1981 KOO f 1.61 (0.94, 2.74)
          1981 LAMWK f 2.11 (1.23, 3.61)
          1981 XU3 m 4.84 (1.37, 17.10)
          1981 XU3 f 1.09 (0.26, 4.50)
          1982 ZHENG m 1.83 (1.14, 2.93)
          1982 ZHENG f 1.16 (0.70, 1.93)
          1983 LAMTH f 1.87 (1.23, 2.85)
          1984 GAO m 1.60 (1.10, 2.40)
          1984 GAO f 1.50 (1.00, 2.10)
          1984 LUBIN m 0.71 (0.25, 2.05)
          1985 CHOI m 1.34 (0.59, 3.06)
          1985 CHOI f 0.64 (0.23, 1.77)
          1985 WUWILL f 1.50 (1.10, 1.90)
          1986 SOBUE m 1.83 (1.21, 2.77)
          1986 SOBUE f 1.41 (1.00, 1.99)
          1988 WAKAI m 1.93 (0.90, 4.18)
          1988 WAKAI f 1.39 (0.66, 2.90)
          1990 FAN c 1.39 (0.94, 2.07)
          1990 GER c 1.10 (0.55, 2.19)
          1990 LUO c 1.50 (0.70, 3.00)
          1991 KIHARA c 1.70 (1.22, 2.38)
          1997 SEOW f 2.36 (1.13, 4.95)
OTHER 1978 JOLY m 4.43 (1.77, 11.10)
          1978 JOLY f 3.06 (1.75, 5.37)
          1987 PEZZOT m 7.32 (2.25, 23.79)
)00.05,07.0(00.6c2KUZUS1991
)04.11,06.1(03.4m2ETSED3991
          1994 MATOS m 6.21 (2.42, 15.96)
Total (95% CI) 2.84 (2.41, 3.35)
Figure 9 Forest plot of ever smoking of any product and adeno – part 2. This is a continuation of Figure 8, presenting the remaining
individual study data included in the main meta-analysis for adeno shown in Table 5. Also shown are the combined random-effect estimates.
These are represented by a diamond of standard height, with the width indicating the 95% CI.
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For all three outcomes, RRs were lower from studies
conducted in Europe and Asia than from studies con-
ducted in North America. While for all lung cancer
and adeno RRs were noticeably lower in Asia than in
Europe, this difference was not evident for squamous.
The difference in RRs by continent was very marked and
highly significant (p< 0.001) for all lung cancer and
adeno, but less marked, though still significant (p < 0.01)
for squamous.Start year of study
For all lung cancer and squamous, variation by start year
was not significant (p ≥ 0.05) although there was some
tendency for RRs to be higher in more recent studies.
For adeno, the variation was significant (p < 0.01) but
there was no clear trend.
Study type
For all three outcomes, RRs were somewhat lower for
case–control studies than for prospective studies (or other
Table 5 Main meta-analyses for ever smoking of any product (or cigarettes if any product not available)a
Characteristic Level Statisticb All lung cancerc Squamousd Adenoe
All All n 328 102 107
F 4.22 (4.16-4.28) 9.52 (8.94-10.13) 3.44 (3.27-3.61)
R 5.50 (5.07-5.96) 10.47 (8.88-12.33) 2.84 (2.41-3.35)
H, PH 22.84, p < 0.001 5.17, p < 0.001 8.78, p < 0.001
PE p < 0.001 NS p < 0.01
Sex Male n 171 49 51
F 3.74 (3.67-3.82) 10.74 (9.82-11.74) 4.09 (3.76-4.44)
R 6.18 (5.49-6.95) 11.98 (9.68-14.82) 3.55 (2.83-4.45)
Female n 108 42 45
F 3.95 (3.86-4.05) 8.86 (8.05-9.75) 3.27 (3.05-3.50)
R 4.43 (3.84-5.10) 8.97 (6.95-11.57) 2.32 (1.78-3.02)
Combined n 49 11 11
F 8.26 (7.94-8.60) 7.04 (5.76-8.60) 2.29 (1.93-2.71)
R 6.09 (4.98-7.44) 10.70 (4.89-23.40) 2.52 (1.56-4.08)
Between levels PB <0.01 NS <0.05
Location North America n 116 38 40
F 8.86 (8.63-9.10) 12.69 (11.63-13.84) 5.75 (5.36-6.16)
R 7.49 (6.78-8.27) 13.42 (10.45-17.24) 4.37 (3.48-5.48)
United Kingdom n 29 4 4
F 5.22 (4.72-5.78) 4.75 (3.00-7.51) 2.74 (1.52-4.94)
R 5.83 (4.54-7.49) 6.27 (2.49-15.83) 2.68 (1.31-5.47)
Scandinavia n 32 7 7
F 6.43 (5.88-7.04) 8.67 (5.88-12.78) 2.04 (1.49-2.78)
R 6.39 (5.29-7.71) 8.62 (4.81-15.43) 2.05 (1.37-3.06)
Other Europe n 50 15 15
F 5.55 (5.22-5.90) 6.56 (5.72-7.52) 2.30 (1.99-2.65)
R 6.09 (4.95-7.51) 8.87 (5.50-14.31) 2.72 (2.01-3.68)
China n 51 12 12
F 2.77 (2.72-2.83) 5.65 (4.71-6.78) 1.48 (1.28-1.70)
R 2.69 (2.50-2.88) 6.39 (4.73-8.63) 1.48 (1.28-1.70)
Japan N 18 8 11
F 3.19 (2.91-3.49) 13.94 (9.71-20.00) 1.74 (1.47-2.06)
R 3.21 (2.68-3.85) 14.54 (9.78-21.62) 1.80 (1.34-2.41)
Other Asia N 18 12 12
F 3.79 (3.41-4.20) 7.87 (6.31-9.81) 1.88 (1.56-2.26)
R 3.76 (2.72-5.18) 8.02 (5.54-11.60) 1.87 (1.29-2.71)
Other or multiregion n 14 6 6
F 6.25 (5.45-7.16) 16.70 (10.07-27.70) 4.20 (2.91-6.06)
R 7.41 (5.72-9.60) 16.70 (10.07-27.70) 4.20 (2.91-6.06)
Between levels PB <0.001 <0.01 <0.001
Start year of study Before 1960 n 54 14 14
F 3.96 (3.71-4.23) 4.35 (3.66-5.18) 1.64 (1.27-2.10)
R 4.67 (3.75-5.82) 5.89 (3.89-8.92) 1.64 (1.27-2.10)
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Table 5 Main meta-analyses for ever smoking of any product (or cigarettes if any product not available)a (Continued)
1960-69 n 52 14 14
F 5.16 (4.88-5.45) 11.87 (9.75-14.44) 4.38 (3.78-5.08)
R 5.45 (4.60-6.46) 12.88 (7.71-21.52) 3.62 (2.00-6.54)
1970-79 n 71 26 31
F 4.58 (4.34-4.82) 8.76 (7.74-9.92) 2.47 (2.21-2.76)
R 5.05 (4.27-5.96) 10.08 (7.21-14.09) 2.69 (2.14-3.37)
1980-89 n 114 40 40
F 4.11 (4.04-4.17) 11.42 (10.46-12.47) 4.17 (3.90-4.45)
R 5.95 (5.18-6.83) 11.74 (9.40-14.66) 3.23 (2.48-4.20)
1990 or later n 37 8 8
F 5.28 (4.83-5.77) 12.39 (8.51-18.05) 1.76 (1.44-2.17)
R 6.22 (4.89-7.92) 12.21 (7.56-19.72) 1.99 (1.40-2.83)
Between levels PB NS <0.1 <0.01
Study type Case–control n 262 93 98
F 4.12 (4.06-4.18) 9.46 (8.89-10.08) 3.41 (3.24-3.59)
R 5.32 (4.87-5.82) 10.31 (8.70-12.22) 2.78 (2.33-3.32)
Prospectivef n 66 9 9
F 6.01 (5.69-6.34) 12.23 (8.00-18.69) 3.95 (3.11-5.01)
R 6.24 (5.34-7.28) 12.78 (7.29-22.41) 3.66 (2.67-5.03)
Between levels PB <0.1 NS NS
National cigarette tobacco type Virginia n 50 9 9
F 5.60 (5.22-6.00) 12.69 (9.36-17.20) 4.36 (3.48-5.48)
R 6.24 (5.16-7.54) 13.80 (6.53-29.17) 4.37 (3.01-6.34)
Blended n 225 80 85
F 7.48 (7.32-7.65) 10.12 (9.46-10.83) 3.90 (3.69-4.12)
R 6.30 (5.79-6.87) 11.07 (9.21-13.31) 3.07 (2.55-3.69)
Other n 53 13 13
F 2.77 (2.72-2.83) 5.56 (4.65-6.66) 1.46 (1.27-1.67)
R 2.68 (2.49-2.87) 6.15 (4.60-8.23) 1.46 (1.27-1.67)
Between levels PB <0.001 <0.01 <0.001
Any proxy use Nog n 227 76 79
F 6.87 (6.72-7.03) 8.95 (8.37-9.56) 3.41 (3.23-3.61)
R 5.51 (5.02-6.04) 9.64 (7.99-11.64) 2.63 (2.15-3.20)
Yes n 101 26 28
F 3.15 (3.09-3.20) 14.65 (12.30-17.46) 3.56 (3.13-4.04)
R 5.39 (4.84-6.02) 13.82 (10.45-18.27) 3.61 (2.73-4.76)
Between levels PB NS <0.05 <0.1
Full histological confirmation No n 245 59 59
F 3.86 (3.80-3.92) 7.21 (6.57-7.90) 2.43 (2.24-2.63)
R 5.25 (4.80-5.74) 9.39 (7.54-11.68) 2.56 (2.09-3.15)
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Table 5 Main meta-analyses for ever smoking of any product (or cigarettes if any product not available)a (Continued)
Yes n 83 43 48
F 7.67 (7.38-7.98) 11.97 (11.01-13.02) 4.37 (4.09-4.66)
R 6.30 (5.47-7.25) 12.32 (9.78-15.52) 3.22 (2.53-4.10)
Between levels PB <0.05 <0.1 NS
Number of casesh 100-249 n 115 22 27
F 3.74 (3.51-3.99) 6.02 (4.86-7.45) 1.93 (1.67-2.24)
R 4.43 (3.86-5.09) 8.39 (5.91-11.92) 2.31 (1.71-3.12)
250-499 n 86 31 31
F 4.85 (4.59-5.12) 8.89 (7.51-10.52) 2.37 (2.10-2.68)
R 5.75 (4.95-6.69) 10.17 (7.81-13.22) 2.37 (1.81-3.09)
500-999 n 64 18 18
F 4.93 (4.68-5.19) 8.26 (6.92-9.85) 2.40 (2.07-2.77)
R 6.17 (5.25-7.25) 11.35 (7.79-16.53) 2.86 (2.08-3.92)
1000+ n 63 31 31
F 4.15 (4.08-4.21) 10.51 (9.74-11.35) 4.61 (4.32-4.92)
R 6.14 (5.15-7.32) 10.88 (8.16-14.51) 3.77 (2.82-5.02)
Between levels PB <0.01 NS <0.1
Smoking product Any n 205 54 55
F 3.79 (3.73-3.85) 6.86 (6.16-7.65) 2.42 (2.20-2.66)
R 5.41 (4.90-5.97 8.94 (7.02-11.39) 2.27 (1.87-2.76)
Cigarettes (ignoring n 114 46 50
other products) F 6.52 (6.31-6.73) 10.99 (10.18-11.85) 3.94 (3.71-4.19)
R 5.54 (4.87-6.30) 11.86 (9.57-14.71) 3.46 (2.70-4.44)
Cigarettes only n 9 2 2
F 8.11 (7.11-9.26) 38.79 (18.74-80.31) 4.26 (3.15-5.74)
R 6.83 (4.63-10.08) 38.79 (18.74-80.31) 4.26 (3.15-5.74)
Between levels PB NS <0.001 <0.001
Unexposed base Never any product n 236 64 67
F 3.84 (3.78-3.90) 8.06 (7.37-8.82) 2.57 (2.38-2.77)
R 5.31 (4.84-5.81) 9.68 (7.81-12.01) 2.46 (2.09-2.89)
Never cigarettes n 92 38 40
F 7.01 (6.77-7.26) 11.04 (10.13-12.02) 4.30 (4.02-4.60)
R 5.96 (5.17-6.88) 11.92 (9.24-15.38) 3.56 (2.66-4.78)
Between levels PB NS NS <0.05
Number of adjustment factors 0 n 164 53 54
F 7.12 (6.92-7.33) 7.93 (7.20-8.74) 2.40 (2.21-2.60)
R 5.44 (4.86-6.09) 9.86 (7.79-12.49) 2.61 (2.11-3.23)
1 n 69 18 20
F 5.13 (4.90-5.37) 12.59 (10.37-15.30) 3.24 (2.81-3.73)
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Table 5 Main meta-analyses for ever smoking of any product (or cigarettes if any product not available)a (Continued)
R 5.48 (4.72-6.37) 11.34 (7.36-17.47) 2.66 (1.74-4.06)
2+ n 95 31 33
F 3.40 (3.34-3.46) 10.48 (9.59-11.45) 4.61 (4.29-4.95)
R 5.56 (4.87-6.34) 11.02 (8.35-14.54) 3.30 (2.50-4.36)
Between levels PB NS NS NS
a Within each study, results for ever smokers are selected in the following preference order, within each sex, for:
smoking product – any, cigarettes (ignoring other products), cigarettes only;
cigarette type – any, manufactured (with or without handrolled), manufactured only;
unexposed group – never any product, never cigarettes, near equivalent (see Methods);
follow-up period – longest available;
lung cancer type – see notes c to e;
race – all or nearest available, otherwise by race;
overlapping studies – principal, subsidiary;
age – whole study, widest available age group.
Results are then selected for:
sex – single sex results, combined sex results;
adjustment for potential confounders – most available.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.01, p < 0.05, p < 0.1 or NS (p≥ 0.1), PE = probability value for Egger’s test of
publication bias similarly expressed, PB = probability value for between levels (see Methods) similarly expressed.
c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
d Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
e Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
f Or nested case–control or case-cohort in the case of 5 estimates for all lung cancer, 4 for squamous and 4 for adeno.
g Or not known in the case of 10 estimates for all lung cancer, 2 for squamous, and 2 for adeno.
h In the study as a whole.
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lung cancer diagnosis). However, the difference was never
statistically significant (p≥0.05).National cigarette tobacco type
For all three outcomes, there was significant (p <0.01
or< 0.001) variation. This was mainly due to low estimates
in the “other” group, which mainly included results from
China. For all lung cancer, RRs for Virginia (6.24, 5.16-7.54,
n=50) and blended (6.30, 5.79-6.87) were quite similar. For
squamous and adeno, there were limited results for Vir-
ginia, and no clear difference from blended was evident.Any proxy use
There was some evidence that RRs were higher where
proxy respondents were used for squamous (p < 0.05)
and adeno (p < 0.1), but not for all lung cancer.Full histological confirmation
RR estimates were somewhat higher where full histological
confirmation of diagnosis was a study requirement, but
this was only significant at p < 0.05 for all lung cancer.Number of cases
Some tendency for RRs to increase with increasing num-
ber of cases was evident for all three outcomes, but vari-
ation in number of cases was only significant for all lung
cancer (p < 0.01).Smoking product
The analyses in Table 5 are based on a preference order
of any product, cigarettes (ignoring other products) and
cigarettes only. For all lung cancer, where 205 of the 328
estimates were for any product, 114 were for cigarettes
and 9 for cigarettes only, there was no evidence that the
RRs included varied by smoking product. For squamous
and adeno (both p < 0.001), however, RRs were lowest
for smoking any product, intermediate for cigarettes,
and highest for cigarettes only (though based on only
two RRs for cigarettes only for each outcome).Unexposed base
RRs were somewhat higher where the unexposed base
group was never cigarettes than when it was never any
product, though this was only significant (p < 0.05) for
adeno. This result is somewhat counter-intuitive, as
lower RRs might be expected where the base (never
cigarettes) includes some smokers (pipe/cigar only), and
probably arises from the strong correlation between the
definitions of smoking product and unexposed base.
Two combinations – any product vs. never any product
(n = 203) and cigarettes vs. never cigarettes (n = 90) –
form a large proportion of the total RRs (with any prod-
uct vs never cigarettes not a valid possibility).Number of adjustment factors
There was no evidence that RR estimates varied by
whether they were adjusted for 0, 1 or 2+ potential con-
founding variables.
Table 6 Some alternative meta-analyses for ever smoking compared to those in Table 5
Analysis description Statisticb All lung cancerc Squamousd Adenoe
As Table 5a n 328 102 107
F 4.22 (4.16-4.28) 9.52 (8.94-10.13) 3.44 (3.27-3.61)
R 5.50 (5.07-5.96) 10.47 (8.88-12.33) 2.84 (2.41-3.35)
H, PH 22.84, p < 0.001 5.17, p < 0.001 8.78, p < 0.001
Using more precise outcome definitionf n 317 74 87
F 4.23 (4.17-4.29) 10.43 (9.72-11.20) 3.58 (3.39-3.78)
R 5.59 (5.15-6.07) 11.56 (9.68-13.81) 2.99 (2.49-3.58)
H, PH 23.48, p < 0.001 4.18, p < 0.001 9.18, p < 0.001
Using least rather than most adjusted estimates n 331 102 107
F 4.23 (4.17-4.29) 9.49 (8.93-10.09) 3.38 (3.21-3.55)
R 5.48 (5.06-5.93) 10.37 (8.83-12.18) 2.83 (2.39-3.34)
H, PH 23.36, p < 0.001 5.23, p < 0.001 9.57, p < 0.001
Omitting study LIU4 n 326 NAg NAg
F 6.47 (6.34-6.60)
R 5.52 (5.10-5.97)
H, PH 12.54, p < 0.001
Preferring results for cigarettes to results for any product n 327 102 107
F 4.73 (4.66-4.80) 9.48 (8.91-10.08) 3.43 (3.27-3.61)
R 5.49 (5.10-5.92) 10.44 (8.88-12.29) 2.82 (2.39-3.32)
H, PH 19.39, p < 0.001 5.12, p < 0.001 8.72, p < 0.001
Selecting results for cigarettes onlyh n 54 11 11
F 4.37 (4.28-4.47) 9.05 (7.84-10.45) 1.93 (1.70-2.18)
R 6.45 (5.41-7.70) 11.50 (7.47-17.69) 2.87 (1.49-5.55)
H, PH 22.68, p < 0.001 4.57, p < 0.001 16.64, p < 0.001
Selecting results specific for age <56 years n 38 10 10
F 5.79 (5.15-6.51) 11.04 (7.08-17.20) 4.94 (3.73-6.56)
R 6.57 (4.94-8.74) 14.73 (6.83-31.76) 4.17 (1.86-9.35)
H, PH 4.17, p < 0.001 2.35, p < 0.05 7.00, p < 0.001
Selecting results specific for age 50–70 years n 31 6 4
F 5.77 (5.29-6.29) 16.32 (11.11-23.95) 5.62 (3.91-8.07)
R 6.46 (4.99-8.35) 17.30 (10.78-27.74) 5.31 (3.20-8.79)
H, PH 7.67, p < 0.001 1.37, NS 1.14, NS
Selecting results specific for age 65+ years n 37 2 2
F 2.88 (2.78-3.00) 15.00 (6.46-34.80) 1.73 (0.99-3.02)
R 5.48 (4.59-6.55) 15.00 (6.46-34.80) 1.73 (0.99-3.02)
H, PH 9.66, p < 0.001 0.02, NS 0.19, NS
a See Table 5 for details of the definition of this analysis.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.01, p < 0.05, p < 0.1 or NS (p≥ 0.1), PB = probability value for between
levels (see methods) similarly expressed.
c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
d Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
e Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
f Only including results for all lung cancer, squamous cell carcinoma specifically, or adenocarcinoma specifically.
g Not applicable as results by histological type were not available for study LIU4.
h See also Table 13 (footnote c).
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Table 7 Meta-regression results for ever smoking of any product (or cigarettes if any product not available)a
Characteristic Level All lung cancer Squamous Adeno
Estimateb (SEc) pd Estimateb (SEc) pd Estimateb (SEc) pd
Constant +1.280 (0.052) +1.281 (0.174) +0.368 (0.178)
Sex Male Base NS Base NS Base <0.05
Female −0.040 (0.016) −0.046 (0.072) −0.275 (0.058)
Combined +0.018 (0.029) −0.130 (0.141) +0.102 (0.138)
Location North America Base <0.001 Base <0.001 Base <0.001
United Kingdom −0.108 (0.057) −0.861 (0.266) −0.535 (0.324)
Scandinavia −0.095 (0.051) −0.484 (0.241) −0.630 (0.190)
Other Europe −0.319 (0.039) −0.609 (0.114) −0.731 (0.107)
China −1.320 (0.024) −1.028 (0.120) −1.356 (0.094)
Japan −0.858 (0.053) −0.562 (0.226) −1.158 (0.119)
Other Asia −0.646 (0.060) −0.390 (0.158) −0.557 (0.127)
Other or multiregion −0.173 (0.076) −0.031 (0.301) −0.024 (0.213)
Start year of study Before 1960 Base <0.001 Base <0.001 Base <0.05
1960-69 +0.384 (0.047) +0.819 (0.154) +0.750 (0.166)
1970-79 +0.430 (0.045) +0.802 (0.130) +0.672 (0.150)
1980-89 +0.783 (0.042) +0.990 (0.134) +0.857 (0.155)
1990 or later +0.872 (0.063) +1.788 (0.263) +0.892 (0.200)
Study type Case–control Base <0.01 Base NS Base NS
Prospectivee +0.238 (0.036) +0.395 (0.233) +0.352 (0.140)
Number of casesf 100-249 Base <0.001 Base <0.05 Base <0.05
250-499 +0.101 (0.044) +0.251 (0.152) +0.265 (0.107)
500-999 +0.293 (0.043) +0.729 (0.162) +0.550 (0.121)
1000+ +0.290 (0.038) +0.655 (0.145) +0.594 (0.100)
Number of adjustment factors 0 Base <0.05 Base <0.05 Base <0.1
1 −0.171 (0.034) +0.477 (0.147) +0.391 (0.110)
2+ +0.017 (0.025) −0.226 (0.097) +0.272 (0.078)
a Based on the same data as for Table 5. See that table for further definition of RRs selected for analysis, and numbers of estimates of each characteristic level.
b Estimates are of log RR. The predicted RR of a given estimate can be calculated by adding the constant to the values for the level of each characteristic
applicable to the estimate (taking the value for a base level as zero) and taking the exponential of the result.
c SE = standard error.
d The p value is estimated from the drop in deviance from removing the characteristic from the fixed model using an F-test. It is expressed as p < 0.001, p < 0.01,
p < 0.05, p < 0.1 or NS (p≥ 0.1).
e Or nested case–control or case-cohort in the case of 5 estimates for all lung cancer, 4 for squamous and 4 for adeno.
f In the study as a whole.
Note For the forward stepwise analyses, deviances, degrees of freedom and p values for inclusion in order of inclusion are as follows:
All lung cancer: Constant 7470.075 on 327 d.f. (p < 0.001), location 2247.358 on 320 d.f. (p < 0.001), start year of study 1599.339 on 316 d.f. (p < 0.001), number of
cases 1523.722 on 313 d.f. (p < 0.01), study type 1497.854 on 312 d.f. (p < 0.05) and number of adjustment variables 1463.482 on 310 d.f. (p < 0.05). Fixed model
deviance 1454.810 on 308 d.f.
Squamous: Constant 522.221 on 101 d.f. (p < 0.001), start year of study 419.586 on 97 d.f. (p < 0.001) and location 308.715 on 90 d.f. (p < 0.001). Fixed model
deviance 260.432 on 82 d.f.
Adeno: Constant 930.356 on 106 d.f. (p < 0.001), location 431.955 on 99 d.f. (p < 0.001), number of cases 369.648 on 96 d.f. (p <0.01), start year of study 328.896
on 92 d.f. (p < 0.05) and sex 307.336 on 90 d.f. (p < 0.05). Fixed model deviance 284.147 on 87 d.f.
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Analysis Tables) also includes results by levels of some
other characteristics. In an attempt to evaluate the inde-
pendent role of a whole range of characteristics, prelim-
inary meta-regression analyses were conducted for each
outcome (results not shown). As a result, it was decidedto present findings for a fixed model involving six major
characteristics (see Table 7), test the effect of each by de-
leting each of the six individually from the fixed model
(and also by allowing each to enter a step-wise model in
order of significance), and test the effect of a range of
other characteristics by adding each individually into the
0.20 0.40 1.00 25.00 50.00
START REF SEX Relative RiskRelative Risk
95% CI95% CI
)69.31,17.2(51.6mREHCRA0591ACIREMAN
          1951 BOUCOT m 62.29 (3.86, 1004.01)
)66.91,53.6(71.11mRABMOL1591
          1952 HAMMON m 11.52 (6.83, 19.42)
          1954 DORN m 8.23 (6.55, 10.35)
          1955 BEST m 14.91 (7.05, 31.52)
          1955 HAENSZ f 2.14 (1.43, 3.19)
          1956 GRAHAM m 6.06 (3.78, 9.70)
)89.61,25.2(45.6mUDNAMA9591
          1959 AMES m 4.56 (2.48, 8.39)
          1959 CPSI m 11.94 (9.52, 14.97)
          1959 CPSI f 3.20 (2.53, 4.04)
)31.61,64.01(99.21mORTSNE9591
          1959 ENSTRO f 6.95 (6.01, 8.04)
          1960 BROSS m 4.84 (3.35, 6.99)
)78.82,23.31(16.91mRESIAK4691
          1964 KAISER f 6.53 (4.50, 9.48)
          1965 CHYOU m 11.40 (6.50, 20.10)
          1966 CHOW m 14.07 (6.23, 31.78)
          1966 WYNDE3 m 10.72 (5.26, 21.84)
          1967 HAMMO2 m 10.14 (4.19, 24.55)
          1969 WYNDE6 m 16.05 (12.62, 20.41)
          1969 WYNDE6 f 14.63 (11.90, 17.99)
          1970 AUSTIN c 19.60 (6.70, 57.00)
          1970 LIDDEL m 4.41 (2.77, 7.01)
          1971 WIGLE m 10.40 (6.07, 17.83)
          1971 WIGLE f 5.20 (3.34, 8.08)
          1971 YONG m 28.71 (6.98, 118.16)
          1971 YONG f 5.20 (2.38, 11.35)
          1972 CHANG m 8.39 (3.32, 21.21)




          1975 COMSTO f 13.10 (6.68, 25.67)
          1976 BUFFLE m 11.03 (4.31, 28.22)
          1976 BUFFLE f 8.26 (5.63, 12.11)
          1976 SPEIZE f 12.69 (9.97, 16.16)
)07.81,08.01(02.41cAERROC9791
          1979 KAISE2 m 8.04 (4.41, 14.66)
          1979 KAISE2 f 14.48 (7.47, 28.04)
)10.03,45.9(29.61mNAGROD0891
)66.731,71.21(39.04mNAGROD0891
          1980 DORGAN f 12.16 (8.99, 16.46)
          1980 DORGAN f 11.43 (4.16, 31.43)
          1980 HUMBLE m 19.96 (8.27, 48.21)
          1980 HUMBLE m 15.79 (3.43, 72.69)
          1980 HUMBLE f 16.72 (7.44, 37.61)
          1980 HUMBLE f 23.50 (6.79, 81.36)
)38.01,84.5(07.7mIHSRAG1891
          1981 JAIN m 12.40 (6.45, 26.60)
          1981 JAIN f 16.80 (9.93, 30.60)
          1981 KAUFMA c 20.63 (14.18, 30.01)
          1981 STOCKW c 14.16 (13.38, 14.99)
          1981 WU f 4.86 (2.76, 8.57)
          1982 CPSII m 20.25 (16.37, 25.05)
          1982 CPSII f 11.78 (10.14, 13.68)
)24.42,96.9(83.51mKENNEH2891
          1983 GOODMA m 17.43 (8.90, 34.14)
          1983 GOODMA f 9.65 (5.30, 17.56)
          1984 BROWN2 m 11.30 (10.20, 12.40)
          1984 BROWN2 f 13.60 (12.30, 15.10)
          1984 OSANN m 26.50 (19.20, 36.50)
          1984 OSANN f 19.60 (15.20, 25.20)
          1984 SCHWAR m 14.96 (11.81, 18.94)
          1984 SCHWAR m 9.64 (6.56, 14.15)
          1984 SCHWAR f 15.64 (12.75, 19.19)
Figure 10 Forest plot of current smoking of any product and all lung cancer – part 1. Table 8 presents the results of a main meta-analysis for
all lung cancer based on 195 relative risk (RR) and 95% confidence interval (CI) estimates for current smoking of any product (or cigarettes if any product
not available). The individual study estimates are shown numerically and graphically on a logarithmic scale in Figures 10, 11, 12. The studies are sorted in
order of sex within study reference (REF) within start year of study (START) within continent (CONT). In the graphical representation individual RRs are
indicated by a solid square, with the area of the square proportional to the weight (inverse-variance of log RR). Arrows indicate where the CI extends
outside the range allocated. For study DORGAN separate estimates, within sex, are shown for whites then blacks. For study HUMBLE they are shown for
non-hispanic whites then hispanics, and for study SCHWAR for whites then non-whites.
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0.20 0.40 1.00 25.00 50.00
START REF SEX Relative RiskRelative Risk
95% CI95% CI
          1984 SCHWAR f 17.56 (11.64, 26.50)
)51.51,54.11(71.31mRELLEK5891
)96.22,13.01(92.51mRELLEK5891
          1985 KELLER f 14.54 (12.79, 16.53)
          1985 KELLER f 11.64 (8.35, 16.24)
          1985 KHUDER m 8.10 (5.20, 12.70)
          1986 ANDERS f 23.43 (17.02, 32.27)
          1986 NAM m 8.67 (5.66, 13.26)
          1986 NAM f 10.84 (7.26, 16.18)
          1988 SHAW c 21.26 (10.93, 41.36)
)58.04,69.21(30.32cNEPRAC1991
          1992 GARCIA c 15.12 (8.86, 25.79)
          1992 LEMARC c 13.49 (8.39, 21.68)
          1992 SPITZ c 21.16 (9.40, 47.66)
          1992 TANG c 9.01 (3.78, 21.46)
)03.761,00.12(02.95mYESUOT3991
          1993 TOUSEY f 30.20 (16.00, 57.40)
EUROPE 1948 DOLL m 9.52 (4.34, 20.89)
          1948 DOLL f 2.09 (1.18, 3.68)
)30.7,74.3(49.4mLLENAK0591
          1951 DOLL2 m 10.99 (6.97, 17.36)
          1951 DOLL2 f 8.65 (2.93, 25.55)
          1954 PETO m 7.17 (1.78, 28.92)
          1959 TIZZAN m 1.90 (1.53, 2.35)
          1959 TIZZAN f 4.31 (1.95, 9.51)
          1960 BRETT m 3.92 (1.73, 8.88)
          1960 DEAN2 m 3.80 (2.54, 5.68)
          1960 DEAN2 f 2.90 (1.71, 4.91)
          1962 TENKAN m 16.81 (7.22, 39.14)
)98.11,10.5(27.7mLREDEC3691
          1963 CEDERL f 4.82 (3.38, 6.88)
)68.51,24.3(73.7mALEGNE4691
          1964 ENGELA f 5.78 (2.68, 12.46)
)06.01,64.1(39.3mNARGIM4691
          1964 MIGRAN f 4.99 (1.76, 14.16)
          1965 KUBIK m 33.00 (8.14, 133.74)




          1967 TULINI m 9.99 (5.42, 18.40)
          1967 TULINI f 16.24 (9.02, 29.25)
          1969 DEAN3 m 6.72 (4.28, 10.55)
          1969 DEAN3 f 5.77 (3.75, 8.86)
          1970 HEIN m 17.27 (2.42, 123.25)
)02.41,06.6(06.9mREBMAD2791
          1972 HOLE m 8.10 (3.80, 17.26)
          1972 HOLE f 1.53 (0.64, 3.70)
          1972 TVERDA m 4.09 (2.65, 6.31)
          1972 TVERDA f 11.05 (3.33, 36.71)
          1975 WALD m 16.40 (7.55, 44.20)
          1976 GREGOR m 1.29 (0.53, 3.18)
          1976 GREGOR f 14.38 (1.77, 116.90)
          1976 LANGE m 5.70 (2.13, 15.27)
          1976 LANGE f 5.02 (2.52, 10.01)
          1976 LUBIN2 m 10.67 (9.14, 12.46)
          1976 LUBIN2 f 3.84 (3.17, 4.64)
)18.42,32.8(92.41mSREDLA7791
          1977 ALDERS f 5.80 (4.27, 7.87)
)21.4,84.2(02.3mKMHOLB8791
)04.12,05.8(04.31mNOBRAB9791
          1979 KJUUS m 21.04 (4.84, 91.45)
)20.01,68.6(92.8c2HSREP0891
          1983 JARVHO m 40.28 (5.10, 317.77)
          1983 JARVHO f 15.50 (4.56, 52.66)
          1983 SVENSS f 9.06 (5.31, 15.48)
)90.94,25.4(09.41mREHCEB5891
          1985 BECHER f 6.60 (2.82, 15.44)
Figure 11 Forest plot of current smoking of any product and all lung cancer – part 2. This is a continuation of Figure 10, presenting
further individual study data included in the main meta-analysis for all lung cancer shown in Table 8. For study KELLER separate estimates,
within sex, are shown for whites then non-whites.
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          1986 ARMADA m 24.66 (8.75, 69.44)
          1986 DORANT m 10.82 (5.02, 23.32)
          1987 KATSOU f 3.40 (1.75, 6.61)
          1988 DARBY m 90.98 (28.96, 285.90)
          1988 DARBY f 20.67 (13.05, 32.74)
          1988 GARDIN c 13.71 (5.13, 36.68)
          1988 JAHN m 10.03 (5.99, 16.81)
          1989 AGUDO f 3.61 (1.57, 8.32)
)21.62,35.8(29.41mSSLEXA9891
          1989 AXELSS f 11.90 (6.68, 21.22)
          1989 STUCKE m 104.50 (6.32, 1727.39)
          1990 KREUZE m 15.27 (6.34, 36.79)
          1990 KREUZE m 41.86 (27.17, 64.51)
          1990 KREUZE f 15.14 (5.63, 40.72)
          1990 KREUZE f 5.87 (3.95, 8.70)
          1991 RACHTA f 6.77 (3.71, 12.35)
          1992 ODRISC c 54.22 (23.98, 122.60)
          1995 DROSTE m 14.50 (6.30, 33.40)
)90.6,72.1(97.2mUSOTIH0691AISA
          1960 HITOSU f 3.09 (1.82, 5.27)
          1962 SEGI2 m 3.74 (1.75, 8.00)
          1962 SEGI2 f 1.65 (0.90, 3.02)
          1963 AKIBA m 5.10 (3.30, 7.90)
          1963 AKIBA f 3.90 (2.90, 5.30)
          1965 HIRAYA m 4.45 (3.60, 5.50)
          1965 HIRAYA f 2.34 (1.87, 2.92)
          1965 SOBUE2 m 4.47 (3.89, 5.14)
          1965 SOBUE2 f 3.28 (2.79, 3.87)
          1972 MACLEN m 3.81 (1.34, 10.80)
          1972 MACLEN f 2.38 (1.37, 4.12)
          1976 TSUGAN m 1.22 (0.60, 2.50)
          1980 WANG2 c 2.40 (1.14, 5.05)
          1981 KOO f 2.55 (1.40, 4.64)
          1982 LIAW m 3.70 (2.10, 6.60)
          1982 LIAW f 3.60 (1.00, 12.20)
          1984 GAO m 3.90 (2.90, 5.40)
          1984 GAO f 2.90 (2.20, 3.80)
          1984 LUBIN m 3.64 (1.80, 7.38)
          1985 CHOI m 5.15 (2.82, 9.42)
          1985 CHOI f 1.22 (0.59, 2.54)
          1986 SOBUE m 4.10 (2.80, 5.90)
          1986 SOBUE f 2.80 (2.00, 3.90)
          1988 GAO2 m 6.61 (3.47, 12.58)
          1988 WAKAI m 4.40 (2.19, 8.85)
          1988 WAKAI f 4.37 (2.21, 8.62)
          1989 YAMAGU c 4.90 (2.55, 9.44)
          1991 KIHARA c 4.06 (3.00, 5.49)
          1992 QIAO2 m 1.59 (0.84, 3.01)
OTHER 1961 DEKLER m 23.03 (3.21, 164.97)
)32.5,81.3(80.4mNIKRAP3691
          1978 JOLY m 13.30 (7.35, 24.07)
          1978 JOLY f 7.48 (5.04, 11.12)
          1987 PEZZOT m 32.60 (11.70, 90.81)
          1988 DESTEF m 10.90 (6.90, 17.10)
          1990 WUNSCH m 6.59 (3.59, 12.10)
          1990 WUNSCH f 5.98 (3.25, 11.00)
)00.67,05.6(00.22c2KUZUS1991
          1992 PEZZO2 m 22.95 (9.89, 53.26)
          1993 DESTE2 c 9.10 (5.20, 15.90)
          1994 MATOS m 8.50 (4.30, 16.70)
Total (95% CI) 8.43 (7.63, 9.31)
Figure 12 Forest plot of current smoking of any product and all lung cancer – part 3. This is a continuation of Figure 11, presenting
the remaining individual study data included in the main meta-analysis for all lung cancer shown in Table 8. Also shown are the combined
random-effect estimates. These are represented by a diamond of standard height, with the width indicating the 95% CI. For study KREUZE
separate estimates, within sex, are shown for age≤ 45 and 55–69.
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)73.844,96.1(45.72mTOCUOB1591ACIREMAN
          1952 HAMMON m 26.42 (9.78, 71.34)
          1954 DORN m 17.09 (8.96, 32.60)
          1955 HAENSZ f 3.02 (1.90, 4.82)
          1959 CPSI m 29.35 (4.02, 214.28)
          1959 CPSI f 4.25 (1.23, 14.68)
          1964 OSANN2 f 39.00 (5.30, 287.00)
          1966 WYNDE3 m 24.23 (7.53, 77.95)
          1969 WYNDE6 m 29.46 (20.06, 43.26)
          1969 WYNDE6 f 31.30 (22.21, 44.12)
          1975 COMSTO m 11.34 (2.62, 49.09)
          1975 COMSTO f 72.60 (4.27, 1233.12)
          1976 BUFFLE f 13.24 (3.97, 44.10)
)04.25,08.22(06.43cAERROC9791
          1981 JAIN m 38.54 (9.26, 160.45)
          1981 JAIN f 29.18 (12.31, 69.15)
          1981 WU f 35.30 (4.70, 267.30)
          1982 CPSII m 39.26 (10.38, 148.55)
          1982 CPSII f 78.91 (15.83, 393.37)
          1984 BROWN2 m 13.70 (11.70, 16.10)
          1984 BROWN2 f 20.60 (16.60, 25.60)
          1984 OSANN m 49.30 (24.10, 101.00)
          1984 OSANN f 35.20 (19.10, 65.10)
          1985 KHUDER m 8.60 (4.20, 17.60)
EUROPE 1964 ENGELA m 10.89 (3.25, 36.43)
          1976 LUBIN2 m 19.65 (14.95, 25.82)
          1976 LUBIN2 f 6.16 (4.55, 8.32)
          1979 BARBON m 18.80 (8.20, 43.40)
          1980 JEDRYC m 21.94 (9.63, 49.96)
          1983 SVENSS f 21.92 (6.63, 72.51)
          1987 KATSOU f 6.45 (2.73, 15.25)
          1988 JAHN m 26.16 (8.19, 83.54)
)05.6,02.4(02.5m2EUBOS5691AISA
          1965 SOBUE2 f 7.20 (4.80, 10.80)
          1976 TSUGAN m 15.07 (0.77, 296.43)
          1986 SOBUE m 18.10 (7.90, 41.30)
          1986 SOBUE f 9.70 (5.50, 16.80)
          1988 WAKAI m 9.82 (2.36, 41.00)
          1988 WAKAI f 28.20 (7.55, 105.00)
          1991 KIHARA c 32.48 (12.97, 81.34)
OTHER 1994 MATOS m 10.40 (3.60, 35.50)
Total (95% CI) 16.91 (13.14, 21.76)
Figure 13 Forest plot of current smoking of any product and squamous. Table 8 presents the results of a main meta-analysis for squamous
based on 41 relative risk (RR) and 95% confidence interval (CI) estimates for current smoking of any product (or cigarettes if any product not
available). The individual study estimates are shown numerically and graphically on a logarithmic scale. The studies are sorted in order of sex
within study reference (REF) within start year of study (START) within continent (CONT). In the graphical representation individual RRs are
indicated by a solid square, with the area of the square proportional to the weight (inverse-variance of log RR). Arrows indicate where the CI
extends outside the range allocated. Also shown are the combined random-effect estimates. These are represented by a diamond of standard
height, with the width indicating the 95% CI.
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Tables). The main conclusions to be drawn from these
analyses are summarized below.For all lung cancer, by far the strongest source of vari-
ation was location, with the overall heterogeneity
reduced from 22.84 per d.f. to 7.02 per d.f. after
0.20 0.40 1.00 25.00 50.00
CONT START REF SEX Relative RiskRelative Risk
95% CI95% CI
)75.381,56.0(59.01mTOCUOB1591ACIREMAN
         1954 DORN m 5.95 (3.85, 9.22)
         1955 HAENSZ f 1.09 (0.58, 2.05)
          1959 CPSI m 4.58 (1.74, 12.05)
          1959 CPSI f 1.43 (0.47, 4.39)
          1964 OSANN2 f 3.20 (1.50, 6.60)
          1966 WYNDE3 m 3.97 (1.65, 9.55)
          1969 WYNDE6 m 9.35 (7.00, 12.48)
          1969 WYNDE6 f 9.03 (7.14, 11.42)
          1975 COMSTO m 12.60 (2.92, 54.28)
          1975 COMSTO f 6.36 (2.67, 15.16)
          1976 BUFFLE f 8.15 (3.56, 18.65)
)06.01,03.4(07.6cAERROC9791
          1981 JAIN m 10.81 (3.78, 30.87)
          1981 JAIN f 6.21 (3.69, 10.47)
          1981 WU f 4.10 (2.30, 7.50)
          1982 CPSII m 19.22 (6.46, 57.16)
          1982 CPSII f 8.23 (4.36, 15.54)
          1983 WU2 f 4.50 (3.00, 6.90)
          1984 BROWN2 m 9.10 (7.60, 10.80)
          1984 BROWN2 f 7.20 (6.20, 8.30)
          1984 OSANN m 21.70 (12.50, 39.70)
          1984 OSANN f 11.60 (8.20, 16.40)
          1985 KHUDER m 8.20 (3.60, 18.40)
EUROPE 1964 ENGELA m 7.06 (2.69, 18.50)
          1976 LUBIN2 m 3.36 (2.54, 4.44)
          1976 LUBIN2 f 1.44 (1.06, 1.96)
          1979 BARBON m 7.90 (3.60, 17.40)
          1980 JEDRYC m 5.44 (2.47, 12.00)
          1983 SVENSS f 3.78 (1.91, 7.48)
          1987 KATSOU f 1.70 (0.75, 3.89)
          1988 JAHN m 4.81 (2.26, 10.26)
)07.3,04.2(01.3m2EUBOS5691AISA
          1965 SOBUE2 f 1.80 (1.40, 2.20)
          1976 TSUGAN m 0.85 (0.39, 1.85)
          1976 TSUGAN f 0.55 (0.18, 1.68)
          1978 SUZUKI m 5.00 (2.71, 9.27)
          1978 SUZUKI f 2.40 (1.19, 4.86)
          1986 SOBUE m 1.90 (1.30, 3.00)
          1986 SOBUE f 1.30 (0.90, 2.00)
          1988 WAKAI m 2.18 (1.00, 4.76)
          1988 WAKAI f 1.14 (0.49, 2.61)
          1991 KIHARA c 1.93 (1.35, 2.76)
OTHER 1994 MATOS m 7.90 (3.00, 20.90)
Total (95% CI) 4.21 (3.32, 5.34)
Figure 14 Forest plot of current smoking of any product and adeno. Table 8 presents the results of a main meta-analysis for adeno based
on 44 relative risk (RR) and 95% confidence interval (CI) estimates for current smoking of any product (or cigarettes if any product not available).
The individual study estimates are shown numerically and graphically on a logarithmic scale. The studies are sorted in order of sex within study
reference (REF) within start year of study (START) within continent (CONT). In the graphical representation individual RRs are indicated by a solid
square, with the area of the square proportional to the weight (inverse-variance of log RR). Arrows indicate where the CI extends outside the
range allocated. Also shown are the combined random-effect estimates. These are represented by a diamond of standard height, with the width
indicating the 95% CI.
Lee et al. BMC Cancer 2012, 12:385 Page 38 of 90
http://www.biomedcentral.com/1471-2407/12/385
Table 8 Main meta-analyses for current smoking of any product (or cigarettes, if any product not available)a
Characteristic Level Statisticb All lung cancerc Squamousd Adenoe
All All n 195 41 44
F 9.29 (9.07-9.52) 13.77 (12.75-14.87) 4.77 (4.49-5.07)
R 8.43 (7.63-9.31) 16.91 (13.14-21.76) 4.21 (3.32-5.34)
H, PH 13.76, p < 0.001 7.22, p < 0.001 12.28, p < 0.001
PE p < 0.05 NS NS
Sex Male n 108 22 22
F 8.68 (8.36-9.02) 13.11 (11.85-14.51) 5.54 (5.04-6.09)
R 9.16 (8.00-10.49) 17.73 (12.78-24.59) 5.56 (4.06-7.61)
Female n 68 17 20
F 8.06 (7.75-8.38) 13.44 (11.86-15.23) 4.40 (4.05-7.79)
R 6.76 (5.65-8.08) 14.77 (9.42-23.17) 3.20 (2.18-4.71)
Combined n 19 2 2
F 13.19 (12.55-13.86) 34.23 (23.43-50.00) 3.11 (2.35-4.11)
R 12.09 (9.38-15.60) 34.23 (23.43-50.00) 3.57 (1.06-12.07)
Between levels PB <0.001 <0.01 <0.1
Location North America n 84 24 24
F 12.45 (12.09-12.82) 17.99 (16.29-19.85) 7.63 (7.05-8.25)
R 11.68 (10.61-12.85) 20.95 (15.41-28.48) 6.72 (5.50-8.21)
United Kingdom n 25 0 0
F 6.90 (6.10-7.81)
R 7.53 (5.40-10.50)
Scandinavia n 21 2 2
F 8.16 (7.30-9.12) 15.51 (6.63-36.28) 4.66 (2.67-8.13)
R 8.68 (7.14-10.54) 15.51 (6.63-36.28) 4.69 (2.62-8.40)
Other Europe n 23 6 6
F 5.88 (5.43-6.38) 12.22 (10.16-14.69) 2.65 (2.20-3.18)
R 8.65 (5.98-12.51) 13.66 (7.38-25.30) 3.30 (1.93-5.65)
China n 5 0 0
F 3.07 (2.56-3.68)
R 2.94 (2.23-3.88)
Japan n 18 8 11
F 3.68 (3.43-3.95) 6.85 (5.77-8.13) 2.11 (1.87-2.37)
R 3.55 (3.05-4.14) 11.25 (6.89-18.35) 1.87 (1.42-2.47)
Other Asia n 7 0 0
F 2.91 (2.26-3.76)
R 2.90 (2.04-4.13)
Other or multiregion n 12 1 1
F 7.09 (6.10-8.24) 10.40 (3.31-32.66) 7.90 (2.99-20.85)
R 9.88 (6.89-14.17) 10.40 (3.31-32.66) 7.90 (2.99-20.85)
Between levels PB <0.001 NS <0.001
Start year of study Before 1960 n 22 6 5
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Table 8 Main meta-analyses for current smoking of any product (or cigarettes, if any product not available)a
(Continued)
F 6.13 (5.70-6.59) 6.87 (4.93-9.08) 3.35 (2.43-4.62)
R 6.39 (4.70-8.69) 11.05 (4.07-30.00) 2.92 (1.17-7.28)
1960-69 n 40 7 7
F 5.43 (5.12-5.75) 10.55 (9.07-12.26) 4.22 (3.76-4.74)
R 6.44 (5.21-7.95) 15.48 (7.08-33.83) 4.55 (2.50-8.30)
1970-79 n 41 8 11
F 7.27 (6.79-7.79) 14.53 (12.21-17.29) 2.99 (2.55-3.50)
R 7.34 (5.94-9.06) 16.43 (8.67-31.14) 3.41 (2.10-5.53)
1980-89 n 70 18 19
F 12.35 (11.97-12.75) 16.70 (14.93-18.67) 6.38 (5.84-6.96)
R 10.18 (9.02-11.49) 19.69 (15.08-25.71) 5.06 (3.65-7.02)
1990 or later n 22 2 2
F 10.32 (9.10-11.70) 20.79 (10.16-42.55) 2.28 (1.63-3.19)
R 12.81 (8.70-18.85) 19.39 (6.38-58.88) 3.62 (0.92-14.29)
Between levels PB <0.001 NS NS
Study type Case–control n 128 30 34
F 9.69 (9.43-9.95) 13.59 (12.56-14.70) 4.71 (4.42-5.01)
R 8.56 (7.58-9.68) 16.21 (12.23-21.50) 3.88 (2.96-5.07)
Prospectivef n 67 11 10
F 8.04 (7.65-8.46) 18.87 (12.90-27.59) 5.93 (4.59-7.66)
R 8.15 (6.87-9.67) 19.63 (12.21-31.56) 5.95 (4.07-8.69)
Between levels PB NS NS p< 0.1
National cigarette tobacco type Virginia n 34 2 2
F 6.75 (6.12-7.44) 31.44 (15.03-65.78) 6.93 (4.35-11.07)
R 8.01 (6.16-10.41) 31.44 (15.03-65.78) 6.93 (4.35-11.07)
Blended n 154 39 42
F 9.70 (9.46-9.95) 13.65 (12.63-14.75) 4.74 (4.45-5.04)
R 8.92 (8.01-9.94) 16.41 (12.68-21.24) 4.10 (3.21-5.23)
Other n 7 0 0
F 3.13 (2.64-3.72)
R 3.09 (2.50-3.83)
Between levels PB <0.001 NS p < 0.1
Any proxy use Nog n 156 35 38
F 9.24 (9.00-9.48) 13.09 (12.09-14.18) 4.67 (4.39-4.98)
R 8.04 (7.17-9.01) 15.78 (12.00-20.74) 3.88 (2.99-5.03)
Yes n 39 6 6
F 9.68 (9.05-10.36) 27.96 (20.74-37.69) 6.88 (5.27-8.97)
R 10.03 (8.32-12.09) 27.96 (20.74-37.69) 6.88 (5.27-8.97)
Between levels PB <0.05 <0.01 p < 0.01
Full histological confirmation No n 144 24 23
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Table 8 Main meta-analyses for current smoking of any product (or cigarettes, if any product not available)a
(Continued)
F 8.87 (8.62-9.12) 11.53 (10.05-13.23) 3.99 (3.59-4.43)
R 7.91 (7.00-8.93) 19.20 (12.62-29.22) 5.59 (3.98-7.84)
Yes n 51 17 21
F 10.45 (9.99-10.92) 14.94 (13.61-16.40) 5.25 (4.87-5.67)
R 10.08 (8.46-12.01) 14.77 (10.61-20.57) 3.20 (2.28-4.49)
Between levels PB <0.05 NS p < 0.05
Number of casesh 100-249 n 56 8 11
F 5.50 (4.96-6.11) 5.62 (3.96-7.98) 2.54 (2.02-3.19)
R 6.90 (5.46-8.72) 11.28 (5.08-25.04) 2.45 (1.54-3.90)
250-499 n 48 9 9
F 8.47 (7.79-9.22) 16.67 (11.49-24.18) 3.20 (2.59-3.95)
R 8.60 (7.02-10.52) 17.09 (11.28-25.91) 3.83 (2.41-6.09)
500-999 n 38 4 4
F 7.56 (7.04-8.13) 22.44 (13.58-37.07) 7.35 (5.12-10.55)
R 9.54 (7.65-11.89) 22.44 (13.58-37.07) 7.35 (5.12-10.55)
1000+ n 53 20 20
F 10.01 (9.74-10.29) 14.15 (13.03-15.35) 5.18 (4.84-5.54)
R 9.03 (7.63-10.69) 17.87 (12.92-24.70) 4.97 (3.54-6.97)
Between levels PB NS NS p <0.01
Smoking product Any n 85 9 11
F 8.00 (7.64-8.37) 17.58 (11.99-25.77) 2.61 (2.16-3.14)
R 7.57 (6.47-8.84) 17.76 (11.75-26.86) 2.40 (1.59-3.61)
Cigarettes (ignoring n 95 26 28
other products) F 9.84 (9.56-10.14) 13.51 (12.47-14.64) 5.11 (4.79-5.46)
R 8.95 (7.76-10.33) 16.43 (12.08-22.33) 5.02 (3.76-6.70)
Cigarettes only n 15 6 5
F 9.77 (8.92-10.69) 17.80 (11.39-27.83) 5.69 (4.00-8.09)
R 10.51 (7.70-14.34) 18.04 (9.79-33.27) 5.56 (2.61-11.85)
Between levels PB NS NS p< 0.05
Unexposed base Never any product n 134 24 27
F 8.80 (8.55-9.06) 9.80 (8.75-10.98) 3.01 (2.75-3.29)
R 8.24 (7.28-9.34) 14.05 (9.75-20.23) 3.10 (2.37-4.07)
Never cigarettes n 61 17 17
F 10.43 (10.00-10.88) 18.44 (16.60-20.48) 7.17 (6.59-7.80)
R 8.89 (7.52-10.51) 21.71 (16.38-28.76) 6.61 (4.89-8.95)
Between levels PB NS <0.1 <0.001
Number of adjustment variables 0 n 86 16 17
F 10.84 (10.46-11.23) 14.93 (13.02-17.12) 4.28 (3.83-4.79)
R 9.40 (8.02-11.03) 17.15 (10.78-27.27) 3.90 (2.54-6.00)
1 n 62 15 14
F 7.80 (7.43-8.19) 19.11 (15.33-23.83) 3.25 (2.76-3.83)
R 7.28 (6.14-8.63) 18.27 (12.55-26.60) 3.46 (2.27-5.29)
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Table 8 Main meta-analyses for current smoking of any product (or cigarettes, if any product not available)a
(Continued)
2+ n 47 10 13
F 8.49 (8.13-8.87) 12.24 (11.04-13.57) 5.58 (5.13-6.05)
R 8.54 (7.02-10.39) 15.20 (9.40-24.58) 5.68 (3.80-8.49)
Between levels PB p < 0.1 NS NS
a Within each study, results for current smokers are selected in the following preference order, within each sex, for:
smoking product – any, cigarettes (ignoring other products), cigarettes only;
cigarette type – any, manufactured (with or without handrolled), manufactured only;
unexposed group – never any product, never cigarettes, near equivalent (see Methods);
follow-up period – longest available;
lung cancer type – see notes c to e;
race – all or nearest available, otherwise by race;
overlapping studies – principal, subsidiary;
age – whole study, widest available age group.
Results are then selected for:
sex – single sex results, combined sex results;
adjustment for potential confounders – most available.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p≥ 0.1), PE = probability value for Egger’s test of
publication bias similarly expressed, PB = probability value for between levels (see Methods) similarly expressed.
c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
d Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
e Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
f Or nested case–control or case-cohort in the case of 5 estimates for all lung cancer, 3 for squamous and 3 for adeno.
g Including not known.
h In the study as a whole.
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this was mainly due to relatively high RRs in North
America and low RRs in Asia. Other clear effects were
also associated with start year of study (p < 0.001, higher
risks in later studies, much more clearly evident than in
the univariable analyses in Table 5), study type (p < 0.01,
higher risks in prospective studies) and number of cases
(p < 0.001, higher risks in larger studies). There was no
significant effect of sex, and the weakly significant
(p < 0.05) effect for number of adjustment factors was
associated with an erratic pattern, with lower RRs where
the number of factors was 1, and higher RRs where it
was 0 or 2+. The heterogeneity for the fixed model
including all the six characteristics included in Table 7
was 4.72 per d.f., with the model explaining 80.5% of the
overall variation between the RRs. Inspection of standar-
dized residuals revealed eight estimates where the value
was outside the range +/− 2.5 SEs : MILLS/males (RR
1.33, fitted 3.35), LOMBA2/females (RR 1.33, fitted
5.07), TIZZAN/males (RR 1.93, fitted 3.50), WANG4/
males (RR 1.16, fitted 2.01), PERNU/males (RR 8.93, fit-
ted 4.37), LUBIN2/males (RR 8.50, fitted 5.47), BOFFET/
males (RR 14.20, fitted 7.78) and JUSSAW/males (RR
16.83, fitted 3.77). Only two other characteristics studied
significantly (p < 0.05) improved the fit of the model,
both related to study location. One was a variable
subdividing “Other Europe” (i.e. other than UK and
Scandinavia) into five smaller regions, with risk relatively
low in the Balkans (Greek and Turkish studies) and rela-
tively high in multiregional studies compared with the
rest, and the other a variable subdividing “Other Asia”(i.e. other than China or Japan) into three smaller
regions, with risk higher in India compared to Hong
Kong and the rest of Asia (Taiwan, Thailand, Singapore
and South Korea). No independent effect was evident
for national cigarette tobacco type. Additional analysis
(data not shown) confirmed the strong independent ef-
fect of start year of study separately within studies con-
ducted in North America, Europe and Asia, though the
tendency for higher RRs in more recent studies was
stronger in North America than in Europe, and the pat-
tern of variation was more erratic for Asia. It also con-
firmed the strong independent effects of location and
start year of study separately for males and for females.
For squamous, start year of study was the most im-
portant factor, on its own reducing the heterogeneity
from 5.17 to 4.33 per d.f. (p < 0.001). Other significant
characteristics included location (p < 0.001), with RRs
high in North America and low in China, and number
of cases (p < 0.05), with higher RRs in larger studies.
Number of adjustment factors was also significant
(p < 0.05), but the pattern was erratic and not the same
as for all lung cancer. Though the pattern of results by
study type was similar to that for all lung cancer, this
characteristic did not contribute significantly to the
model. The heterogeneity for the fixed model (Table 7)
was 3.18 per d.f., the model explaining 49.9% of the
overall variation. Two standardized residuals were out-
side the range +/− 2.5 SEs : STAYNE/males (RR 3.47, fit-
ted 10.50) and LUBIN2/males (RR 16.66, fitted 8.41).
Two other characteristics significantly improved the
model fit. One was national cigarette tobacco type, with
Table 9 Some alternative meta-analyses for current smoking compared to those in Table 8
Analysis description Statisticb All lung cancerc Squamousd Adenoe
As Table 8a n 195 41 44
F 9.29 (9.07-9.52) 13.77 (12.75-14.87) 4.77 (4.49-5.07)
R 8.43 (7.63-9.31) 16.91 (13.14-21.76) 4.21 (3.32-5.34)
H, PH 13.76, p < 0.001 7.22, p < 0.001 12.28, p < 0.001
Using more precise outcome definitionf n 187 33 40
F 9.93 (9.68-10.17) 12.74 (11.71-13.87) 4.40 (4.12-4.70)
R 8.79 (7.97-9.68) 16.43 (12.66-21.32) 4.05 (3.15-5.22)
H, PH 11.96, p < 0.001 5.70, p < 0.001 12.28, p < 0.001
Using least rather than most adjusted estimates n 195 41 44
F 9.12 (8.91-9.34) 13.81 (12.79-14.92) 4.82 (4.53-5.12)
R 8.26 (7.49-9.12) 16.83 (13.12-21.60) 4.27 (3.37-5.40)
H, PH 13.91, p < 0.001 7.17, p < 0.001 12.33, p < 0.001
Denominator non-smoker rather than never smoker n 188 36 38
F 3.99 (3.92-4.05) 3.59 (3.42-3.77) 2.65 (250–2.80)
R 3.75 (3.48-4.03) 4.71 (3.84-5.79) 2.46 (2.07-2.93)
H, PH 15.67, p < 0.001 12.71, p < 0.001 7.64, p < 0.001
Preferring results for cigarettes to results for any product n 195 41 44
F 9.47 (9.25-9.69) 13.77 (12.75-14.87) 4.77 (4.49-5.07)
R 8.64 (7.83-9.54) 16.91 (13.14-21.76) 4.21 (3.32-5.34)
H, PH 13.72, p < 0.001 7.22, p < 0.001 12.28, p < 0.001
Selecting results for cigarettes onlyg n 38 8 7
F 9.25 (8.81-9.71) 21.49 (16.73-27.61) 7.18 (5.71-9.04)
R 9.52 (7.89-11.49) 20.85 (14.84-29.29) 6.05 (3.69-9.92)
H, PH 10.61, p < 0.001 1.38, NS 2.98, p < 0.1
Selecting results specific for age <56 years n 25 2 3
F 7.64 (6.69-8.73) 6.48 (2.90-14.52) 0.74 (0.42-1.32)
R 6.57 (4.68-9.23) 6.48 (2.90-14.52) 0.74 (0.42-1.32)
H, PH 4.17, p < 0.001 0.33, NS 0.21, NS
Selecting results specific for age 50–70 years n 24 1 0
F 10.45 (9.65-11.31) 26.42 (9.78-71.36)
R 9.62 (7.10-13.05) 26.42 (9.78-71.36)
H, PH 9.99, p < 0.001 NA
Selecting results specific for age 65+ years n 27 0 0
F 8.79 (8.06-9.58)
R 9.07 (6.83-12.04)
H, PH 8.37, p < 0.001)
a See Table 8 for details of the definition of this analysis.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p≥ 0.1), PB = probability value for between levels (see
Methods) similarly expressed.
c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
d Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
e Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
f Only including results for all lung cancer, squamous cell carcinoma specifically, or adenocarcinoma specifically.
g See also Table 13 (footnote c).
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Table 10 Meta-regression analyses for current smoking of any product (or cigarettes if any product not available)a
Characteristic Level All lung cancer Squamous Adeno
Estimateb (SEc) pd Estimateb (SEc) pd Estimateb (SEc) pd
Constant +1.566 (0.081) +1.193 (0.239) +0.816 (0.239)
Sex Male Base <0.01 Base NS Base <0.001
Female −0.204 (0.029) −0.002 (0.088) −0.440 (0.067)
Combined −0.043 (0.039) +0.224 (0.459) −0.612 (0.378)
Location North America Base <0.001 Base <0.05 Base <0.001
United Kingdom −0.345 (0.071) No data No data
Scandinavia −0.417 (0.066) −0.177 (0.513) −0.298 (0.320)
Other Europe −0.602 (0.057) −0.440 (0.266) −1.157 (0.178)
China −1.528 (0.097) No data No data
Japan −1.174 (0.056) −1.174 (0.193) −1.525 (0.136)
Other Asia −1.221 (0.139) No data No data
Other or multiregion −0.593 (0.088) −1.221 (1.045) −1.014 (0.754)
Start year of study Before 1960 Base <0.001 Base <0.1 Base <0.05
1960-69 +0.538 (0.063) +1.374 (0.321) +1.179 (0.231)
1970-79 +0.571 (0.058) +0.896 (0.418) +1.142 (0.258)
1980-89 +0.788 (0.051) +1.276 (0.325) +0.957 (0.224)
1990 or later +1.169 (0.089) +2.817 (0.823) +1.982 (0.575)
Study type Case–control Base <0.1 Base NS Base NS
Prospectivee +0.182 (0.047) +0.404 (0.371) +0.178 (0.224)
Number of casesf 100-249 Base <0.1 Base NS Base NS
250-499 +0.222 (0.071) +0.420 (0.384) −0.002 (0.195)
500-999 +0.266 (0.070) +0.852 (0.400) +0.646 (0.232)
1000+ +0.340 (0.062) +0.803 (0.298) +0.362 (0.149)
Number of adjustment factors 0 Base NS Base <0.05 Base NS
1 +0.002 (0.047) +0.428 (0.277) +0.195 (0.213)
2+ +0.069 (0.034) −0.447 (0.175) +0.283 (0.125)
a Based on the same data as for Table 8. See that table for further definition of RRs selected for analysis, and numbers of estimates of each characteristic level.
b Estimates are of log RR. The predicted RR of a given estimate can be calculated by adding the constant to the values for the level of each characteristic
applicable to the estimate (taking the value for a base level as zero) and taking the exponential of the result.
c SE = standard error.
d The p value is estimated from the drop in deviance from removing the characteristic from the fixed model using an F-test. It is expressed as p < 0.001, p < 0.01,
p < 0.05, p < 0.1 or NS (p≥ 0.1).
e Or nested case–control or case-cohort in the case of 5 estimates for all lung cancer, 3 for squamous and 3 for adeno.
f In the study as a whole.
Note For the forward stepwise analyses, deviances, degrees of freedom and p values for inclusion in order of inclusion are as follows:
All lung cancer: Constant 2669.216 on 194 d.f. (p < 0.001), location 1257.714 on 187 d.f. (p < 0.001), start year of study 918.536 on 183 d.f. (p < 0.001) and sex
869.479 on 181 d.f. (p < 0.01). Fixed model deviance 819.856 on 175 d.f.
Squamous: Constant 288.688 on 40 d.f. (p < 0.001), location 194.753 on 36 d.f. (p < 0.01), start year of study 143.741 on 32 d.f. (p < 0.05) and number of
adjustment variables 100.916 on 30 d.f. (p < 0.01). Fixed model deviance 86.049 on 24 d.f.
Adeno: Constant 528.128 on 43 d.f. (p < 0.001), location 170.181 on 39 d.f. (p < 0.001), sex 128.397 on 37 d.f. (p < 0.01) and start year of study 89.243 on 33 d.f.
(p < 0.05). Fixed model deviance 65.727 on 27 d.f.
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smoked, than where blended tobacco was smoked. Also,
RRs were higher (p < 0.01) where they had been derived
by a relatively complex method (see Methods) than
where they were as reported originally, or derived by
more standard methods.
For adeno, location was the most important factor, on
its own reducing the heterogeneity from 8.78 to 4.36 perd.f. (p < 0.001), with the pattern of results (RRs high in
North America and low in Asia) similar to that for all
lung cancer. As for all lung cancer, there was variation
by start year of study (p < 0.05) and number of cases
(p < 0.05), with RRs higher for recent and larger studies.
RRs were again higher for prospective studies, but here
the difference was not significant (p ≥ 0.05). Here, vari-
ation by sex was significant (p < 0.05) with RRs higher
Table 11 Main meta-analyses for current or ever smoking of any product (or cigarettes, if not available)a
Preference Statisticb All lung cancerc Squamousd Adenoe
Ever smoking to current smoking n 342 110 116
F 4.25 (4.20-4.31) 9.15 (8.63-9.70) 3.38 (3.23-3.55)
R 5.48 (5.07-5.93) 10.58 (9.04-12.37) 2.94 (2.52-3.43)
H, PH 22.46, p < 0.001 5.22, p < 0.001 8.61, p < 0.001
Current smoking to ever smoking n 344 110 116
F 4.45 (4.39-4.51) 10.08 (9.51-10.69) 3.58 (3.41-3.76)
R 6.20 (5.68-6.77) 11.53 (9.73-13.66) 3.13 (2.67-3.67)
H, PH 28.33, p < 0.001 6.30, p < 0.001 8.99, p < 0.001
a Within each study, results are selected in the following preference order, within each sex, for:
smoking status – ever, current or current, ever according to analysis;
smoking product – any, cigarettes (ignoring other products), cigarettes only;
cigarette type – any, manufactured (with or without handrolled), manufactured only;
unexposed group – never any product, never cigarettes, near equivalent (see Methods);
follow-up period – longest available;
lung cancer type – see notes c to e;
race – all or nearest available, otherwise by race;
overlapping studies – principal, subsidiary;
age – whole study, widest available age group.
Results are then selected for:
sex – single sex results, combined sex results;
adjustment for potential confounders – most available.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p≥ 0.1), PB = probability value for between levels (see
Methods) similarly expressed.
c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
d Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
e Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
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tors was not (p≥ 0.05). The heterogeneity for the fixed
model (Table 7) was 3.27 per d.f., the model explaining
69.5% of the overall variation. Two standardized resi-
duals were outside the range +/− 2.5 SEs : LOMBA2/
females (RR 0.53, fitted 2.32) and WYNDER6/females
(RR 13.99 fitted 6.22). Four other characteristics signifi-
cantly improved the model fit. One was “Other Asia”
(p < 0.05) where RRs were high in India (based on a sin-
gle RR from JUSSAW) and relatively low in Hong Kong,
Taiwan, Thailand, Singapore and South Korea. National
cigarette tobacco type was also significant (p < 0.05), with
RRs for blended higher than for Virginia, opposite to the
finding for squamous. RRs were also lower where there
was any use of proxy respondents (p < 0.05). Also, RRs
varied (p < 0.001) by the detailed definition of adenocar-
cinoma used. This appeared to be mainly because of a
low RR for “not squamous or undifferentiated”, a defin-
ition used only for LOMBA2/females, where the stan-
dardized residual of −3.721 SEs was the largest for any
RR (see also above).
The fixed model (Table 7) considered how RR esti-
mates varied by six main characteristics and additional
analyses (see Additional file 5: Detailed Analysis Tables)
tested whether adding in further characteristics
improved the model fit. Characteristics which did not
improve the fit for any of the three outcomesconsidered included whether there was adjustment
for specific factors (such as age), the age of the sub-
jects studied, the definition of smoking product, the
definition of the unexposed base, whether the study
was conducted in a population working in a risky
occupation, and whether the study procedures
required full histological confirmation.
B. Risk from current smoking
Figures 10, 11, 12 (all lung cancer), Figure 13 (squa-
mous) and Figure 14 (adeno) present the results of the
main meta-analyses for current smoking of any product.
As before, RRs for smoking of cigarettes are used if
RRs for any product smoking are not available, and
RRs are most-adjusted. For prospective studies,
current smoking refers to smoking status as at base-
line. Table 8 presents additional results by level of
the same set of characteristics considered in Table 5,
while Table 9 presents results of alternative meta-
analyses of current smoking.
As for ever smoking, the RRs for all three outcomes
are heterogeneous (p < 0.001), with the largest estimates
seen being 104.50 for all lung cancer (STUCKE/males),
78.91 for squamous (CPSII/females), and 21.70 for adeno
(OSANN/males). The random-effects estimates (all lung
cancer 8.43, 95% CI 7.63-9.31, n = 195; squamous 16.91,
13.14-21.76, n = 41; adeno 4.21, 3.32-5.34, n = 44) are all
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Figure 15 Forest plot of ex smoking of any product and all lung cancer – part 1. Table 12 presents the results of a main meta-analysis for all
lung cancer based on 182 relative risk (RR) and 95% confidence interval (CI) estimates for ex smoking of any product (or cigarettes if any product not
available). The individual study estimates are shown numerically and graphically on a logarithmic scale in Figures 15, 16, 17. The studies are sorted in order
of sex within study reference (REF) within start year of study (START) within continent (CONT). In the graphical representation individual RRs are indicated
by a solid square, with the area of the square proportional to the weight (inverse-variance of log RR). Arrows indicate where the CI extends outside the
range allocated. For studies DORGAN and KELLER separate estimates, within sex, are shown for whites then blacks. For study HUMBLE they are shown for
non-hispanic whites then Hispanics. For study KELLER the estimate shown for females is for whites.
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CONT START REF SEX Relative RiskRelative Risk
95% CI95% CI
          1985 KELLER f 5.70 (3.86, 8.42)
          1985 KH )09.11,08.4(05.7mREDU
          1986 ANDERS f 6.57 (4.59, 9.40)
          1986 NAM m 9.17 (6.12, 13.74)
          1986 NAM f 8.27 (5.76, 11.87)
          1988 SHAW c 6.45 (3.32, 12.53)
)37.21,58.3(00.7cNEPRAC1991
          1992 GARCIA c 6.42 (3.92, 10.52)
          1992 LEMARC c 3.34 (2.17, 5.15)
          1992 SPITZ c 15.31 (6.70, 35.02)
          1992 TANG c 7.39 (3.19, 17.11)
)06.63,08.4(02.31mYESUOT3991
          1993 TOUSEY f 9.10 (4.80, 17.10)
)43.11,31.2(29.4mLLOD8491EPORUE
          1948 DOLL f 1.84 (0.67, 5.08)
          1951 DOLL2 m 4.17 (2.61, 6.66)
          1951 DOLL2 f 3.29 (0.88, 12.24)
          1954 PETO m 0.76 (0.11, 5.38)
          1959 TIZZAN m 2.01 (1.58, 2.56)
          1959 TIZZAN f 3.65 (1.31, 10.17)
          1960 BRETT m 0.93 (0.33, 2.62)
          1960 DEAN2 m 3.78 (2.33, 6.13)
          1960 DEAN2 f 3.44 (0.65, 18.13)
)08.01,05.1(20.4mNAKNET2691
)43.2,76.0(52.1mLREDEC3691
          1963 CEDERL f 1.08 (0.34, 3.44)
)02.7,80.1(08.2mALEGNE4691
          1964 ENGELA f 2.00 (0.80, 4.90)
)05.7,78.0(55.2mNARGIM4691
          1964 MIGRAN f 1.54 (0.17, 13.71)
          1965 KUBIK m 11.49 (2.44, 54.04)




          1967 TULINI m 3.03 (1.54, 5.98)
          1967 TULINI f 3.69 (1.71, 7.99)
          1969 DEAN3 m 4.48 (2.75, 7.30)
          1969 DEAN3 f 1.17 (0.51, 2.69)
          1970 HEIN m 5.13 (0.66, 39.65)
)11.6,76.2(40.4mREBMAD2791
          1972 HOLE m 2.69 (1.16, 6.23)
)10.1,42.0(94.0mADREVT2791
          1972 TVERDA f 0.58 (0.03, 11.18)
)68.1,82.0(27.0mROGERG6791
          1976 GREGOR f 5.50 (0.56, 53.99)
          1976 LANGE m 2.10 (0.70, 6.00)
          1976 LANGE f 3.40 (1.10, 11.00)
          1976 LUBIN2 m 4.38 (3.71, 5.16)
          1976 LUBIN2 f 2.61 (1.97, 3.46)
)88.3,03.2(99.2mKMHOLB8791
          1979 BA )06.11,04.4(01.7mNOBR
          1979 KJUUS m 6.24 (1.40, 27.78)
)65.4,41.2(21.3mCYRDEJ0891
          1980 JEDRYC f 3.46 (1.38, 8.69)
)44.3,89.1(16.2c2HSREP0891
          1983 JA )70.021,48.1(68.41mOHVR
          1983 JARVHO f 4.38 (1.19, 16.04)
          1983 SVENSS f 2.60 (1.40, 5.10)
)69.12,39.1(25.6mREHCEB5891
          1985 BECHER f 1.44 (0.44, 4.80)
)91.44,35.5(46.51mADAMRA6891
)63.9,89.1(03.4mTNAROD6891
          1987 KATSOU f 2.84 (0.81, 9.98)
          1988 DARBY m 32.98 (10.51, 103.49)
          1988 DARBY f 6.82 (4.23, 10.99)
          1988 GARDIN c 7.64 (2.75, 21.22)
          1988 JAHN m 8.68 (5.22, 14.44)
Figure 16 Forest plot of ex smoking of any product and all lung cancer – part 2. This is a continuation of Figure 15, presenting further
individual study data included in the main meta-analysis for all lung cancer shown in Table 12. For study KELLER the estimate shown for females
is for non-whites.
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95% CI95% CI
          1989 AGUDO f 1.61 (0.37, 6.91)
)70.8,06.2(85.4mSSLEXA9891
          1989 AXELSS f 2.99 (1.37, 6.53)
          1989 STUCKE m 135.69 (8.30, 2218.34)
          1990 KREUZE m 1.70 (0.60, 5.20)
          1990 KREUZE m 9.10 (5.90, 14.10)
          1990 KREUZE f 2.50 (0.70, 9.00)
          1990 KREUZE f 1.40 (0.80, 2.40)
          1991 RACHTA f 3.80 (1.21, 7.84)
          1992 ODRISC c 40.87 (17.90, 93.34)
          1995 DROSTE m 4.20 (1.80, 9.80)
)55.9,36.1(59.3mUSOTIH0691AISA
          1960 HITOSU f 6.72 (2.55, 17.68)
          1963 AKIBA m 2.50 (1.50, 4.30)
          1963 AKIBA f 1.40 (0.70, 2.60)
          1965 HIRAYA m 1.71 (1.08, 2.72)
          1965 HIRAYA f 2.98 (1.14, 7.77)
)98.5,23.0(63.1mNELCAM2791
          1972 MACLEN f 0.80 (0.21, 3.04)
          1976 TSUGAN m 1.53 (0.50, 4.68)
          1980 WANG2 c 2.00 (0.77, 5.20)
          1981 KOO f 3.34 (1.47, 7.58)
          1984 GAO m 4.17 (2.85, 6.12)
          1984 GAO f 4.24 (2.67, 6.75)
          1984 LUBIN m 4.03 (1.90, 8.53)
          1985 CHOI m 1.88 (0.94, 3.74)
          1985 CHOI f 4.32 (1.05, 17.72)
          1986 SOBUE m 2.80 (1.90, 4.20)
          1986 SOBUE f 2.10 (1.40, 3.20)
          1988 GAO2 m 3.56 (1.83, 6.91)
          1988 WAKAI m 2.43 (1.16, 5.06)
          1988 WAKAI f 5.33 (1.21, 23.50)
)09.5,34.1(09.2cUGAMAY9891
          1991 KIHARA c 1.83 (1.20, 2.79)
          1992 QIAO2 m 1.33 (0.65, 2.71)
OTHER 1961 DEKLER m 10.70 (1.40, 81.90)
)08.5,09.1(04.3mNIKRAP3691
          1978 JOLY m 8.80 (4.71, 16.44)
          1978 JOLY f 6.85 (3.82, 12.31)
          1987 PEZZOT m 10.18 (3.61, 28.67)
)51.01,87.3(02.6mFETSED8891
          1990 WUNSCH m 3.28 (1.77, 6.07)
          1990 WUNSCH f 3.51 (1.74, 7.10)
)00.72,02.2(07.7c2KUZUS1991
          1992 PEZZO2 m 9.21 (3.95, 21.48)
          1993 DESTE2 c 8.10 (4.50, 14.70)
          1994 MATOS m 5.30 (2.60, 10.70)
Total (95% CI) 4.30 (3.93, 4.71)
Figure 17 Forest plot of ex smoking of any product and all lung cancer – part 3. This is a continuation of Figure 16, presenting the
remaining individual study data included in the main meta-analysis for all lung cancer shown in Table 12. Also shown are the combined
random-effect estimates. These are represented by a diamond of standard height, with the width indicating the 95% CI. For study KREUZE
separate estimates, within sex, are shown for age≤ 45 and 55–69.
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for ever smoking, and also show a stronger relationship
with squamous than adeno. Similarly to ever smoking,the individual RRs are virtually all above 1.0, though
varying substantially. The estimates are again little
affected (Table 9) by preferring least, rather than most,
0.20 0.40 1.00 25.00 50.00
CONT START REF SEX Relative RiskRelative Risk
95% CI95% CI
)25.2,06.0(32.1mNOMMAH2591ACIREMAN
          1955 HAENSZ f 1.79 (0.47, 6.87)
          1964 OSANN2 f 12.60 (1.40, 113.00)
          1966 WYNDE3 m 8.45 (2.52, 28.30)
          1969 WYNDE6 m 13.70 (9.33, 20.13)
          1969 WYNDE6 f 10.60 (7.33, 15.33)
)85.42,52.1(35.5mOTSMOC5791
          1975 COMSTO f 9.76 (0.39, 244.93)
          1976 BUFFLE f 12.67 (3.60, 44.62)
)00.62,03.9(05.51cAERROC9791
          1981 JAIN m 12.56 (2.98, 52.99)
          1981 JAIN f 8.09 (3.18, 20.59)
          1981 WU f 7.70 (0.80, 70.30)
          1984 BROWN2 m 8.70 (7.40, 10.20)
          1984 BROWN2 f 19.20 (15.20, 24.20)
          1984 OSANN m 22.90 (11.00, 47.30)
          1984 OSANN f 13.50 (6.80, 27.00)
          1985 KHUDER m 6.70 (3.20, 14.10)
)00.41,02.1(01.4mALEGNE4691EPORUE
          1976 LUBIN2 m 12.40 (9.39, 16.36)
          1976 LUBIN2 f 4.70 (3.12, 7.06)
)00.12,07.3(08.8mNOBRAB9791
)35.61,29.2(59.6mCYRDEJ0891
          1983 SVENSS f 4.00 (1.00, 16.90)
          1987 KATSOU f 4.70 (1.05, 21.14)
          1988 JAHN m 21.74 (6.84, 69.13)
)25.423,73.0(00.11mNAGUST6791AISA
          1986 SOBUE m 13.10 (5.20, 33.40)
          1986 SOBUE f 5.60 (2.30, 13.80)
          1988 WAKAI m 6.16 (1.42, 26.70)
          1988 WAKAI f 9.76 (0.85, 112.00)
          1991 KIHARA c 14.22 (5.17, 39.09)
OTHER 1994 MATOS m 3.60 (1.00, 12.90)
Total (95% CI) 8.74 (6.94, 11.01)
Figure 18 Forest plot of ex smoking of any product and squamous. Table 12 presents the results of a main meta-analysis for squamous
based on 33 relative risk (RR) and 95% confidence interval (CI) estimates for ex smoking of any product (or cigarettes if any product not available).
The individual study estimates are shown numerically and graphically on a logarithmic scale. The studies are sorted in order of sex within study
reference (REF) within start year of study (START) within continent (CONT). In the graphical representation individual RRs are indicated by a solid
square, with the area of the square proportional to the weight (inverse-variance of log RR). Arrows indicate where the CI extends outside the
range allocated. Also shown are the combined random-effect estimates. These are represented by a diamond of standard height, with the width
indicating the 95% CI.
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definition, or by preferring RRs for current smoking of
cigarettes to those for current smoking of any product.
Again estimates based specifically on cigarette only
smoking were slightly higher than those shown in Table 8
– 9.52 (7.89-11.49, n = 38) for all lung cancer, 20.85
(14.84-29.29, n = 8) for squamous, and 6.05 (3.69-9.92,
n = 7) for adeno. More so than in Table 6, data by agewere rather limited for squamous and adeno. For all
lung cancer estimates were 6.57 (4.68-9.23, n = 25) for
age <56 years, 9.62 (7.10-13.05, n = 24) for age 50–
70 years, and 9.07 (6.83-12.04, n = 27) for age 65+ years,
no clear trend being evident. Table 9 also includes
results for the comparison current vs. non-current smo-
kers. The RRs here (3.75, 3.48-4.03 for all lung cancer;
4.71, 3.84-5.79 for squamous; 2.46, 2.07-2.93 for adeno)
0.20 0.40 1.00 25.00 50.00
CONT START REF SEX Relative RiskRelative Risk
95% CI95% CI
N AMERICA 1955 HAENSZ f 1.42 (0.29, 6.82)
          1964 OSANN2 f 1.70 (0.50, 5.30)
          1966 WYNDE3 m 1.41 (0.51, 3.89)
          1969 WYNDE6 m 4.11 (3.07, 5.51)
          1969 WYNDE6 f 3.78 (2.90, 4.94)
          1975 COMSTO m 4.23 (0.93, 19.23)
          1975 COMSTO f 2.46 (0.80, 7.58)
          1976 BUFFLE f 5.71 (2.28, 14.32)
)05.6,01.2(07.3cAERROC9791
          1981 JAIN m 4.01 (1.37, 11.76)
          1981 JAIN f 1.56 (0.80, 3.04)
          1981 WU f 1.20 (0.60, 2.30)
          1984 BROWN2 m 7.40 (6.20, 8.80)
          1984 BROWN2 f 7.20 (6.20, 8.50)
          1984 OSANN m 13.10 (7.40, 23.20)
          1984 OSANN f 5.80 (3.80, 9.00)
          1985 KHUDER m 8.00 (3.50, 18.20)
EUROPE 1964 ENGELA m 1.10 (0.40, 3.10)
          1976 LUBIN2 m 2.30 (1.71, 3.10)
          1976 LUBIN2 f 0.93 (0.54, 1.57)
          1979 BARBON m 5.50 (2.40, 12.60)
          1980 JEDRYC m 2.78 (1.16, 6.63)
          1983 SVENSS f 1.80 (0.80, 4.30)
          1987 KATSOU f 1.81 (0.37, 8.70)
          1988 JAHN m 5.45 (2.60, 11.42)
ASIA 1976 TSUGAN m 1.26 (0.36, 4.39)
          1978 SUZUKI m 3.20 (1.52, 6.63)
          1978 SUZUKI f 1.60 (0.48, 5.51)
          1986 SOBUE m 1.50 (0.90, 2.40)
          1986 SOBUE f 1.70 (1.00, 3.00)
          1988 WAKAI m 1.40 (0.59, 3.31)
          1988 WAKAI f 2.69 (0.68, 10.60)
          1991 KIHARA c 1.17 (0.70, 1.96)
OTHER 1994 MATOS m 4.80 (1.80, 12.90)
Total (95% CI) 2.85 (2.20, 3.70)
Figure 19 Forest plot of ex smoking of any product and adeno. Table 5 presents the results of a main meta-analysis for adeno based
on 34 relative risk (RR) and 95% confidence interval (CI) estimates for ex smoking of any product (or cigarettes if any product not available).
The individual study estimates are shown numerically and graphically on a logarithmic scale. The studies are sorted in order of sex within study
reference (REF) within start year of study (START) within continent (CONT). In the graphical representation individual RRs are indicated by a
solid square, with the area of the square proportional to the weight (inverse-variance of log RR). Arrows indicate where the CI extends outside
the range allocated. Also shown are the combined random-effect estimates. These are represented by a diamond of standard height, with the
width indicating the 95% CI.
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for current vs. never smokers, reflecting the increased
risk in ex-smokers described later (see section D below).
For the main meta-analysis, the studies contributing
most to the total weight for current smoking for all lung
cancer were STOCKW/sexes combined (17.8% of the
total of 6,750) followed by BROWNS/males (6.0%) and
BROWNS/females (5.4%). BROWNS was the majorcontributor for both squamous and adeno, with the two
sex-specific results contributing 36.0% of the total
weight of 646 for squamous, and 30.0% of the total
weight of 1,017 for adeno. The huge LIU4 study did not
provide results for current smoking.
For the characteristics considered in Table 8, the pat-
tern of variation has a number of similarities to that for
ever smoking in Table 5. Thus, as for ever smoking, RRs
Table 12 Main meta-analyses for ex smoking of any product (or cigarettes, if any product not available)a
Characteristic Level Statisticb All lung cancerc Squamousd Adenoe
All All n 182 33 34
F 5.80 (5.63-5.96) 10.25 (9.34-11.24) 4.38 (4.04-4.73)
R 4.30 (3.93-4.71) 8.74 (6.94-11.01) 2.85 (2.20-3.70)
H, PH 6.98, <0.001 3.54, <0.001 7.91, <0.001
PE p < 0.001 NS p < 0.001
Sex Male n 100 17 17
F 5.15 (4.93-5.37) 9.31 (8.27-10.47) 4.59 (4.10-5.15)
R 4.48 (3.98-5.06) 8.41 (6.18-11.45) 3.45 (2.40-4.96)
Female n 62 14 15
F 5.81 (5.51-6.14) 11.66 (9.94-13.68) 4.48 (4.00-5.02)
R 3.58 (3.00-4.29) 8.03 (5.18-12.45) 2.39 (1.55-3.69)
Combined n 20 2 2
F 6.98 (6.61-7.37) 15.23 (9.63-24.08) 1.97 (1.35-2.88)
R 5.58 (4.23-7.36) 15.23 (9.63-24.08) 2.07 (0.67-6.38)
Between levels PB <0.05 <0.1 NS
Location North America n 80 18 17
F 6.79 (6.57-7.01) 10.83 (9.73-12.05) 5.69 (5.20-6.23)
R 5.44 (4.91-6.03) 9.43 (6.84-13.01) 4.08 (3.08-5.39)
United Kingdom n 21 0 0
F 4.14 (3.48-4.92)
R 3.72 (2.51-5.50)
Scandinavia n 21 2 2
F 2.67 (2.29-3.11) 4.06 (1.61-10.25) 1.48 (0.77-2.83)
R 2.62 (2.01-3.42) 4.06 (1.61-10.25) 1.48 (0.77-2.83)
Other Europe n 24 6 6
F 3.57 (3.26-3.92) 9.10 (7.38-11.22) 2.27 (1.82-2.84)
R 3.96 (3.07-5.12) 8.42 (5.03-14.10) 2.58 (1.47-4.52)
China n 5 0 0
F 3.46 (2.70-4.44)
R 3.09 (2.02-4.74)
Japan n 14 6 8
F 2.35 (2.01-2.76) 9.32 (5.69-15.28) 1.60 (1.25-2.05)
R 2.40 (1.99-2.89) 9.32 (5.69-15.28) 1.60 (1.25-2.05)
Other Asia n 5 0 0
F 2.13 (1.37-3.32)
R 2.12 (1.29-3.47)
Other or multiregion n 12 1 1
F 5.77 (4.73-7.03) 3.60 (1.00-12.93) 4.80 (1.79-12.85)
R 5.84 (4.60-7.41) 3.60 (1.00-12.93) 4.80 (1.79-12.85)
Between levels PB <0.001 NS <0.001
Start year of study Before 1960 n 18 2 1
F 3.55 (3.19-3.94) 1.34 (0.71-2.52) 1.42 (0.29-6.82)
R 3.81 (2.84-5.11) 1.34 (0.71-2.52) 1.42 (0.29-6.82)
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Table 12 Main meta-analyses for ex smoking of any product (or cigarettes, if any product not available)a (Continued)
1960-69 n 36 5 5
F 4.06 (3.68-4.48) 11.29 (8.77-14.54) 3.56 (2.95-4.29)
R 3.32 (2.71-4.08) 11.29 (8.77-14.54) 2.80 (1.86-4.21)
1970-79 n 36 8 10
F 3.81 (3.50-4.14) 9.85 (8.08-12.02) 2.38 (1.95-2.91)
R 3.48 (2.85-4.25) 9.39 (6.00-14.68) 2.59 (1.75-3.84)
1980-89 n 70 16 16
F 6.91 (6.68-7.15) 10.97 (9.75-12.36) 5.67 (5.13-6.26)
R 5.22 (4.65-5.86) 10.35 (7.57-14.15) 3.37 (2.35-4.85)
1990 or later n 22 2 2
F 4.73 (4.11-5.43) 8.38 (3.79-18.53) 1.58 (1.00-2.49)
R 5.17 (3.66-7.31) 7.58 (1.98-29.00) 2.22 (0.56-8.79)
Between levels PB <0.001 <0.001 NS
Study type Case–control n 123 28 30
F 6.28 (6.09-6.48) 10.71 (9.74-11.76) 4.44 (4.10-4.81)
R 4.88 (4.41-5.41) 9.94 (8.05-12.28) 2.96 (2.26-3.87)
Prospectivef n 59 5 4
F 3.84 (3.58-4.12) 2.34 (1.35-4.03) 1.87 (1.04-3.36)
R 3.18 (2.70-3.74) 3.54 (1.38-9.09) 1.87 (1.04-3.36)
Between levels PB <0.001 <0.05 NS
National cigarette tobacco type Virginia n 30 2 2
F 3.95 (3.45-4.53) 9.22 (4.21-20.18) 2.03 (1.15-3.57)
R 3.79 (2.85-5.04) 9.22 (4.21-20.18) 2.27 (0.92-5.59)
Blended n 147 31 32
F 5.94 (5.77-6.12) 10.26 (9.35-11.27) 4.44 (4.10-4.81)
R 4.45 (4.04-4.91) 8.68 (6.83-11.04) 2.89 (2.22-3.77)
Other n 5 0 0
F 3.46 (2.70-4.44)
R 3.09 (2.02-4.74)
Between levels PB NS NS NS
Any proxy use Nog n 141 27 28
F 6.02 (5.84-6.21) 10.17 (9.23-11.20) 4.46 (4.11-4.84)
R 4.12 (3.70-4.59) 8.33 (6.38-10.89) 2.73 (2.04-3.65)
Yes n 41 6 6
F 4.60 (4.26-4.96) 11.24 (8.01-15.78) 3.30 (2.42-4.52)
R 4.79 (4.20-5.47) 11.24 (8.01-15.78) 3.39 (2.25-5.11)
Between levels PB <0.1 NS NS
Full histological confirmation No n 131 16 15
F 5.73 (5.53-5.93) 8.91 (7.03-11.30) 3.50 (2.89-4.23)
R 4.11 (3.68-4.60) 8.11 (5.05-13.01) 3.24 (2.13-4.94)
Yes n 51 17 19
F 5.93 (5.65-6.23) 10.51 (9.50-11.62) 4.59 (4.21-5.00)
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Table 12 Main meta-analyses for ex smoking of any product (or cigarettes, if any product not available)a (Continued)
R 4.76 (4.02-5.63) 9.28 (7.08-12.15) 2.60 (1.85-3.65)
Between levels PB NS NS NS
Number of casesg 100-249 n 51 7 9
F 3.18 (2.79-3.64) 4.03 (2.17-7.49) 1.95 (1.40-2.70)
R 3.36 (2.65-4.25) 4.03 (2.17-7.49) 1.95 (1.40-2.70)
250-499 n 45 9 8
F 4.21 (3.80-4.66) 4.59 (3.17-6.65) 1.86 (1.36-2.54)
R 4.13 (3.42-4.99) 5.48 (2.84-10.58) 2.10 (1.21-3.64)
500-999 n 37 4 4
F 4.61 (4.21-5.04) 9.58 (5.65-16.25) 3.23 (2.13-4.90)
R 4.86 (4.07-5.80) 9.58 (5.65-16.25) 3.58 (1.79-7.13)
1000+ n 49 13 13
F 6.39 (6.19-6.60) 11.13 (10.08-12.28) 5.00 (4.59-5.45)
R 4.76 (4.13-5.48) 11.53 (8.87-14.99) 3.69 (2.60-5.22)
Between levels PB <0.05 <0.01 <0.05
Smoking product Any n 81 9 9
F 4.76 (4.51-5.02) 8.13 (5.16-12.79) 1.60 (1.21-2.12)
R 4.09 (3.53-4.74) 8.13 (5.16-12.79) 1.68 (1.17-2.40)
Cigarettes (ignoring n 90 23 25
other products) F 6.38 (6.16-6.60) 10.75 (9.77-11.83) 4.77 (4.40-5.18)
R 4.49 (3.98-5.06) 9.99 (7.93-12.58) 3.35 (2.54-4.41)
Cigarettes only n 11 1 0
F 4.96 (4.36-5.64) 1.23 (0.60-2.52)
R 4.18 (2.63-6.66) 1.23 (0.60-2.52)
Between levels PB NS <0.001 <0.01
Unexposed base Never any product n 121 17 18
F 5.64 (5.44-5.85) 8.41 (7.12-9.94) 2.38 (2.06-2.76)
R 4.35 (3.89-4.88) 6.63 (4.39-10.02) 2.17 (1.61-2.94)
Never cigarettes n 61 16 16
F 6.08 (5.80-6.37) 11.19 (10.00-12.51) 5.60 (5.10-6.15)
R 4.18 (3.56-4.91) 11.13 (8.48-14.60) 3.83 (2.78-5.27)
Between levels PB NS <0.05 <0.05
Number of adjustment factors 0 n 86 16 16
F 6.10 (5.87-6.34) 9.81 (8.41-11.45) 2.82 (2.47-3.22)
R 4.84 (4.26-5.50) 9.11 (6.95-11.94) 2.61 (1.91-3.58)
1 n 48 10 9
F 4.40 (4.11-4.71) 7.03 (5.21-9.47) 2.13 (1.66-2.73)
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Table 12 Main meta-analyses for ex smoking of any product (or cigarettes, if any product not available)a (Continued)
R 3.96 (3.37-4.65) 6.43 (3.31-12.47) 2.17 (1.56-3.03)
2+ n 48 7 9
F 6.23 (5.91-6.58) 11.28 (9.94-12.80) 6.64 (5.97-7.39)
R 3.81 (3.11-4.66) 11.09 (6.78-18.13) 4.42 (3.05-6.40)
Between levels PB <0.1 NS <0.05
a Within each study, results for ex smokers are selected in the following preference order, within each sex, for:
smoking product – any, cigarettes (ignoring other products), cigarettes only;
cigarette type – any, manufactured (with or without handrolled), manufactured only;
unexposed group – never any product, never cigarettes, near equivalent (see Methods);
follow-up period – longest available;
lung cancer type – see notes c to e;
race – all or nearest available, otherwise by race;
overlapping studies – principal, subsidiary;
age – whole study, widest available age group.
Results are then selected for:
sex – single sex results, combined sex results;
adjustment for potential confounders – most available.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p≥ 0.1), PE = probability value for Egger’s test of
publication bias similarly expressed, PB = probability value for between levels (see Methods) similarly expressed.
c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
d Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
e Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
f Or nested case–control or case-cohort in the case of 5 estimates for all lung cancer, 3 for squamous and 3 for adenocarcinoma.
g In the study as a whole.
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North American studies, and where the unexposed base
is never cigarettes, and smaller for older studies and
smaller studies, with no clear variation by extent of
adjustment. A tendency for RRs to be higher where data
may be reported by proxy respondents seems somewhat
stronger for current smoking, although based on few esti-
mates for squamous and adeno. A tendency for RRs to be
higher where the smoking product is cigarettes or cigar-
ettes only than when it is any product is also evident,
though not for squamous, whereas it was seen most clearly
in squamous for ever smoking. There is also some indica-
tion that RRs are higher in prospective studies, though
interestingly not for all lung cancer. Whereas for ever
smoking, RRs for studies requiring full histological con-
firmation were higher than for those that did not for all
three outcomes, the tendency was in the reverse direction
for squamous and adeno for current smoking. For national
cigarette tobacco type, current smoking RRs for squamous
and adeno are virtually all for blended, so are unhelpful.
For all lung cancer, RRs are quite similar for Virginia and
blended, the significant (p < 0.001) variation shown in
Table 8 arising because of the low RRs in the “Other”
group, mainly for China.
As for ever smoking, meta-regression analyses were
conducted to give further insight, the results from the
same fixed model including six characteristics being
summarized in Table 10. Based on these results and
those for other characteristics in Additional file 5:
Detailed Analysis Tables various conclusions can be
drawn.For all lung cancer, as was the case for ever smoking
RRs, by far the strongest source of variation in current
smoking RRs was location with relatively high risks in
North America and low risks in Asia. The overall het-
erogeneity reduced from 13.76 per d.f. to 6.73 per d.f.
after including location only into the model. Higher risks
were also seen in the fixed model in more recent studies
(p < 0.001) and for males than females (p < 0.01). There
was some evidence (p < 0.1) of higher RRs in larger stud-
ies and in prospective studies, but no association was
seen with the number of adjustment factors. The hetero-
geneity for the fixed model shown in Table 10 was 4.68
per d.f., with the model explaining 69.3% of the overall
variation between the current smoking RRs. Four stan-
dardized residuals were outside the range +/− 2.5 SEs :
BROWN2/males (RR 11.30, fitted 15.86), TIZZAN/males
(RR 1.90, fitted 3.68), CPSI/females (RR 3.20, fitted 6.59)
and KREUZE/males aged 55–69 (RR 41.86, fitted 11.85).
No other characteristic significantly improved the fit
when added to the fixed model. Additional analysis (data
not shown) confirmed the effect of start year of study
separately for North America and Europe (though no
such relationship was seen in Asia) and also confirmed
that the effects of location and start year of study were
evident separately for males and for females.
For squamous and adeno, numbers of current smoking
RRs (41 and 44 respectively) were much lower than those
for all lung cancer, with no data for China or the United
Kingdom, or for national cigarette type “other”. For squa-
mous, only two characteristics in the fixed model
(Table 10) were significant, and then only at p < 0.05, and
Table 13 Meta-analyses for smoking of cigarettes, cigars and pipes (all lung cancer)a
Product smoked Statisticb Ever smoking Current smoking Ex smoking
Cigarettes only n 53c 35c 21
F 4.37 (4.27-4.47) 9.32 (8.87-9.80) 4.36 (4.05-4.69)
R 6.36 (5.33-7.59) 9.57 (7.90-11.59) 4.22 (3.29-5.40)
H, PH 22.95, p < 0.001 10.91, p < 0.001 7.96, p < 0.001
Pipes/cigars only n 38 26 7
F 3.46 (3.20-3.73) 3.74 (3.29-4.26) 2.00 (1.50-2.65)
R 2.92 (2.38-3.57) 4.76 (3.44-6.59) 2.00 (1.50-2.65)
H, PH 3.60, p < 0.001 4.18, p < 0.001 0.46, NS
Pipes only n 23 12 5
F 3.36 (2.95-3.81) 5.28 (4.55-6.13) 3.32 (2.42-4.55)
R 3.31 (2.51-4.35) 5.20 (3.50-7.73) 2.69 (1.53-4.72)
H, PH 3.49, p < 0.001 5.43, p < 0.001 2.66, p < 0.05
Cigars only n 15 15 5
F 2.73 (2.32-3.21) 4.05 (3.61-4.54) 3.27 (2.36-4.52)
R 2.95 (1.91-4.56) 4.67 (3.49-6.25) 2.85 (1.45-5.61)
H, PH 5.68, p < 0.001 4.27, p < 0.001 4.11, p < 0.01
Mixed n 27 9 7
F 7.87 (7.22-8.59) 9.63 (8.46-10.96) 4.79 (4.10-5.60)
R 7.37 (5.97-9.11) 9.60 (8.37-11.00) 5.51 (3.88-7.82)
H, PH 4.09, p < 0.001 1.05, NS 3.72, p < 0.01
a Within each study, results for the relevant smoking product and smoking status are selected in the following preference order, within each sex, for:
unexposed group – never any product, near equivalent (see Methods);
follow-up period – longest available;
lung cancer type – all or nearest available, must include at least squamous cell carcinoma and adenocarcinoma;
race – all or nearest available, otherwise by race;
overlapping studies – principal, subsidiary;
age – whole study, widest available age group;
sex – single sex results, combined sex results;
adjustment for potential confounders – most available.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p≥ 0.1), PB = probability value for between levels (see
Methods) similarly expressed.
c Results differ from those shown earlier (Tables 6, 9) because RRs with unexposed group “never cigarettes” are excluded here.
Lee et al. BMC Cancer 2012, 12:385 Page 55 of 90
http://www.biomedcentral.com/1471-2407/12/385one of these was number of adjustment factors, where the
pattern of response was erratic. Location was the other,
with RRs again highest in North America and lowest in
Asia. There were no estimates with large standardized
residuals, and no other characteristic improved the model
fit.
For adeno, three of the characteristics considered
in Table 10 contributed significantly to the model,
sex (p < 0.001), location (p < 0.001) and start year of
study (p < 0.05), with the direction of effect similar
to that noted earlier for ever smoking. There were
no large standardized residuals, and the only add-
itional characteristic which improved the model fit
(p < 0.05) related to somewhat lower RRs being seen
for studies with full histological confirmation.
For none of the three outcomes did characteristics
associated with detailed location, national cigarettetobacco type, the precise definition of the outcome, ad-
justment for specific factors, the definitions of smoking
product or of the unexposed base, whether the study
was conducted in a population working in a risky occu-
pation or whether proxy respondents were used, add sig-
nificantly to the model.C. Risk from ever or current smoking
In an attempt to incorporate data from a greater number
of studies, additional analyses were carried out for ever/
current smoking and for current/ever smoking. The
meta-analysis RRs are shown in Table 11. The number
of studies included increased from 236 to 242 for all
lung cancer, from 73 to 78 for squamous and from 75 to
81 for adeno, compared with Table 5. Note that the
slightly higher number of RR estimates in the current/
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          1952 HAMMON m 1.55 (0.83, 2.90)
          1954 DORN m 1.60 (0.81, 3.16)
          1955 BEST m 7.68 (0.96, 61.38)
          1956 GRAHAM m 2.55 (1.49, 4.38)
          1959 CPSI m 1.94 (1.44, 2.62)
          1962 WYNDE2 m 1.77 (0.71, 4.39)
          1966 CHOW m 3.95 (1.18, 13.26)
          1966 WYNDE3 m 2.01 (0.82, 4.93)
          1967 HAMMO2 m 0.88 (0.21, 3.67)
          1969 WYNDE6 m 2.07 (1.43, 2.99)
          1971 WIGLE m 3.61 (1.86, 6.99)
          1971 WIGLE f 36.12 (1.45, 902.62)
)37.31,93.0(03.2mOTSMOC5791




          1981 STOCKW c 4.16 (3.71, 4.66)
)06.11,07.0(08.2mYESUOT3991
          1993 TOUSEY f 8.69 (0.74, 102.22)
)00.721,23.7(94.03mNILEBA1491EPORUE
          1951 DOLL2 m 6.14 (1.85, 20.40)
          1952 GOLLED m 3.13 (1.73, 5.67)
          1954 STASZE m 1.25 (0.33, 4.77)
          1960 DEAN2 m 2.15 (1.33, 3.46)
)90.01,06.4(18.6mREBMAD2791
          1976 LUBIN2 m 3.14 (2.41, 4.08)
)04.8,47.1(28.3mSREDLA7791
          1979 KJUUS m 11.04 (2.34, 52.00)
)65.81,51.1(26.4mREHCEB5891
          1986 ARMADA m 9.14 (1.86, 44.85)
          1988 BOFFET m 6.64 (4.98, 8.84)
OTHER 1947 DEAN m 3.50 (1.71, 7.16)
Total (95% CI) 2.92 (2.38, 3.57)
Figure 20 Forest plot of ever pipe and/or cigar smoking and all lung cancer. Table 13 presents the results of a meta-analysis for all lung
cancer based on 56 relative risk (RR) and 95% confidence interval (CI) estimates for ever pipe and/or cigar smoking. The individual study estimates
are shown numerically and graphically on a logarithmic scale. The studies are sorted in order of sex within study reference (REF) within start year
of study (START) within continent (CONT). In the graphical representation individual RRs are indicated by a solid square, with the area of the
square proportional to the weight (inverse-variance of log RR). Arrows indicate where the CI extends outside the range allocated. Also shown are
the combined random-effects estimates. These are represented by a diamond of standard height, with the width indicating the 95% CI.
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specific results.
As many of the RRs are common between the spe-
cific ever smoking analyses in Table 5 and the ever/
current smoking analyses in Table 11, the meta-analysis
RRs tend to be quite similar. However those for current/ever smoking are intermediate between those specifically
for ever smoking (Table 5) and those specifically for
current smoking (Table 8). For example, for all lung
cancer, random-effects estimates are 5.50 (95% CI 5.07-
5.96, n = 328) for ever smoking, 5.48 (5.07-5.93, n = 342)
for ever/current smoking, 6.20 (5.68-6.77, n = 344) for
Table 14 Meta-analyses by type of cigarette smokeda
Type of cigarette smoked Statisticb All lung cancerc Squamousd Adenoe
Only filter vs. only plainf n 42 13 10
F 0.67 (0.64-0.72) 0.58 (0.52-0.64) 0.88 (0.75-1.03)
R 0.69 (0.61-0.78) 0.52 (0.40-0.68) 0.84 (0.66-1.08)
H, PH 3.18, p < 0.001 4.73, p < 0.001 1.90, p < 0.05
Ever filter vs. only plaing n 42 11 10
F 0.79 (0.75-0.83) 0.85 (0.79-0.91) 1.00 (0.89-1.12)
R 0.73 (0.65-0.82) 0.55 (0.41-0.74) 0.99 (0.84-1.16)
H, PH 3.60, p < 0.001 7.73, p < 0.001 1.35, NS
Only filter vs. ever plainh n 42 13 10
F 0.67 (0.63-0.71) 0.87 (0.81-0.92) 1.05 (0.93-1.18)
R 0.70 (0.62-0.78) 0.69 (0.57-0.83) 0.98 (0.80-1.21)
H, PH 3.30, p < 0.001 3.15, p < 0.001 1.88, p < 0.05
Handrolled vs. manufacturedi n 20 5 4
F 1.27 (1.16-1.40) 1.47 (1.24-1.76) 2.12 (1.53-2.96)
R 1.29 (1.12-1.49) 1.62 (1.18-2.21) 2.09 (0.83-5.25)
H, PH 1.81, p < 0.05 2.61, p < 0.05 6.54, p < 0.001
Mentholated vs. non-mentholated n 6 1 1
F 0.99 (0.86-1.14) 1.04 (0.75-1.44) 0.96 (0.73-1.27)
R 0.98 (0.80-1.20) 1.04 (0.75-1.44) 0.96 (0.73-1.27)
H, PH 1.89, p < 0.1 NA NA
a Within each study, results for the relevant smoking product and smoking status are selected in the following preference order, within each sex, for:
cigarette type – see notes f to i;
unexposed group – see notes f to i;
smoking product – any, cigarettes (ignoring other products), cigarettes only;
smoking status – ever, current;
lung cancer type – see notes c to e;
race – all or nearest available, otherwise by race;
follow-up period – longest available;
overlapping studies – principal, subsidiary;
age – whole study, widest available age group;
Results are then selected for:
sex – single sex results, combined sex results;
adjustment for potential confounders – most available.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p≥ 0.1), PB = probability value for between levels (see
Methods) similarly expressed.
c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
d Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
e Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
f Or nearest available.
Preference order for cigarette type – filter only/NOS, always, mainly, both, equally, ever.
Preference order for comparison group – plain only/NOS, always, mainly, ever.
g Or nearest available.
Preference order for cigarette type – filter ever, equally, both, mainly, always, only/NOS.
Preference order for comparison group – plain only/NOS, always, mainly, ever.
h Or nearest available.
Preference order for cigarette type – filter only/NOS, always, mainly, both, equally, ever.
Preference order for comparison group – plain ever, mainly, always, only/NOS.
i Preference order for cigarette type – handrolled any, both, mainly, only.
Preference order for comparison group – manufactured only ever, only current, any, ever.
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for current smoking. The pattern of RRs by level of
the characteristics studied for both ever/current and
current/ever smoking tends to be quite similar to
that for the specific analyses. Results for ever or cur-
rent smoking by level of selected characteristics aretherefore only presented in Additional file 5: Detailed
Analysis Tables.
D. Risk from ex smoking
Figures 15, 16, 17 (all lung cancer), Figure 18 (squa-
mous) and Figure 19 (adeno) present the results of the
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          1979 KAISE2 m 1.03 (0.61, 1.75)
          1979 KAISE2 f 0.65 (0.32, 1.31)
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          1985 KHUDER m 0.46 (0.36, 0.59)
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          1964 MIGRAN f 1.44 (0.61, 3.40)
          1967 TANG2 m 0.94 (0.75, 1.18)
          1969 DEAN3 m 0.54 (0.40, 0.73)
          1969 DEAN3 f 0.68 (0.42, 1.11)
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          1976 LANGE m 0.90 (0.60, 1.40)
          1976 LANGE f 0.70 (0.40, 1.40)
          1976 LUBIN2 m 0.48 (0.40, 0.56)
          1976 LUBIN2 f 0.43 (0.22, 0.85)
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          1977 ALDERS f 0.85 (0.52, 1.38)
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          1986 ARMADA m 0.70 (0.40, 1.20)
          1989 AGUDO f 0.22 (0.04, 1.27)
ASIA 1962 SEGI2 m 0.62 (0.45, 0.85)
          1972 MACLEN f 0.77 (0.28, 2.10)
          1985 CHOI m 0.06 (0.01, 0.25)
          1985 CHOI f 0.16 (0.01, 4.58)
          1986 SOBUE m 0.67 (0.38, 1.11)
          1988 WAKAI m 1.02 (0.31, 3.33)
OTHER 1987 PEZZOT m 0.29 (0.20, 0.41)
)69.0,45.0(27.0mFETSED8891
          1993 DESTE2 c 0.73 (0.51, 1.05)
          1994 MATOS m 1.25 (0.67, 2.50)
Total (95% CI) 0.69 (0.61, 0.78)
Figure 21 Forest plot of only filter vs. only plain cigarette smoking and all lung cancer. Table 14 presents the results of a meta-analysis for
all lung cancer based on 42 relative risk (RR) and 95% confidence interval (CI) estimates for only filter vs. only plain cigarette smoking. The
individual study estimates are shown numerically and graphically on a logarithmic scale. The studies are sorted in order of sex within study
reference (REF) within start year of study (START) within continent (CONT). In the graphical representation individual RRs are indicated by a solid
square, with the area of the square proportional to the weight (inverse-variance of log RR). Arrows indicate where the CI extends outside the
range allocated. Also shown are the combined random-effects estimates. These are represented by a diamond of standard height, with the width
indicating the 95% CI.
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          1988 GARDIN c 0.74 (0.28, 2.01)
ASIA  1963 NOTAN2 m 1.43 (1.05, 1.95)
          1964 JUSSAW m 2.54 (1.12, 5.77)
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Figure 22 Forest plot of handrolled vs. manufactured cigarette smoking and all lung cancer. Table 14 presents the results of a
meta-analysis for all lung cancer based on 20 relative risk (RR) and 95% confidence interval (CI) estimates for handrolled vs. manufactured
cigarette smoking. The individual study estimates are shown numerically and graphically on a logarithmic scale. The studies are sorted on
sex within study reference (REF) within start year of study (START) within continent (CONT). In the graphical representation individual RRs are
indicated by a solid square, with the area of the square proportional to the weight (inverse-variance of log RR). Arrows indicate where the
CI extends outside the range allocated. Also shown are the combined random-effects estimates. These are represented by a diamond of
standard height, with the width indicating the 95% CI.
Lee et al. BMC Cancer 2012, 12:385 Page 59 of 90
http://www.biomedcentral.com/1471-2407/12/385main meta-analyses for ex smoking of any product (or
cigarettes if any product was not available), based on
most-adjusted RRs. Some results by levels of characteris-
tics are shown in Table 12.
Again the RRs are markedly heterogeneous (p< 0.001 for
all three outcomes), ranging up to 135.69 for all lung cancer
(STUCKE/males), 22.90 for squamous (OSANN/males)
and 13.10 for adeno (OSANN/males). The random-effects
estimates (all lung cancer 4.30, 95% CI 3.93-4.71, n=182,
squamous 8.74, 6.94-11.01, n=33, and adeno 2.85, 2.20-
3.70, n=34), though all clearly positive, are smaller than
the corresponding estimates for current smoking. Individ-
ual RRs are only very occasionally below 1.0 and never sig-
nificantly so. Estimates are little affected by using the more
specific definition of each outcome, preferring least-
adjusted RRs to most-adjusted RRs, or preferring RRs for
ever smoking cigarettes to those for ever smoking any
product. RRs for ever smoking cigarettes only were too fewfor useful analysis for squamous and adeno, but for all lung
cancer were similar to those for ever smoking any product.
Fuller details are given in the Additional file 5: Detailed
Analysis Tables.
For the main meta-analysis of ex smoking, the studies
contributing most to the total weight for all lung cancer
were STOCKW/sexes combined (22.4% of the total of
4,739), followed by BROWNS/males (8.5%) and BROWNS/
females (6.5%). BROWNS was the major contributor for
both squamous and adeno, with the two sex-specific
results contributing 49.4% of the total weight of 446 for
squamous, and 45.2% of the total weight of 619 for adeno.
For the characteristics considered in Table 12 the
sources of variation for all lung cancer are generally
quite similar to those seen for ever smoking in Table 5
and for current smoking in Table 8. Thus, RRs are
higher for males, for North America, for more recent
studies and for larger studies. Interestingly RRs are
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          1979 KAISE2 f 0.75 (0.51, 1.11)
          1985 WYNDE8 m 1.06 (0.82, 1.37)
          1985 WYNDE8 f 0.78 (0.57, 1.08)
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          1991 CARPEN f 0.88 (0.50, 1.57)
Total (95% CI) 0.98 (0.80, 1.20)
Figure 23 Forest plot of mentholated vs. non-mentholated cigarette smoking of any product and all lung cancer. Table 14 presents the
results of a meta-analysis for all lung cancer based on six relative risk (RR) and 95% confidence interval (CI) estimates for mentholated vs.
non-mentholated cigarette smoking. The individual study estimates are shown numerically and graphically on a logarithmic scale sorted on
sex within study reference (REF) within start year of study (START) within continent (CONT). The studies are sorted in order of sex within study
reference (REF). In the graphical representation individual RRs are indicated by a solid square, with the area of the square proportional to
the weight (inverse-variance of log RR). Arrows indicate where the CI extends outside the range allocated. Also shown are the combined
random-effects estimates. These are represented by a diamond of standard height, with the width indicating the 95% CI.
Lee et al. BMC Cancer 2012, 12:385 Page 60 of 90
http://www.biomedcentral.com/1471-2407/12/385clearly lower for prospective than for case–control stud-
ies. Numbers of ex smoking RRs are less for squamous
(33) and for adeno (34) than for all lung cancer (182),
but nevertheless some associations are evident in rela-
tion to location for adeno, to study type for squamous,
to number of adjustment factors for adeno, and to
number of cases, smoking product and unexposed base
for both squamous and adeno. Meta-regression analyses
were not attempted for ex smoking.
E. Risk from smoking specific products compared to
smoking of any product
Table 13 summarizes the results of meta-analyses for all
lung cancer for cigarette only smokers, smokers of
pipes/cigars only, smokers of pipes only, and smokers of
cigars only. In each analysis, the base is never smokers
of any product. The results for ever smoking of pipes/
cigars only are also shown in Figure 20.
For ever smoking, current smoking and ex smoking
the random-effects RRs are similarly elevated for pipes/
cigars, pipes only and cigars only, but to a markedly
lesser extent than for cigarettes only. As for cigarette
smoking, RRs for pipe and cigar smoking are clearly
higher for current smokers than for ex smokers.
Available results for squamous and adeno are limited,
and mainly for ever smoking. For pipe and/or cigar
smoking, the RR for squamous (3.72, 95% CI 1.95-7.10,
n = 8) is somewhat higher than that for all lung cancer
(2.92, 2.38-3.57, n = 38), but the RR for adeno is notelevated (0.93, 0.62-1.40, n = 7). The lack of association
of adeno with pipe and cigar smoking is also evident in
the RRs for pipes only (0.50, 0.23-1.10, n = 4) and for
cigars only (0.55, 0.11-2.88, n = 3).
The results for pipe and cigar smoking mainly apply to
males, as the few available estimates for females have
wide variability. The increased risk in smokers of pipes
and cigars is evident in each location studied, though
data for Asia are extremely sparse. Unlike for cigarettes,
higher RRs are seen for Scandinavia (7.02, 4.72-10.44,
n = 6) and for Other Europe (5.17, 2.91-9.19, n = 8) than
for North America (2.27, 1.79-2.89, n = 26) or the UK
(4.32, 2.73-6.84, n = 11). These results are for ever/
current smoking, with the full results given in Additional
file 5: Detailed Analysis Tables.
Table 13 also shows results for lung cancer for mixed
smokers. For ever, current and ex smoking, the random-
effects RRs are slightly, but not significantly, higher than
those for smokers of cigarettes only. Available results for
squamous and adeno are again limited, and mainly for
ever smokers. The RRs for squamous (9.78, 4.94-19.35,
n = 6) and for adeno (2.48, 1.25-4.95, n = 6) do not
clearly differ from the RRs for squamous (11.09, 7.19-
17.09, n = 10) and for adeno (2.63, 1.32-5.24, n = 10) for
smokers of cigarettes only.
F. Risk by type of cigarette smoked
Table 14 summarizes results by type of cigarette smoked.
For filter and plain cigarette smoking results are shown
Table 15 Meta-analyses for number of cigarettes smokeda
Amount smoked Statisticb All lung cancerc Squamousd Adenoe
Number of setsf 190 48 46
About 5 cigs/dayg n 174 41 39
F 3.25 (3.17-3.34) 6.07 (5.50-6.70) 2.70 (2.47-2.96)
R 3.49 (3.13-3.89) 4.98 (3.93-6.31) 1.83 (1.40-2.39)
H, PH 10.77, p < 0.001 3.85, p < 0.001 6.19, p < 0.001
About 20 cigs/dayh n 113 30 28
F 5.30 (5.18-5.43) 12.36 (10.89-14.03) 3.58 (3.18-4.04)
R 7.33 (6.29-8.54) 11.86 (8.92-15.76) 2.73 (2.06-3.61)
H, PH 22.45, p < 0.001 3.72, p < 0.001 4.27, p < 0.001
About 45 cigs/dayi n 128 37 34
F 10.17 (9.89-10.45) 28.95 (25.42-32.98) 7.20 (6.38-8.13)
R 13.69 (11.80-15.89) 27.65 (20.42-37.44) 4.80 (3.29-7.01)
H, PH 14.89, p < 0.001 3.98, p < 0.001 7.69, p < 0.001
a Within each study, results are selected in the following preference order, within each sex, for:
smoking status – ever, current;
smoking product – any, cigarettes (ignoring other products), cigarettes only;
cigarette type – any, manufactured (with or without handrolled), manufactured only;
unexposed group – never any product, never cigarettes, near equivalent (see Methods);
follow-up period – longest available;
lung cancer type – see notes c to e;
race – all or nearest available, otherwise by race;
overlapping studies – principal, subsidiary;
age – whole study, widest available age group;
Results are then selected for:
sex – single sex results, combined sex results;
adjustment for potential confounders – most available.
Results are by number of cigarettes or cigarette equivalents.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p≥ 0.1).
c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
d Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
e Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
f Number of sets of RRs available for the key value analysis, where base for comparison is never smoked.
g Category for which results are provided includes 5 cigs/day but does not include 20 cigs/day.
h Category for which results are provided includes 20 cigs/day but does not include 5 or 45 cigs/day.
i Category for which results are provided includes 45 cigs/day but does not include 20 cigs/day.
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is a choice, the nearest available equivalents to only filter
vs. only plain (with results for all lung cancer also shown
in Figure 21), ever filter vs. only plain, and only filter vs.
ever plain. Results are also shown for the comparison
of handrolled and manufactured cigarette smoking, and
for mentholated vs. non-mentholated cigarette smoking,
with results for all lung cancer also shown in Figures 22
and 23.
The random-effects RRs show a reduction in risk for
only filter vs. only plain cigarette smoking that is signifi-
cant for all lung cancer (RR 0.69, 95% CI 0.61-0.78,
n = 42), and squamous (0.52, 0.40-0.68, n = 13), though
not for adeno (0.84, 0.66-1.08, n = 10). The alternative
comparisons for filter and plain, where only a third to a
half of the RRs included actually differ, show clear reduc-
tions for all lung cancer and squamous associated with
filter cigarette smoking, though no difference for adeno
(see Table 14). The reductions for all lung cancer andsquamous are evident in both sexes and all continents
(see Additional file 5: Detailed Analysis Tables).
The risk associated with handrolled smoking is greater
than that with manufactured cigarette smoking, with
RRs of 1.29 (1.12-1.49, n = 20) for all lung cancer and
1.62 (1.18-2.21, n = 5) for squamous. The RR of 2.09
(0.83-5.25, n = 4) for adeno is based on very heteroge-
neous estimates, varying from 0.43 to 8.76, and allows
no clear conclusion. As results for females are limited,
and have wide variability, the conclusions mainly apply
to males. The estimated RR for all lung cancer is greater
than 1 in all locations studied, though not always sta-
tistically significant. However, there are no data from
North America.
Data on mentholated cigarette smoking are limited,
particularly by histological type. For all lung cancer,
the RR of 0.98 (0.80-1.20, n = 6) is consistent with
no effect of mentholation on risk, five RR estimates
close to or below 1.0, counterbalancing one reported
Table 16 Meta-analyses for age started to smokea
Age started Statisticb All lung cancerc Squamousd Adenoe
Number of setsf 69 15 14
About age 26 yearsg n 60 14 13
F 2.70 (2.62-2.79) 10.42 (8.25-13.15) 3.79 (3.12-4.60)
R 3.89 (3.33-4.56) 11.06 (6.87-17.81) 3.21 (2.12-4.87)
H, PH 8.73, p < 0.001 3.36, p < 0.001 4.09, p < 0.001
About age 18 yearsh n 29 6 5
F 7.75 (7.18-8.37) 20.15 (15.26-26.61) 9.74 (7.63-12.43)
R 7.48 (5.94-9.42) 20.28 (13.92-29.53) 8.84 (6.14-12.73)
H, PH 7.44, p < 0.001 1.60, NS 1.80, NS
About age 14 yearsi n 35 6 5
F 11.11 (10.23-12.06) 29.91 (22.62-39.54) 13.62 (10.78-17.22)
R 10.32 (8.04-13.26) 31.07 (17.93-53.85) 12.34 (7.23-21.08)
H, PH 7.42, p < 0.001 3.28, p < 0.01 3.76, p < 0.01
Earliest vs. latestj n 73 18 17
F 1.69 (1.64-1.74) 1.99 (1.72-2.29) 1.94 (1.64-2.29)
R 2.35 (2.08-2.65) 2.23 (1.66-2.98) 1.99 (1.48-2.67)
H, PH 4.52, p < 0.001 3.19, p < 0.001 2.62, p < 0.001
a Within each study, results are selected in the following preference order, within each sex, for:
smoking status – ever, current;
smoking product – any, cigarettes (ignoring other products), cigarettes only;
cigarette type – any, manufactured (with or without handrolled), manufactured only;
unexposed group – never any product, never cigarettes, near equivalent (see Methods), but see also footnote j;
follow-up period – longest available;
lung cancer type – see notes c to e;
race – all or nearest available, otherwise by race;
overlapping studies – principal, subsidiary;
age – whole study, widest available age group;
Results are then selected for:
sex – single sex results, combined sex results;
adjustment for potential confounders – most available.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p≥ 0.1).
c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
d Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
e Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
f Number of sets of RRs available for the key value analysis, where base for comparison is never smoked.
g Category for which results are provided includes 26 years but does not include 18 years.
h Category for which results are provided includes 18 years but does not include 14 or 26 years.
i Category for which results are provided includes 14 years but does not include 18 years.
j For this analysis only, the exposed and unexposed group have the same smoking status, product and cigarette type. There is an additional preference to select
the results with least adjustment for other aspects of smoking, followed by a preference to select the results for the earliest (=exposed) and latest (=unexposed)
starters. Alternatively preferring results with most adjustment for other aspects of smoking gives n = 73, F = 1.67 (1.62-1.72), R = 2.20 (1.96-2.47), H, PH = 4.01,
p < 0.001 for all lung cancer.
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1.45 (1.03-2.02). There is some evidence (p < 0.05) of
heterogeneity by sex with estimates of 1.15 (0.93-
1.43, n = 3) for males, and 0.78 (0.63-0.98, n = 3) for
females.
G. Risk by amount smoked
Table 15 summarizes the results of meta-analyses
using RRs categorized by number of cigarettes (or
cigarette equivalents) smoked per day and based on
data for ever/current smoking and for smoking of
any product (or cigarettes if not available). These arebased on those 140 studies for all lung cancer, 36 for
squamous, and 34 for adeno which provided data
that could be used in the meta-analyses. For all three
outcomes, results are shown for one of the sets of
“key values” (see Methods). For all lung cancer, squa-
mous and adeno, a clear increase is seen for RRs for
categories including 5, but not 20, cigarettes/day, with
the meta-analysis RR increasing monotonically with in-
creasing amount smoked. Random-effects estimates for
categories including 45, but not 20 cigarettes/day, are
13.69 (11.80-15.89, n = 128) for all lung cancer, 27.65
(20.42-37.44, n = 37) for squamous and 4.80 (3.29-7.01,
Table 17 Meta-analyses for duration of smokinga
Duration of smoking Statisticb All lung cancerc Squamousd Adenoe
Number of setsf 72 26 23
About 20 yearsg n 55 23 21
F 2.46 (2.31-2.63) 6.46 (5.60-7.45) 2.33 (2.04-2.66)
R 2.48 (2.09-2.95) 4.66 (3.03-7.16) 1.72 (1.20-2.46)
H, PH 5.70, p < 0.001 6.52, p < 0.001 6.04, p < 0.001
About 35 yearsh n 39 15 12
F 6.17 (5.80-6.55) 18.25 (15.61-21.34) 5.13 (4.43-5.95)
R 5.90 (4.75-7.32) 14.06 (7.45-26.52) 3.53 (1.81-6.88)
H, PH 10.39, p < 0.001 11.37, p < 0.001 15.91, p < 0.001
About 50 yearsi n 45 16 13
F 13.46 (12.61-14.36) 26.27 (22.20-31.09) 5.24 (4.41-6.23)
R 10.13 (7.66-13.39) 27.18 (13.36-55.28) 5.25 (2.70-10.20)
H, PH 15.58, p < 0.001 13.13, p < 0.001 12.82, p < 0.001
Longest vs. shortestj n 76 27 23
F 3.81 (3.62-4.02) 3.55 (3.25-3.89) 2.39 (2.09-2.72)
R 3.56 (2.90-4.35) 3.93 (3.10-4.97) 2.64 (2.04-3.43)
H, PH 11.48, p < 0.001 4.23, p < 0.001 3.00, p < 0.001
a Within each study, results are selected in the following preference order, within each sex, for:
smoking status – ever, current;
smoking product – any, cigarettes (ignoring other products), cigarettes only;
cigarette type – any, manufactured (with or without handrolled), manufactured only;
unexposed group – never any product, never cigarettes, near equivalent (see Methods), but see also footnote j;
follow-up period – longest available;
lung cancer type – see notes c to e;
race – all or nearest available, otherwise by race;
overlapping studies – principal, subsidiary;
age – whole study, widest available age group;
Results are then selected for:
sex - single sex results, combined sex results;
adjustment for potential confounders – most available.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p≥ 0.1).
c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
d Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
e Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
f Number of sets of RRs available for the key value analysis, where base for comparison is never smoked.
g Category for which results are provided includes 20 years but does not include 35 years.
h Category for which results are provided includes 35 years but does not include 20 or 50 years.
i Category for which results are provided includes 50 years but does not include 35 years.
j For this analysis only, the exposed and unexposed group have the same smoking status, product and cigarette type. There is an additional preference to select
the results with least adjustment for other aspects of smoking, followed by a preference to select the results for the longest (=exposed) and shortest
(=unexposed) duration smokers. Alternatively preferring results with most adjustment for other aspects of smoking gives n = 77, F = 2.67 (2.53-2.82), R = 3.00
(2.57-3.49), H, PH = 5.82, p < 0.001 for all lung cancer.
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also clearly evident when an alternative set of key values (1,
10, 20, 30, 40, 999) is used, though numbers of available
RRs are quite sparse for the higher key values, when least-
adjusted RRs are considered, and in both sexes (see
Additional file 5: Detailed Analysis Tables). The key value
analyses do not use results for all the dose–response data
available, as a number of the studies use broad dose–
response categories (such as 1–20 or 20+ cigs/day) which
span more than one of the key values. Additional file 5:Detailed Analysis Tables also includes results for alternative
definitions of smoking status and product smoked, which
show a similarly clear dose–response. For example, for cur-
rent smoking of any product, the RRs for squamous rise
from 9.92 (7.41-13.28, n=8) for key value 5 cigs/day
to 39.16 (23.67-64.79, n= 12) for key value 45 cigs/day.
Additional file 4: Dose Not Meta also includes available
results for some other studies which present dose–
response data in a form that cannot readily be included
in the meta-analyses (e.g. where the only available
Table 18 Meta-analyses for duration of quitting (vs. never smoked)a
Duration of quitting Statisticb All lung cancerc Squamousd Adenoe
Number of setsf 68 16 16
About 12 yearsg n 53 13 12
F 3.62 (3.34-3.93) 7.76 (6.07-9.91) 2.13 (1.64-2.76)
R 2.97 (2.48-3.55) 5.89 (3.85-9.08) 2.10 (1.49-2.94)
H, PH 3.93, p < 0.001 1.69, p < 0.1 1.45, NS
About 7 yearsh n 33 6 6
F 6.07 (5.56-6.63) 14.34 (11.10-18.54) 3.29 (2.47-4.39)
R 5.08 (4.24-6.10) 14.34 (11.10-18.54) 3.74 (2.23-6.25)
H, PH 3.20, p < 0.001 0.49, NS 2.33, p < 0.05
About 3 yearsi n 43 6 6
F 9.69 (8.96-10.47) 24.95 (19.45-31.99) 5.05 (3.85-6.64)
R 8.60 (7.22-10.23) 26.22 (17.19-39.98) 6.73 (3.46-13.12)
H, PH 3.93, p < 0.001 1.46, NS 3.86, p < 0.01
Shortest vs. longestj n 65 14 14
F 3.94 (3.68-4.22) 5.09 (4.33-5.99) 2.63 (2.11-3.28)
R 3.97 (3.32-4.75) 6.22 (3.75-10.30) 3.32 (1.98-5.58)
H, PH 5.47, p < 0.001 6.00, p < 0.001 4.41, p < 0.001
a Within each study, results for ex smokers are selected in the following preference order, within each sex, for:
smoking product – any, cigarettes (ignoring other products), cigarettes only;
cigarette type – any, manufactured (with or without handrolled), manufactured only;
unexposed group – never any product, never cigarettes, near equivalent (see Methods) but see also footnote j;
follow-up period – longest available;
lung cancer type – see notes c to e;
race – all or nearest available, otherwise by race;
overlapping studies – principal, subsidiary;
age – whole study, widest available age group;
Results are then selected for:
sex – single sex results, combined sex results;
adjustment for potential confounders – most available.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p≥ 0.1).
c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
d Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
e Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
f Number of sets of RRs available for the key value analysis, where base for comparison is never smoked.
g Category for which results are provided includes 12 years but does not include 7 years.
h Category for which results are provided includes 7 years but does not include 3 or 12 years.
i Category for which results are provided includes 3 years but does not include 7 years.
j For this analysis only, the exposed and unexposed group have the same smoking status, product and cigarette type. There is an additional preference to select
the results with least adjustment for other aspects of smoking, followed by a preference to select the results for the shortest (=exposed) and longest
(=unexposed) duration quitters. Alternatively preferring results with most adjustment for other aspects of smoking gives n = 65, F = 3.59 (3.35-3.85), R = 3.61
(3.04-4.28), H, PH = 4.79, p < 0.001 for all lung cancer. Note that the “shortest” group, as reported by some studies, may omit (unlimited) recent quitters.
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results do not appear inconsistent with those summarized
in Table 15.
Dose–response by amount smoked was investigated
for pipe and cigar smoking, but the number of estimates
available was small, and referred only to males. However,
there was some evidence of dose–response. Thus for
all lung cancer, one can compare RRs for cigar only
smoking for the highest (8.21, 4.36-15.49, n = 6) and low-
est exposure groups (1.84, 1.22-2.79, n = 5), and can also
compare RRs for pipe only smoking for the highest
(5.99, 3.57-10.04, n = 9) and lowest exposure groups
(3.68, 2.75-4.93, n = 8).H. Risk by age of starting to smoke
Table 16 summarizes meta-analysis results for age of start-
ing to smoke based on data for ever/current smoking and
for smoking of any product (or cigarettes if not available).
Random-effects RRs for earliest compared to latest start-
ing, and selecting results least-adjusted for other aspects of
smoking, are significantly elevated for all lung cancer (2.35,
2.08-2.65, n=73), squamous (2.23, 1.66-2.98, n=18) and
adeno (1.99, 1.48-2.67, n= 17). Alternatively selecting
results most-adjusted for other aspects of smoking, the RR
for all lung cancer is 2.20 (1.96-2.47, n=73). The increase
in risk with earlier starting is consistent with the results of
the key value analyses, with, for example, random-
Table 19 Meta-analyses for duration of quitting (vs. current smoking)a
Duration of quitting Statisticb All lung cancerc Squamousd Adenoe
Number of setsf 58 11 11
About 3 yearsg n 41 6 6
F 0.98 (0.93-1.04) 1.15 (1.03-1.28) 1.02 (0.85-1.22)
R 0.95 (0.84-1.08) 1.15 (1.03-1.28) 1.02 (0.85-1.22)
H, PH 3.55 p< 0.001 0.51, NS 0.74, NS
About 7 yearsh n 29 4 4
F 0.60 (0.56-0.64) 0.74 (0.65-0.85) 0.73 (0.58-0.92)
R 0.57 (0.50-0.64) 0.74 (0.65-0.85) 0.73 (0.58-0.92)
H, PH 2.09, p < 0.001 0.09, NS 0.59, NS
About 12 yearsi n 48 9 9
F 0.32 (0.30-0.34) 0.40 (0.35-0.47) 0.50 (0.41-0.60)
R 0.28 (0.24-0.32) 0.27 (0.18-0.40) 0.39 (0.26-0.58)
H, PH 4.22, p < 0.001 4.07, p < 0.001 3.68, p < 0.001
Longest vs. shortestj n 61 12 12
F 0.23 (0.21-0.25) 0.19 (0.16-0.22) 0.30 (0.23-0.37)
R 0.24 (0.20-0.29) 0.14 (0.08-0.25) 0.21 (0.10-0.46)
H, PH 5.21, p < 0.001 6.68 p < 0.001 9.44, p < 0.001
a Within each study, results for ex smokers are selected in the following preference order, within each sex, for:
smoking product – any, cigarettes (ignoring other products), cigarettes only;
cigarette type – any, manufactured (with or without handrolled), manufactured only;
adjustment for other aspects of smoking – least available;
comparison group – current smokers, current and recent smokers (up to 2 years);
follow-up period – longest available;
lung cancer type – see notes c to e;
race – all or nearest available, otherwise by race;
overlapping studies – principal, subsidiary;
age – whole study, widest available age group;
Results are then selected for:
sex –- single sex results, combined sex results;
adjustment for potential confounders – most available.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared per
degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p≥ 0.1).
c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
d Squamous cell carcinoma or nearest available, but not including adenocarcinoma.
e Adenocarcinoma or nearest available, but not including squamous cell carcinoma.
f Number of sets of RRs available for the key value analysis, where base for comparison is never smoked.
g Category for which results are provided includes 3 years but does not include 7 years.
h Category for which results are provided includes 7 years but does not include 3 or 12 years.
i Category for which results are provided includes 12 years but does not include 7 years.
j For this analysis only, the exposed and unexposed group have the same smoking status (i.e. ex-smokers), product and cigarette type. There is a preference
(instead of that for comparison group) to select the results for the longest (=exposed) and shortest (=unexposed) duration quitters. Note that (unlike the inverse
results shown in Table 18), the “shortest” quitters here may omit recent quitters, but subject to a limit of no more than two years.
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mous rising from 11.06 (6.87-17.81, n = 14) for cat-
egories including 26 years but not including 18 years
to 31.07 (17.93-53.85, n = 6) for categories including
14, but not 18 years. As seen in Additional file 5:
Detailed Analysis Tables, a similar pattern is gener-
ally seen for other definitions of smoking status and
product smoked, although data for smokers of pipes
and/or cigars are very limited.
I. Risk by duration of smoking
Table 17 is laid out similarly to Table 16 and also pre-
sents results for ever/current smoking. Random-effectsRRs for longest compared to shortest duration of smok-
ing, and selecting results least adjusted for other aspects
of smoking, are significantly elevated for all lung cancer
(3.56, 2.90-4.35, n = 76), squamous (3.93, 3.10-4.97,
n = 27) and adeno (2.64, 2.04-3.43, n = 23). Alternatively
selecting results most adjusted for other aspects of
smoking, the RR for all lung cancer is 3.00 (2.57-3.49,
n = 77). The increase in risk with longer duration is
consistent with the results of the key value analyses,
with, for example, random-effects estimates for all lung
cancer rising from 2.48 (2.09-2.95, n = 55) for cate-
gories including 20 years but not including 35 years to
10.13 (7.66-13.39, n = 45) for categories including 50, but
Table 20 Meta-analyses for additional lung cancer types (all lung cancer)a
Lung cancer type Statisticb Ever smoking Current smoking Ever/current smoking
All lung cancerc n 328 195 342
F 4.22 (4.16-4.28) 9.29 (9.07-9.52) 4.25 (4.20-4.31)
R 5.50 (5.07-5.96) 8.43 (7.63-9.31) 5.48 (5.07-5.93)
H, PH 22.84, p < 0.001 13.76, p < 0.001 22.46, p < 0.001
Squamous cell carcinoma n 74 33 82
F 10.43 (9.72-11.20) 12.74 (11.71-13.87) 9.80 (9.18-10.47)
R 11.56 (9.68-13.81) 16.43 (12.66-21.32) 11.62 (9.80-13.78)
H, PH 4.18, p < 0.001 5.70, p < 0.001 4.44, p < 0.001
Adenocarcinoma n 87 40 96
F 3.58 (3.39-3.78) 4.40 (4.12-4.70) 3.50 (3.33-3.67)
R 2.99 (2.49-3.58) 4.05 (3.15-5.22) 3.10 (2.52-3.65)
H, PH 9.18, p < 0.001 12.28, p < 0.001 8.96, p < 0.001
Large cell carcinoma n 26 15 29
F 6.11 (4.78-7.81) 8.41 (6.36-11.12) 5.57 (4.48-6.92)
R 5.59 (4.05-7.72) 8.56 (5.29-13.86) 5.33 (4.02-7.07)
H, PH 1.47, p < 0.1 2.13, p < 0.01 1.40, p < 0.1
Small cell carcinoma n 54 27 61
F 9.88 (8.94-10.02) 15.31 (13.64-17.19) 9.99 (9.09-10.97)
R 10.98 (8.25-14.61) 18.17 (12.92-25.56) 11.14 (8.59-14.46)
H, PH 6.08, p < 0.001 5.67, p < 0.001 5.70, p < 0.001
a Within each study, results for the relevant lung cancer type and smoking status are selected in the following preference order, within each sex, for:
smoking product – any, cigarettes (ignoring other products), cigarettes only;
cigarette type – any, manufactured (with or without handrolled), manufactured only;
unexposed group – never any product, never cigarettes, other;
follow-up period – longest available;
race – all or nearest available, otherwise by race;
overlapping studies – principal, subsidiary;
age – whole study, widest available age group;
Results are then selected for:
sex – single sex results, combined sex results;
adjustment for potential confounders – most available.
b n = number of estimates combined, F = fixed-effect meta-analysis RR (95% CI), R = random-effects meta-analysis RR (95% CI), H = heterogeneity chisquared
per degree of freedom, PH = probability value for heterogeneity expressed as p < 0.001, p < 0.05, p < 0.1 or NS (p≥ 0.1), PB = probability value for between levels
(see Methods) similarly expressed.
c All or nearest available, must include at least squamous cell carcinoma and adenocarcinoma.
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ation is also seen for other definitions of smoking status
and product smoked (see Additional file 5: Detailed Ana-
lysis Tables). Data for pipe and cigar smoking are limited,
though even so there is some evidence of a trend. Thus, for
all lung cancer longest to shortest RRs are elevated, both in
smokers of pipes only (4.32, 1.57-11.89, n=5) and smokers
of cigars only (2.43, 1.02-5.79, n=3).
J. Risk by duration of quitting (vs. never smoking)
Table 18 presents results for duration of quitting (vs.
never smoking) based on results for smoking of any
product (or cigarettes if not available). Random-effects
RRs for shortest compared to longest duration of quit-
ting, selecting results least adjusted for other aspects of
smoking, are significantly elevated for all lung cancer(3.97, 3.32-4.75, n = 65), squamous (6.22, 3.75-10.30,
n = 14) and adeno (3.32, 1.98-5.58, n = 14). Alternatively
selecting results most adjusted for other aspects of
smoking, the RR for all lung cancer is 3.61 (3.04-4.28,
n = 65). The increase in risk with shorter duration of
quitting is consistent with the results of the key value
analyses, with, for example, random-effects estimates
relative to never smokers for adeno rising from 2.10
(1.49-2.94, n = 12) for categories including 12 years but
not including 7 years to 6.73 (3.46-13.12, n = 6) for cat-
egories including 3, but not 7 years. A clear trend of risk
with increasing duration of quitting is also seen for
cigarette smoking (or any product if not available), and
for cigarette only smoking (see Additional file 5: Detailed
Analysis Tables). Data for pipe and cigar smoking were














Figure 24 Funnel plot for ever smoking and all lung cancer. Funnel plot of the 328 relative risk estimates for ever smoking and all lung
cancer included in the main meta-analysis in Table 5 against their weight (inverse-variance of log RR). The dotted vertical line indicates the fixed-
effect meta-analysis estimate.
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For duration of quitting compared to current smoking
the number of data sets available are somewhat less than
the corresponding number for duration of quitting com-
pared to never smoking. Results included in the longest
vs. shortest analysis shown in Table 19 are generally the
inverse of those in the shortest vs. longest analysis in












Figure 25 Funnel plot for ever smoking and squamous. Funnel plot of
included in the main meta-analysis in Table 5 against their weight (inverse
meta-analysis estimate.current smokers and recent quitters of more than
2 years). While the key value analyses shown in Table 19
echo the trends shown in Table 18, they also show that
for shorter term quitting (categories including 3 but not
7 years) there is no evidence of a decline in risk from
quitting. Thus the RRs for all lung cancer (0.95, 0.84-
1.08, n = 41) and adeno (1.02, 0.85-1.22, n = 6) are close
to 1.00, and the RR for squamous (1.15, 1.03-1.28, n = 6)543
(RR)
the 102 relative risk estimates for ever smoking and squamous














Figure 26 Funnel plot for ever smoking and adeno. Funnel plot of the 107 relative risk estimates for ever smoking and adeno included in the
main meta-analysis in Table 5 against their weight (inverse-variance of log RR). The dotted vertical line indicates the fixed-effect meta-analysis
estimate.
Lee et al. BMC Cancer 2012, 12:385 Page 68 of 90
http://www.biomedcentral.com/1471-2407/12/385is slightly elevated. Longer quit durations are, however,
clearly associated with a reduction in risk. For all lung
cancer, almost 40% of the RRs used in the key value
analyses included short-term quitters (of up to 2 years)
in the current smoker base. No difference was seen
between those RRs and those with a more precisely
defined current smoker base.
L. Risk by tar level
Due to the variety of different methods of quantifying tar
levels, only highest vs. lowest analyses have been carried
out. No data were available by histological type, and all data
relate to cigarette smoking. For all lung cancer and for
ever/current smoking of cigarettes the 14 available esti-
mates, from 9 studies, showed some evidence of heterogen-
eity (H=2.29, p <0.01). However, 12 of the estimates
showed a higher risk in the higher tar group, and the
random-effect estimate (1.42, 1.18-1.71) confirmed the rela-
tionship between risk and tar level. The increase was evi-
dent for males (1.29, 1.08-1.53, n=7) and females (1.48,
1.05-2.09, n=6). There was no evidence of heterogeneity
by any specific characteristic, including extent of adjust-
ment, 7 of the 14 estimates being adjusted for one or more
of aspects of smoking. These results are based on RRs that
are selected as being least adjusted for other aspects of
smoking. Alternatively, using RRs selected as most adjusted
for other aspects of smoking, the overall estimate was 1.34
(1.16-1.56, n=14).
M. Risk by butt length and fraction smoked
All the available data relate to cigarette smoking. As the
number of available estimates were quite limited,particularly for butt length, they have been combined
into a single analysis including RRs for shortest vs. long-
est butt lengths and for greatest vs. smallest fraction
smoked, and including results for ever smoking and
current smoking. The combined estimates were 1.43
(1.14-1.79, n = 11) for all lung cancer, 1.39 (1.04-1.86,
n = 7) for squamous, and 1.30 (1.07-1.58, n = 6) for
adeno. There was some evidence of heterogeneity for all
lung cancer (H= 2.29, p < 0.05) and for squamous
(H= 2.96, p <0.01), though not for adeno (H= 0.75), but
a clear majority (18/24 = 75.0%) of the estimates indi-
cated a higher risk associated with smoking more of the
cigarette.
N. Further analyses by histological type
The results so far have been restricted to all lung cancer,
squamous or adeno. Table 20 gives results for ever,
current and ever/current smoking of any product (or
cigarettes if not available) for small cell carcinoma and
large cell carcinoma, with corresponding results also
shown for all lung cancer, squamous cell carcinoma and
for adenocarcinoma. For ever/current smoking, the RR for
large cell carcinoma (5.33, 4.02-7.07, n= 29) is quite simi-
lar to that for all lung cancer (5.48, 5.07-5.93, n = 342),
while the RR for small cell carcinoma (11.14, 8.59-14.46,
n = 61) is markedly higher, and similar to that for squa-
mous cell carcinoma (11.62, 9.80-13.78, n = 82). This pat-
tern is also true for current smoking, where RR estimates
are higher than for ever/current smoking, and for ever
smoking. Additional file 5: Detailed Analysis Tables gives
results by level of the various characteristics studied. As
for all lung cancer, squamous and adeno, RRs for small
Lee et al. BMC Cancer 2012, 12:385 Page 69 of 90
http://www.biomedcentral.com/1471-2407/12/385cell and large cell carcinoma varied substantially by loca-
tion, with RRs much higher in North America than in
China, and no clear pattern for the other regions, some of
which have sparse data. There was also a tendency for
RRs to be higher where there was 100% histological con-
firmation. For ever/current smoking RRs and for small cell
carcinoma, the RRs were 9.84 (7.19-13.45, n = 42) without
such confirmation, and 14.62 (9.38-22.80, n = 19) with it
(p < 0.01). For large cell carcinoma, the corresponding RRs
were 3.90 (2.90-5.24, n = 19) without confirmation and
8.28 (5.89-11.65, n = 10) with it (p < 0.01). There was also
some evidence for small cell carcinoma only that RRs
were higher from more recent studies.
O. Further analyses based on independent pairs of
relative risks
Some studies provide independent RRs for males and
females for the same definition of outcome and expos-
ure. Random-effects meta-analysis of the male/female
sex ratio confirms the impression already gained from
the analyses shown in earlier Tables that RRs tend
to be somewhat higher for males, although estimates
are heterogeneous. For ever/current smoking, the sex
ratio is 1.38 (1.23-1.54) for all lung cancer, based on
93 ratios, 64 higher in males; 1.31 (0.91-1.90) for squa-
mous, based on 30 ratios, 18 higher in males, and 1.43
(1.14-1.78) for adeno, based on 33 ratios, 27 higher
in males.
As sex differences may reflect greater cigarette con-
sumption in males, meta-analysis estimates of the sex
ratio for ever/current smokers and for all lung cancer
were also calculated within levels of amount smoked (as
defined in section G). The sex ratio is 1.33 (1.05-1.68)
for smokers of about 5 cigs/day, based on 46 ratios, 26
higher in males, 1.59 (1.25-2.01) for smokers of about
20 cigs/day, based on 25 ratios, 20 higher in males, and
1.21 (0.99-1.49) for smokers of about 45 cigs/day, based
on 26 ratios, 17 higher in males.
A number of studies provide RR estimates for ever/
current smoking separately by age, and random-effects
meta-analysis were conducted, based on the ratio of the
estimate for the oldest age group for which data were
available compared to that for the youngest. Despite only
22 of the 45 (48.9%) of the ratios showing a greater risk
in the oldest age group, the meta-analysis showed a sig-
nificantly higher risk in the oldest age group (ratio 1.17,
95% CI 1.10-1.25), the seven ratios with most weight all
being greater than 1.0.
There were also eight studies, all conducted in the US,
which provide comparable sex-specific results for ever/
current smoking separately for white people and black
people (or non-white people). Random-effects meta-
analyses of the white/black race ratio showed no differ-
ence between the races (1.05, 0.90-1.23, n = 14).P. Further analyses based on non-independent pairs
of relative risks
Some studies also provide separate non-independent
least-adjusted and most-adjusted RRs for the same defin-
ition of exposure. There is little evidence that adjust-
ment reduces the RR for ever/current smoking. Using
the same preferences as in Table 11, the most-adjusted
estimate is lower than the least-adjusted estimate for
57 of the 126 (45.2%) pairs for all lung cancer, for 14 of
the 36 (38.9%) pairs for squamous, and for 21 of the 41
(51.2%) pairs for adeno. In no case do the percentages
differ from 50% (at p < 0.05), and in each case the
random-effects meta-analysis estimate based on the
most-adjusted pair members is similar to the corre-
sponding estimate based on the least-adjusted pair mem-
bers (data not shown).
RRs for a dose-related index of smoking may be
adjusted for other such indices. For all lung cancer, and
for four dose-related indices of smoking, pairs of other-
wise similar highest vs lowest RRs were identified in
which one of the pair was adjusted for the most available
other aspects of smoking, and the other had no such ad-
justment. Both were also chosen as adjusted for the most
possible other variables (although those other variables
may differ between the pair). There was a clear tendency
for the additional adjustment for other aspects of smok-
ing, typically including amount smoked, to produce
lower RR estimates. This was true for 18/22 (81.8%,
p < 0.01) of the pairs of estimates for age of starting to
smoke, 12/15 (80.0%, p < 0.05) of the pairs for duration
of smoking, all 17 (100%, p < 0.001) of those for years
quit, and 5/7 (71.4%, NS) of those for tar level.
Based on results for ever/current smoking and for all
lung cancer, RRs for mixed smokers were compared with
those for smokers of cigarettes only. For 22 of the 34
(64.7%) pairs, the RR was lower for mixed smokers, but
this tendency was not significant (p = 0.12). RRs for
mixed smokers were also compared with those for smo-
kers of pipes/cigars only. Here 23 of the 24 (95.8%,
p < 0.001) pairs showed a lower risk in the smokers of
pipes/cigars only.
Q. Publication bias
Some results of Egger’s test [17] for publication bias are
presented in Tables 5, 8 and 12, with further results
given in Additional file 5: Detailed Analysis Tables, but
have not previously been referred to in the text. For ever
smoking there is evidence of publication bias for all
lung cancer (p < 0.001) and adeno (p < 0.01), but not for
squamous (p ≥ 0.1). For current smoking, some evidence
of publication bias is seen for all lung cancer (p < 0.05),
but not for squamous or adeno (p≥ 0.1). For ex smoking,
there is again evidence of bias for all lung cancer and
for adeno (p < 0.001) but not for squamous. Figure 24
Lee et al. BMC Cancer 2012, 12:385 Page 70 of 90
http://www.biomedcentral.com/1471-2407/12/385(all lung cancer), Figure 25 (squamous) and Figure 26
(adeno) show funnel plots for ever smoking. Where
asymmetry is seen, this in the direction of there being
more higher-weight RRs above the mean. This is consist-
ent with the evidence in Table 5 of higher RRs for larger
studies. Inspection of a funnel plot for ex-smoking for
all lung cancer (data not shown) also showed the high
weight RRs tended to be above the mean.
Discussion
Evidence of a relationship
The meta-analyses carried out demonstrate a clear rela-
tionship of smoking to overall lung cancer risk. This is
evident for ever, current and ex smoking, for pipes
and cigars, and for all types of cigarette studied. The
increased risk in smokers is evident in both sexes, in
younger and older subjects, in all continents studied
and in prospective and case–control studies. That this
relationship is causal is supported by the evidence of a
dose–response, risk increasing with increasing amount
smoked, duration of smoking, tar level and fraction
smoked, and with earlier age of starting to smoke, and
decreasing with duration of quitting. It is also supported
by the similarity of results based on most-adjusted and
least-adjusted RRs (though adjustment for amount
smoked reduces the association with other dose–response
indices of smoking). The association is clearly evident
with each of the major histological types of lung cancer
studied, being stronger for squamous and small cell car-
cinoma, intermediate for large cell carcinoma, and weak-
est for adenocarcinoma. Exceptionally, no relationship is
seen between adenocarcinoma and pipe or cigar smoking.
Heterogeneity
The studies are remarkably consistent in reporting an
increased risk in ever smokers. Only two of the 328 all
lung cancer RRs, none of the 102 squamous RRs, and
nine of the 107 adeno RRs considered in Figures 1, 2, 3,
4, 5, 6, 7, 8, 9 are less than 1.0. However, studies also
vary markedly in the magnitude of the estimated RR, as
illustrated by the high values of H seen in the meta-
analysis of the major smoking indices, which often
exceed 5 and sometimes exceed 20. (H values of 5, 10
and 20 are the same as I2 values [16] of 80%, 90% and
95%). This heterogeneity is perhaps unsurprising given
the many sources of variation involved, including sex,
location, timing, study design and populations, definition
of outcome and type of product smoked, and extent of
confounder adjustment.
Using univariable and multivariable (meta-regression)
methods, we investigated variation in risk by a number
of characteristics of the study and the RR for the out-
comes all lung cancer, squamous and adeno. While our
“fixed” multivariable models involving six characteristics(sex, location, start year of study, study type, number of
cases and number of adjustment factors) explained a
substantial proportion of the variation (e.g. reducing H
from 22.84 to 4.72 for all lung cancer for ever smoking),
there was always substantial residual heterogeneity (with
H varying from 2.43 to 4.72 in the six analyses in
Tables 7 and 10). Of the six characteristics studied, loca-
tion was generally the most important characteristic,
with RR estimates for ever and for current smoking and
for all three outcomes always highest in North America,
and lowest in China, and (with the exception of ever
smoking for squamous) lower in the rest of Asia than in
Europe, with no consistent differences seen between
results for the United Kingdom, Scandinavia and the rest
of Europe. Another consistently seen relationship was
the tendency for RRs to vary by start year of study, with
higher RRs seen in more recent studies. Three other ten-
dencies were generally seen, though the level of signifi-
cance varied according to the analysis. One was the
tendency for RRs to vary by number of cases, with the
lowest estimates always seen for the smaller studies, (in-
volving 100 to 249 cases), another was the tendency for
RRs to be higher in prospective studies than in case–
control studies, and the third was the tendency for RRs
to be somewhat higher in males than females. The final
characteristic included in the fixed model, number of ad-
justment factors, showed no clear relationship with the
RR, with significance either not present or weak
(0.01 < p < 0.05), and the direction of effect inconsistent.
We also tested for the effect of a number of other
characteristics on the estimated RR. A number of rela-
tionships were seen in the univariable models that
were significant. However, these mainly became non-
significant in the multivariable models, presumably due
to correlations between the characteristics. Where a
characteristic was significant, this tended to be only in
one of the six analyses, so not providing convincing evi-
dence of a true effect. It would have been possible, for
each of the six combinations of smoking status and out-
come we considered, to present analyses of “best” mod-
els, based on forward stepwise regression, that each
included a different set of predictive characteristics.
However we felt that the regressions we presented based
on a fixed model were more useful. Sources of variation
are discussed further in the following paragraphs.
Sex
If possible, sex-specific results are included in the meta-
analyses, with combined sex results included only if
not. Though variation by sex was not significant in all
the main analyses, risk estimates generally tended to
be higher for males than females. This is supported
by additional analyses comparing RRs within study for
the same outcome and exposure definition. Somewhat
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comparisons were made within the same levels of daily
cigarette consumption (about 5, 20 or 45 cigs/day). Even
so, the existence of somewhat higher RRs for males does
not necessarily indicate any greater susceptibility, as it
may reflect their increased exposure to occupational car-
cinogens, or other differences in smoking history such
as greater duration of smoking or increased use of plain
and higher tar cigarettes. It should be noted however
that in prospective studies where smoking habits were
determined at baseline, the greater tendency of males to
quit during follow-up may cause bias in the reverse
direction. It should also be noted that comparison of
smoker/never smoker RRs for men and women does not
take account of possible differences in risk between male
and female never smokers, the base groups for these
comparisons. A detailed overall assessment of this aspect
is beyond the scope of this paper, and ideally would
involve direct comparison of risk in male and female
smokers, with detailed adjustment for age, smoking
characteristics and major potential confounding vari-
ables. We note that Bain et al. [18] concluded, based on
analysis of two large prospective studies and review of
results from six other such studies, that “women do not
appear to have a greater susceptibility to lung cancer
than men, given equal smoking exposure”.Age
While it is clear that absolute risk of lung cancer
rises markedly with age, both in smokers and never
smokers, it is far less clear whether the smoker/never
smoker RR also does. Predictions based on the multi-
stage model [19] suggest that there should be a mod-
est rise, but there is difficulty in establishing this,
especially when the great majority of the studies do
not give results by age. Possible effects of age were
investigated in two ways. The first method (see
Tables 6 and 9) was to compare RRs which were spe-
cific to subjects in specific age groups. Data here
were limited for squamous and adeno, and for all
lung cancer suggested a possible increase in RR with
age for current smoking, but not for ever smoking.
More reliable are the comparisons (described in
results section O), of RRs for the highest and lowest
age groups within study for ever/current smoking;
between-study differences are automatically controlled
for under this approach. These showed a 17% greater
risk for the highest age group (95% CI 10% to 25%).
Whether or not a RR was adjusted for age was con-
sidered as a characteristic in the meta-regression ana-
lyses, but it never added significantly to the fixed
model for either ever or current smoking for any of
the three outcomes.Race
Although RRs were entered onto the database, if available,
there were few studies that provided such data. For eight
studies which provided pairs of comparable RRs for ever/
current smoking, there was no indication that RRs for
white people differed systematically from those for black
people (or non-white people). This, of course, does not rule
out the possibility that absolute risks for white people and
black people with similar smoking habits may differ. As our
concern was only with RRs for smoking, and whether these
vary by other characteristics, we have not attempted to col-
lect data comparing absolute risk according to these char-
acteristics, such as white/black RRs within never smokers,
or within smokers. Detailed analysis and discussion of racial
differences in lung cancer risk between black people and
white people is therefore beyond the scope of this paper.
Elsewhere Lee [20] points out that in the USA black men
have a higher risk of lung cancer than do white men. How-
ever, interpretation of this difference in terms of effects of
smoking is not straightforward for various reasons. Thus
Lee notes that though black people are more often current
smokers, are less likely to quit smoking, smoke cigarettes
with a higher tar level, and have higher cotinine levels, all
characteristics predictive of a higher risk of lung cancer,
they are also less likely to have ever smoked, smoke fewer
cigarettes a day and start to smoke later, all characteristics
predictive of a lower risk. Also little or no difference in lung
cancer rate is seen between black and white women. Black
people are much more likely than white people to use men-
tholated cigarettes, but no evidence of a difference in lung
cancer risk associated with mentholation was found, either
in the present analysis or in other reviews [20,21].
Location and national cigarette tobacco type
A consistent tendency in our meta-analyses was for RRs to
be highest in studies in North America, intermediate in
Europe and lowest in Asia, particularly in China. There was
no very clear evidence of a difference between European
countries, or between other countries in Asia, though some
of the analyses suggested relatively lower RRs in Greece
and Turkey than in the rest of Europe, and higher RRs in
India than in the rest of Asia. In an attempt to study a pos-
sible explanation for this difference we divided countries
into three groups by national cigarette tobacco type. One
was the countries (Australia, Canada, India, South Africa,
UK and Zimbabwe) which typically use flue-cured Virginia
tobacco, another was the countries (all except those in the
other two groups) which typically use blended tobacco, and
the third included Taiwan and China (countries which used
both types quite commonly or where we lacked confirmed
information). Including this variable into the meta-analyses
did not consistently improve the prediction of our model, a
finding which is consistent with the conclusions of other
analyses we have conducted based on national data on lung
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course other possible explanations of the clear differences
in lung cancer RRs between continents, including genetic
differences, and differences in baseline rates of the disease.
Study timing
Our meta-regressions generally showed a tendency for
RRs to be lower in studies which started earlier. There
may be a number of reasons for this, such as changes in
the relative use of cigarettes and pipes or cigars, and im-
provement of study quality, with better standardization
of questionnaires and definition of products smoked.
However we consider the most plausible reason to be
changes in patterns of uptake of smoking, with smokers
in earlier born cohorts being less likely to have a lengthy
smoking career than smokers in later born cohorts.
Study type
Though this was only clearly significant in the analyses
of ever smoking for all lung cancer, there was a consist-
ent tendency for RRs to be somewhat higher from pro-
spective studies than from case–control studies. If this is
a true effect, the explanation for it is unclear.
Number of cases
In order to limit the considerable amount of work
needed, we limited attention to studies involving at
least 100 lung cancer cases. Given that smaller stud-
ies would have contributed much less weight to the
meta-analyses than would the studies that were
included, we consider that this restriction unlikely to
have any material effect on our conclusions. The
meta-regression analyses did show a consistent ten-
dency for RRs to be higher in larger studies, though
this was only significant for ever smoking (all lung
cancer p < 0.001), squamous and adeno p < 0.05). This
tendency is in the opposite direction to that pre-
dicted from publication bias. The explanation
is unclear.
Adjustment for other factors
Generally our analyses showed that adjustment for age
and other factors had very little effect on the meta-
analysis estimates of smoking-related RR, whether one
considered the total number of adjustment factors, or
the effect of specific factors. This conclusion of a min-
imal effect of confounding is consistent with that of a
detailed analysis of data from the huge CPSII prospective
study [23], and means that though the main results we
report are based on most-adjusted estimates, this deci-
sion had little or no effect on our conclusions or on the
magnitude of our estimates.
Adjustment for other aspects of smoking is, how-
ever, important when considering the dose-relatedvariables. Though studies rarely, if ever, present
results to allow detailed analysis of the effect of ad-
justment for one specific aspect of smoking on RRs
for another aspect, we have shown that adjustment
for other aspects of smoking (which typically
includes amount smoked) consistently tends to re-
duce associations with age of starting to smoke, dur-
ation of smoking, years quit and tar level. This is
presumably due to the tendency for earlier starters
and high tar smokers to smoke more heavily than do
later starters and low tar smokers, and for lighter
smokers to be more ready to quit smoking. Below,
we further discuss the effect of adjustment on results
for type of cigarette.Product smoked
There was consistent evidence that risk of lung cancer
was higher for cigarette only smokers than for smokers
of any product, and substantially higher than for
smokers of pipes only, cigars only or pipes/cigars only.
For current smokers, for example, RRs were 9.57 (7.90-
11.59) for cigarettes only, as compared to 4.76 (3.44-
6.59) for pipes/cigars only. Mixed smokers tended to
have similar risks to cigarette only smokers. Interpret-
ation of this finding is difficult as mixed smokers and
cigarette only smokers may have a different total expos-
ure to tobacco, as well as a different cigarette consump-
tion. Data on the types of cigars or pipes smoked have
not been recorded on the database, but the increased
risk is evident in each continent. The results for pipes
and cigars mainly apply to males and to RRs for all lung
cancer. Though there are only limited results by histo-
logical type, it is interesting that there is no indication
of an increased risk of adenocarcinoma for pipe and
cigar smokers.Type of cigarette smoked
The conclusions drawn from the results in Table 14
are consistent with those drawn by one of us in a review
of the relationship between lung cancer and type of
cigarette conducted in 2001 [24]. This is unsurprising,
because the data sets considered are very similar. The
conclusions are also very similar to those of a review by
Kabat carried out in 2003 [25].
Comparisons between filter and plain smoking are
made more difficult by the variety of ways in which
different reports present their results, but based on the
index most closely equivalent to only filter vs. only plain,
the present report shows a reduction in risk that is sig-
nificant for all lung cancer (0.69, 95% CI 0.61-0.78) and
for squamous (0.52, 0.40-0.68), though not for adeno
(0.84, 0.66-1.08). Significant reductions in risk for all
lung cancer and squamous, but not for adeno were also
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only plain, and only filter vs. ever plain. Our analyses
were based on most-adjusted RR estimates, with many
of the estimates adjusted for other aspects of smoking,
such as number of cigarettes smoked. In 2001, a Na-
tional Cancer Institute monograph [26] claimed that ap-
parent benefits of filter vs. plain and of low tar vs. high
tar cigarettes may be illusory if RRs are adjusted for daily
consumption, as switching to cigarettes with a lower
machine-smoked delivery of tar and nicotine leads to
“compensation” for the reduced nicotine intake by in-
creasing numbers of cigarettes smoked. Lee and Sanders
[27] investigated this claim in detail by comparing RRs
for all lung cancer adjusted and unadjusted specifically
for daily cigarette consumption, and concluded that
“whether or not relative risk estimates are adjusted for
cigarette consumption is not crucial to the conclusion of
a clear advantage to filter cigarettes and tar reduction”.
This analysis is more precise than that used in this
report, but its conclusions are similar, as we also found
adjustment not to affect our overall conclusion that filter
vs. plain cigarette smoking was associated with a lower
risk of all lung cancer and of squamous. It should be
noted that although no significant reduction in risk for
filter cigarette smoking was seen for adeno, there was
also no evidence of an increase. This would seem to
argue against the claim often made that the observed
rise over time in the incidence of adenocarcinoma rela-
tive to squamous cell carcinoma seen in many countries
is due to changes in cigarette design increasing the
risk of smoking-related adenocarcinoma. In this context,
it should be noted that though our database contains
evidence by histological type for filter vs. plain cigarette
smoking, no such data were found relating to tar level.
Our conclusions of a higher RR in handrolled vs. man-
ufactured cigarette smokers is consistent with that of the
2001 review [24], with the increased risk evident, despite
the limited amount of data, for squamous and adeno as
well as for all lung cancer.
Our review also found no difference in risk between
smokers of mentholated and non mentholated cigarette
smokers, though based on data from only three studies,
only one of which provided results by histological type.
Though no more recent studies have reported results
by histological type, five further studies have reported
results for all lung cancer, and a recently published
systematic review [20] confirms the lack of apparent ef-
fect of cigarette mentholation on the lung carcinogen-
icity of cigarettes.
Dose–response relationships
We have investigated the relationship of lung cancer
risk to various indices of the dose–response relation-
ship. We did not record data on our database forpack-years, as we wished to investigate the separate
roles of daily amount smoked and duration of smok-
ing. Indeed, previous work (e.g. [19,28]) has in fact
suggested that pack-years is not a valid measure, as
for example, smokers of 20 cigs/day for 40 years and
smokers of 40 cigs/day for 20 years have very differ-
ent smoking RRs despite their identical pack-years.
For those indices that we did consider where there
were substantial amounts of data – daily amount
smoked, duration, age of starting to smoke, and time
of quit (relative both to current smoking and to
never smoking) – there was very clear evidence that
greater exposure leads to greater risk, not only for
all lung cancer, but also for squamous and adeno.
The results by time of quit extend the observation
that RRs in ex smokers are intermediate between
those of never smokers and current smokers. Because
dose–response results are expressed in categories of
exposure which vary from study to study, there are
difficulties in combining the evidence over studies.
We have used two approaches. One is to consider
the RR for the highest vs. lowest level of exposure
(where highest and lowest refer to expected risk, so
that early ages of starting, for example, are consid-
ered highest). The other is the key value approach
where we consider categories including a specified
level of exposure and not including another specified
level. Both approaches have limitations. The highest
vs. lowest approach will vary between study in the
ratio of exposures considered, while the key value ap-
proach, although combining results relating to differ-
ent exposures in different studies to a lesser extent,
necessarily omits results from studies with broader
categories while somewhat arbitrarily selecting or dis-
carding RRs from studies with narrow categories.
Work is ongoing on a third approach to fit a dose–
response curve to the RRs and estimated dose mid-
points of the categories for each study. This ap-
proach is complex, and was considered outside the
scope of the current paper, which was more intended
to summarize major features of the data. However, a
future paper is planned which will describe the shape
of these dose–response relationships including char-
acteristics of the curves, such as the estimated time
after quitting by which half the excess risk associated
with continued smoking has disappeared. We note
that, when considering RR for time of quitting, the
problem of “reverse causation” needs to be taken
into account, as evidenced by the data in Table 19
showing no decrease in risk compared to current
smokers for quitters of about 3 years. Our analyses
also showed that for all lung cancer, risk increased
with increasing tar level and with increasing fraction
smoked (or equivalently short butt length), data here
Lee et al. BMC Cancer 2012, 12:385 Page 74 of 90
http://www.biomedcentral.com/1471-2407/12/385being more limited and non existent by histological
type. As noted earlier, when discussing cigarette type,
the relationship with tar level is not an artefact of in-
appropriate adjustment for amount smoked [27], as
has been claimed [26].
Derivation of RRs
Almost a third of RRs used in meta-analyses were not
directly available from the source or calculated directly
from cross-tables of exposure by outcome, and required
more complex methods to derive the required RR. It
was reassuring that whether or not the RR was derived
did not (with one minor exception) add predictive power
to the main meta-regression models, suggesting that our
extensive use of derived RRs caused no material bias.
Effect of studies with high RRs or large weight
The statistical analyses investigated the role of various
characteristics on the estimated risk of all lung cancer,
squamous and adeno in relation to ever and current
smoking, but generally did not formally test the effect of
exclusion of specific studies with extreme RRs or large
weights. An exception was the case of study LIU4 for
ever smoking and all lung cancer, this study not giving
data for current smoking or by histological type. The
two sex-specific RRs for this study together contributed
50.9% of the weight for the 328 available RRs from all
the studies, and its exclusion increased the overall fixed-
effect RR from 4.22 (95% CI 4.16-4.28) to 6.47 (95%
6.34-6.60). However there was little difference in the
random-effects estimates, and in the meta-regression
analysis the two LIU4 RRs did not produce unusual
standardized residuals, suggesting that the relatively low
RRs from this study (2.76, 2.69-2.83 for males, and 2.86,
2.77-2.95 for females), were due to the characteristics of
the study included in the model (in particular that it was
conducted in China) and not due to its unusual results.
While there are other large studies, none involved nearly
as many lung cancer cases as LIU4, and we feel it
unlikely that excluding other specific studies would have
had a major effect on our meta-analysis estimates or
on our conclusions as to how RRs varied by exposure,
outcome and study and RR characteristics.
Representativeness
We did not exclude studies on the basis of the popula-
tion studied. However, most studies include subjects
broadly representative of the general population. A small
number of studies were conducted in miners or in other
occupations with a known or suspected lung cancer risk,
such as welding or foundry working. Risky occupation
was considered as a characteristic in the meta-regression
models but was never found to be an independent pre-
dictor of RRs associated with ever or current smoking.Publication bias
It is well known that researchers are more likely to wish
to publish, and editors more likely to accept for publica-
tion, studies finding a statistically significant association
between exposure and disease. The published literature
may therefore overstate any true association or produce
a false-positive relationship. As part of each meta-
analysis we have carried out Egger’s test of publication
bias, though results are generally shown only in the
detailed tables. While evidence for such bias generally is
mixed, the results for all lung cancer suggest that, where
significant bias is seen, it is not in the direction of smal-
ler studies with lower-weight RRs producing higher RRs.
Rather it is, as noted above, the larger studies that tend
to produce higher RRs. The reason for this finding is
unclear. It should also be noted that our analyses are
based only on those studies satisfying the inclusion cri-
teria, and that one of these criteria restricted attention
to studies with at least 100 lung cancer cases.
We have not attempted to try to correct for pub-
lication bias for four reasons. Firstly, we feel that
evidence for its existence is not strong. Second, any
adjustment for it seems unlikely to affect our main con-
clusions. Third, any adjustment for it would be com-
plicated by the restriction on study size. Finally, any
correction for publication bias would be open to ques-
tion, as it inevitably involves assumptions that are
impossible to verify.
Bias due to misclassification of smoking status
Another source of bias is misclassification of smoking
status. Random misclassification would dilute the asso-
ciation, as would any tendency for cases to deny or
understate their smoking more than for the general
population. Any tendency for current smokers to claim
to be ex-smokers, as might happen in a study conducted
in a clinical setting or where patients have been advised
to stop smoking, would tend to inflate the risk for ex
smoking. Adjustment for misclassification would be
difficult, as denial rates are likely to vary by aspects of
the study design, the way questions are asked, and also
by sex, age, location and other demographic variables.
Limitations
This review has various limitations, many unavoidable.
Lack of access to individual subject data limits the ability
to carry out meta-analyses using similar exposure indices
and confounder adjustment throughout, but obtaining
such data was not feasible given many studies were
conducted years ago. Obtaining a reliable definition of
outcome and exposure is often hindered by incom-
plete information in the source papers. We do not con-
sider that limiting attention to studies of 100 cases or
more is of particular importance as results from smaller
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meta-analyses. Limiting attention to studies conducted
up to 1999 may be more relevant for some exposures
and issues (particularly the trend in RR over time),
though we feel that our consideration of data from 287
published studies should give a very reliable overall
picture. The problem is that the procedures conducted
for this review were extremely time-consuming and it
would take some years to update the database and
include smaller and more recent studies.
It may also be argued that the analyses presented here
do not make full use of all the data collected. This is
inevitable, given the extensive amount of information
collected and the need to present the findings in a paper
of reasonable length. As noted, when discussing dose–
response, we do plan further analyses. We would also
be willing to make the database available to bona fide
researchers for further analysis.
Conclusions
After excluding studies involving less than 100 lung
cancer cases, we identified 287 epidemiological studies
of lung cancer which provided information on risk in
relation to one or more of a defined list of smoking
indices [2,3,6,29-689]. Of the 267 independent principal
studies, 262 provided RRs relating to all lung cancer, 84
provided RRs relating to squamous cell carcinoma, and
86 provided RRs relating to adenocarcinoma (or to out-
comes that are closely equivalent). One major conclusion
is that for each outcome the RRs for all major smoking
indices were markedly heterogeneous.
Another conclusion is that RR estimates for ever,
current or ex smoking of any product (or cigarettes if
not available) are clearly elevated for all three outcomes.
Individual study RRs virtually all exceed 1.0, and based
on random-effects meta-analyses of most-adjusted RRs,
increases were seen for ever smoking (all lung cancer
5.50, CI 5.07-5.96, n = 328 RRs; squamous, 10.47, 8.88-
12.33, n = 102; adeno 2.84, 2.41-3.35, n = 107), current
smoking (all lung cancer 8.43, 7.63-9.31; squamous
16.91, 13.14-21.76; adeno 4.21, 3.32-5.34) and ex smok-
ing (all lung cancer 4.30, 3.93-4.71; squamous 8.74, 6.94-
11.01; adeno 2.85, 2.20-3.70). For all lung cancer, RRs
were also elevated for cigarettes only smokers (ever
smoking 6.36, 5.33-7.59) and mixed smokers of cigar-
ettes and pipes/cigars (7.37, 5.97-9.11), though lower for
smokers of pipes/cigars only (2.92, 2.38-3.57), pipes only
(3.31, 2.51-4.35) and cigars only (2.95, 1.91-4.56). While
pipe and cigar smoking is associated with an increased
risk for squamous, there is no increase for adeno. The
consistency and strength of the relationships are consist-
ent with a causal relationship (except for pipe and cigar
smoking and adenocarcinoma). A causal relationship is
also supported by the fact that estimates are generallynot materially affected by adjustment for confounding
variables, and by the strong evidence of a dose–re-
sponse relationship, with RRs for all outcomes
clearly increasing with amount smoked, duration and
earlier starting age, and decreasing with time quit,
and for all lung cancer increasing with tar level and
fraction smoked. Relationships were also clearly seen
between smoking and RRs for the other major histo-
logical types, small cell carcinoma and large cell
carcinoma.
Our review also provides evidence that risk varied by
type of cigarette smoked, with filter cigarette smokers
having lower risks than plain cigarette smokers (a con-
clusion not explained by “over-adjustment” for amount
smoked), and that handrolled cigarette smokers have
higher risks than manufactured cigarette smokers,
though mentholation of cigarettes seems unrelated to
risk. It also shows that various characteristics of the
study and of the RR affect risk estimates. Thus RRs were
generally highest for studies in North America and low-
est for Asia, particularly in China, and higher in later
starting, larger and prospective studies. RRs were also
somewhat higher in males than in females, though this
may be related to differences in their detailed smoking
habits. There is no clear tendency for the smoking/lung
cancer relationship to vary with age.
This comprehensive review provides further insight
into the relationship of smoking to lung cancer and its
major histological types.Additional files
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